US20050090533A1 - Dual NK1/NK3 receptor antagonists - Google Patents

Dual NK1/NK3 receptor antagonists Download PDF

Info

Publication number
US20050090533A1
US20050090533A1 US10/884,707 US88470704A US2005090533A1 US 20050090533 A1 US20050090533 A1 US 20050090533A1 US 88470704 A US88470704 A US 88470704A US 2005090533 A1 US2005090533 A1 US 2005090533A1
Authority
US
United States
Prior art keywords
phenyl
methyl
isobutyramide
alkyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/884,707
Inventor
Torsten Hoffmann
Andreas Koblet
Jens-Uwe Peters
Patrick Schnider
Andrew Sleight
Heinz Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33560750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050090533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to F. HOFMANN-LA ROCHE AG reassignment F. HOFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOFFMANN, TORSTEN, KOBLET, ANDREAS, PETERS, JENS-UWE, SCHNIDER, PATRICK, SLEIGHT, ANDREW, STADLER, HEINZ
Publication of US20050090533A1 publication Critical patent/US20050090533A1/en
Priority to US12/361,569 priority Critical patent/US7939533B2/en
Priority to US13/076,891 priority patent/US8404708B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Definitions

  • Schizophrenia is one of the major neuropsychiatric disorders, characterized by severe and chronic mental impairment. This devastating disease affects about 1% of the world's population. Symptoms begin in early adulthood and are followed by a period of interpersonal and social dysfunction. Schizophrenia manifests as auditory and visual hallucinations, paranoia, delusions (positive symptoms), blunted affect, depression, anhedonia, poverty of speech, memory and attention deficits as well as social withdrawal (negative symptoms).
  • an appropriate multireceptor affinity profile might be required for efficacy against positive and negative signs and symptoms.
  • an ideal drug against schizophrenia would preferably have a low dosage allowing once-per-day dosage, due to the low adherence of schizophrenic patients.
  • Osanetant (SR 142,801) from Sanofi-Synthelabo was the first identified potent and selective non-peptide antagonist described for the NK3 tachykinin receptor for the potential treatment of schizophrenia, which was reported in the literature ( Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 and Psychiatric Disorders Study 4 , Schizophrenia , June 2003, Decision Resources, Inc., Waltham, Mass.).
  • the proposed drug SR 142,801 has been shown in a phase II trial as active on positive symptoms of schizophrenia, such as altered behavior, delusion, hallucinations, extreme emotions, excited motor activity and incoherent speech, but inactive in the treatment of negative symptoms, which are depression, anhedonia, social isolation or memory and attention deficits.
  • the neurokinin-3 receptor antagonists have been described as useful in pain or inflammation, as well as in schizophrenia, Exp. Opinion. Ther. Patents (2000), 10(6), 939-960 and Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 956 and Psychiatric Disorders Study 4 , Schizophrenia , June 2003, Decision Resources, Inc., Waltham, Mass.).
  • EP 1 192 952 describes a pharmaceutical composition containing a combination of a NK3 receptor antagonist and a CNS penetrant NK1 receptor antagonist for the treatment of depression and anxiety.
  • This advantage may be realized in the administration of an ideal drug against schizophrenia.
  • NK1 receptors have been described as active at the NK1 receptor for the treatment of diseases related to this receptor, such as inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's disease, anxiety, pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases.
  • CNS central nervous system
  • the neurokinin-1 receptor antagonists are further useful for the treatment of motion sickness, for treatment induced vomiting or for the treatment of psychoimmunologic or psychosomatic disorders, see Neurosci. Res., 1996, 7, 187-214 , Can. J. Phys., 1997, 75, 612-621 , Science, 1998, 281, 1640-1645 , Auton. Pharmacol., 13, 23-93, 1993, WO 95/16679, WO 95/18124 and WO 95/23798 , The New England Journal of Medicine , Vol. 340, No. 3 190-195, 1999, U.S. Pat. No. 5,972,938.
  • the present invention relates to the use of compounds of formula I and pharmaceutically acceptable salts thereof for the treatment of positive and negative symptoms in schizophrenia, novel compounds of formulas I, pharmaceutically active acid-addition salts thereof, all sterioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof, the preparation of the above-mentioned novel compounds, medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier or in the manufacture of corresponding medicaments.
  • the invention provides a method of treating schizophrenia which comprises administering a compound of formula
  • the compounds of formula I may contain some asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof.
  • the compounds of formula I and their salts are characterized by valuable therapeutic properties. It has surprisingly been found that the compounds of formula I show a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
  • lower alkyl denotes a straight- or branched-chain alkyl group containing from 1-4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like.
  • alkyl denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms.
  • lower alkoxy and “alkoxy” denote a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • cycloalkyl denotes a saturated carbocyclic group containing 3-6 carbon atoms.
  • aryl means a monovalent cyclic aromatic hydrocarbon group consisting of one or more fused rings in which at least one ring is aromatic in nature.
  • aryl radicals include, but are not limited to, phenyl, naphthyl, biphenyl, indanyl, anthraquinolyl, and the like.
  • the preferred aryl group is phenyl.
  • Heteroaryl means a monovalent aromatic carbocyclic group having one or more rings incorporating one, two, or three heteroatoms within the ring wherein the heteroatoms are chosen from nitrogen, oxygen, or sulfur.
  • heteroaryl radicals include, but are not limited to, imidazolyl, isoxazolyl, thiazolyl, pyrazinyl, thiophenyl, furanyl, pyranyl, pyridinyl, quinolinyl, isoquinolinyl, benzofuryl, benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzopyranyl, indazolyl, indolyl, isoindolyl, naphtyridinyl, and the like.
  • Preferred heteroaryl groups are isoxazolyl and pyridinyl.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • pharmaceutically acceptable acid addition salt embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • the invention provides a method of treating schizophrenia which comprises administering a compound of formula wherein
  • the invention provides a method of treating schizophrenia which comprises administering a compound of 1 formula
  • the method employs a compound of formula I-1, wherein R 1 , R 4 and R 5 have the definitions as described in formula I-1 and R 2 and R 3 are both CF 3 .
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e -, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R′′) d OH, ⁇ O, —NR′R′′, —(CH 2 ) d NR′—C(O)-lower alkyl, —(CH 2 ) d —C(O)-lower alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′, —(CH 2 ) d —S(O) 2 -lower alkyl, —(CH 2 ) d -pyrrolidinyl, and —C(O)NR′R′′.
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is mono substituted by —CH 2 OH or disubstituted by hydroxy and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is mono substituted by —CH 2 OH or disubstituted by hydroxy and —CH 2 OH.
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is disubstituted by NHC(O)CH 3 and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is disubstituted by NHC(O)CH 3 and —CH 2 OH.
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is disubstituted by ⁇ O and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is disubstituted by ⁇ O and —CH 2 OH.
  • the method employs a compound of formula I-1 wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is di- or tri-substituted by halogen and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, wherein the ring is di- or tri-substituted by halogen and —CH 2 OH.
  • the method employs a compound of formula I-1, wherein R 4 and R 5 are each independently hydrogen, —(CR′R′′) l —(CR′R′′) l —(CR′R′′) a —OH or —(CR′R′′) l —(CR′R′′) l —(CR′R′′) a -lower alkyl, wherein R′ and R′′ on each carbon atom may be the same or different from each other, or are —C b -alkyl, —C(O)H, —(CH 2 ) d cycloalkyl which is unsubstituted or substituted by hydroxy,
  • the method employs a compound of formula I-1, wherein R 4 and R 5 are each independently hydrogen, —CH(CH 2 OH)CH 2 OH or —(CH 2 ) c OH. Examples of such compounds are
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) c —O—(CH 2 ) 2 —, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R′′) d OH, ⁇ O, —NR′R′′, —(CH 2 ) d NR′—C(O)-lower alkyl, —(CH 2 ) d —C(O)-lower alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′, —(CH 2 ) d —S(O) 2 -lower alkyl, —(CH 2 ) d -pyrrolidinyl and —C
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 —O—(CH 2 ) 2 —, wherein the ring is substituted by —CH 2 OH.
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 )C—S(O) f —(CH 2 ) 2 —, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R′′) d OH, ⁇ O, —NR′R′′, —(CH 2 ) d NR′—C(O)-lower alkyl, —(CH 2 ) d —C(O)-lower alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′, —(CH 2 ) d —S(O) 2 -lower alkyl, —(CH 2 ) d -pyrrolidinyl
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 —S(O) 2 —(CH 2 ) 2 —, wherein the ring is mono-substituted by —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 —S(O) 2 —(CH 2 ) 2 —, wherein the ring is mono-substituted by —CH 2 OH.
  • the method employs a compound of formula I-1, wherein R 1 , R 4 and R 5 have the definitions as described above and R 2 and R 3 are other than di-CF 3 .
  • the method employs a compound of formula I-1, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 — wherein the ring is mono substituted by —CH 2 OH or disubstituted by OH and
  • the invention provides a compound of formula
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 are each independently hydrogen,
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl, R 4 is hydrogen and R 5 is —(CH 2 ) d -cycloalkyl, unsubstituted or substituted by hydroxy. Examples of these compounds are
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl, R 4 is hydrogen and R 5 is —(CH 2 ) c NR′C(O)-lower alkyl or —(CH 2 ) d S(O) 2 -lower alkyl. Examples of such compounds are
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, which ring is substituted by one or two groups —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, which ring is substituted by one or two groups —(CR′R′′) d OH.
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 —, which ring is substituted by one to three substituents selected from the group consisting of —NR′R′′, —(CH 2 ) d —C(O)-lower alkyl,
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) h —, which ring is mono- or di-substituted by —(CH 2 ) d OH or —NR′R′′, wherein h is 3 or 5.
  • R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) h —, which ring is mono- or di-substituted by —(CH 2 ) d OH or —NR′R′′, wherein h is 3 or 5.
  • R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) h —,
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 , —O—(CH 2 ) 2 —, which is unsubstituted or mono- or -di-substituted by —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 , —O—(CH 2 ) 2 —, which is unsubstituted or mono- or -di-substituted by —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl and R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) c —S(O) f —(CH 2 ) 2 —, which is unsubstituted or mono-or di-substituted by —(CR′R′′) d OH Examples of such compounds are
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono-substituted by, —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono-substituted by, —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono
  • the invention is a compound of formula I-1, wherein R 1 is unsubstituted or substituted heteroaryl as described above. Examples of such compounds are
  • R 1 , R 4 and R 5 have the definitions as described above and R 2 and R 3 are both CF 3 .
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e —, which ring is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF 3 , —(CR′R′′) d OH, ⁇ O, and —NR′R′′, wherein R′ and R′′ may form together with the N-atom to which they are attached a ring with —(CH 2 ) e , or substituted by —(CH 2 ) d NR′—C(O)-alkyl, —(CH 2 ) d —C(O)-alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′, —(CH 2 ) d —S(O) 2 -alky
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e -, wherein the ring is mono or di-substituted by hydroxy, —CH 2 OH or —C(O)H.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e -, wherein the ring is mono or di-substituted by hydroxy, —CH 2 OH or —C(O)H.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e —, wherein the ring is mono or di-substituted by NH 2 , NHS(O) 2 CH 3 , NCH 3 S(O) 2 CH 3 , N(CH 2 CH 3 )S(O) 2 CH 3 , NHC(O)CH 3 and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e —, wherein the ring is mono or di-substituted by NH 2 , NHS(O) 2 CH 3 , NCH 3 S(O) 2 CH 3 , N(CH 2 CH 3 )S(O) 2 CH 3 , NHC(O)CH 3 and —CH 2 OH.
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e —,
  • a further preferred group of compounds are further those, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 4 — and wherein the ring is disubstituted by ⁇ O and —CH 2 OH, for example the following compounds:
  • a further preferred group of compounds are those, wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e —, wherein the ring is substituted by CH 2 S(O) 2 CH 3 , CH 2 SCH 3 or CH 2 S(O)CH 3 . Examples of such compounds are
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) e -, wherein the ring is substituted by S(O) 2 CH 3 , SCH 3 , S(O)CH 3 or S(O) 2 N(CH 3 ) 2 , for example the following compounds:
  • R 4 and R 5 are each independently hydrogen; —(CR′R′′) l —(CR′R′′) l —(CR′R′′) a —OH or —(CR′R′′) l —(CR′R′′) l —(CR′R′′) a -alkyl, wherein R′ and R′′ on each carbon atom may be the same or different from each other; —C b -alkyl; —C(O)H; —(CH 2 ) d cycloalkyl, unsubstituted or substituted by hydroxy; or is —(CH 2 ) c NR′R′′, —(CH 2 ) c NR′C(O)-alkyl, —(CH 2 ) c NR′S(O) 2 -alkyl, —(CH 2 ) d S(O)-alkyl, —(CH 2 ) d S-alkyl, —(CH 2 ) d S
  • R 4 and R 5 are each independently hydrogen, —CH(CH 2 OH)CH 2 OH or —(CH 2 ) c OH, for example,
  • R 4 and R 5 are each independently hydrogen, (CH 2 ) 2 NH 2 , (CH 2 ) 2 NHS(O) 2 CH 3 or (CH 2 ) 2 NHC(O)CH 3 , for example,
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 —O—(CH 2 ) 2 —, wherein the ring is unsubstituted or substituted by —CH 2 OH, for example,
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) c —S(O) f —(CH 2 ) v —, which is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF 3 , —(CR′R′′) d OH, ⁇ O, —CHO, and —NR′R′′, wherein R′ and R′′ are as described above or may form together with the N-atom to which they are attached a ring with —(CH 2 ) e , or by —(CH 2 ) d NR′—C(O)-alkyl, —(CH 2 ) d —C(O)-alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′,
  • Especially preferred compounds from this group are those wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) 2 —S(O) 2 —(CH 2 ) 2 —, wherein the ring is unsubstituted or substituted by —CH 2 OH or methyl. Examples of such compounds are
  • R 1 , R 4 and R 5 have the definitions as describe above and R 2 and R 3 are other than di-CF 3 . Examples of such compounds are
  • a preferred group of compounds of formula I are compounds wherein R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) c —NR′—(CH 2 ) 2 —, which is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF 3 , —(CR′R′′) d OH, ⁇ O, —CHO, and —NR′R′′, wherein R′ and R′′ are as described above or may form together with the N-atom to which they are attached a ring with —(CH 2 ) e , or by —(CH 2 ) d NR′—C(O)-alkyl, —(CH 2 ) d —C(O)-alkyl, —(CH 2 ) d —C(O)-cycloalkyl, —(CH 2 ) d OC(O)NR′R′′, —(CH
  • R 4 and R 5 form together with the N-atom to which they are attached a ring with —(CH 2 ) c —NR′—(CH 2 ) 2 —, and wherein R′ on the N-atom is hydrogen, lower alkyl, C(O)H, C(O)CH 3 , C(O)-cyclopropyl,
  • Some compounds of formula IC are trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
  • Formula I also encompasses compounds of formula IG I
  • Examples of compounds of formula IG include
  • the invention relates also to compounds of formula I, wherein R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono-substituted by —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono-substituted by —(CR′R′′) d OH.
  • R 1 is unsubstituted or substituted phenyl as described above and R 4 and R 5 form together with the N-atom to which they are attached a ring with —CH 2 CH ⁇ CH—CH 2 —, which is unsubstituted or mono-sub
  • present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, described in schemes 1 to 14 and in specific examples 1 to 421 and, for example, by a process described below, which process comprises
  • the salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.
  • R 1 , R 2 , R 4 and R 5 have the meaning as described above. wherein R 1 , R 2 , R 3 , R 4 and R 5 have the meaning as described above. wherein R 1 , R 2 , R 3 and R 5 have the meaning as described above. wherein R 1 , R 2 and R 3 , have the meaning as described above. wherein R 1 , R 2 and R 3 have the meaning as described above.
  • the —OH group is first transformed into a —OS(O) 2 CH 3 group by reaction with methanesulfonyl chloride and triethylamine in dichloromethane.
  • a thioalkane such as sodium methanethiolate in methanol or DMF
  • the —S-alkyl group can be oxidized to an —S(O)-alkyl group by treatment with Oxone in methanol or MCPBA in dichloromethane.
  • the compounds of formula I containing an —S(O)-alkyl group can be isolated or oxidized further without isolation to compounds containing an —S(O) 2 -alkyl group by treatment with Oxone in methanol or MCPBA in dichloromethane (Examples 331 and 388).
  • the —OH group is transformed into a —SC(O)CH 3 group by reaction with triphenylphosphine, diethyl azodicarboxylate and thioacetic acid in THF.
  • the —SC(O)CH 3 group is oxidized to an —SO 3 H group by reaction with an aqueous solution of hydrogen peroxide in acetic acid.
  • Compounds containing the —SO 3 H are treated consecutively with oxalyl chloride and a catalytic amount of DMF in dichloromethane and an amine to form compounds of formula I wherein R or R 5 contain an —S(O) 2 —NR′R′′ group.
  • the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are dual antagonists of the Neurokinin 1 and 3 receptors.
  • NK 1 receptor The affinity of test compounds for the NK 1 receptor was evaluated at human NK 1 receptors in CHO cells infected with the human NK 1 receptor (using the Semliki virus expression system) and radiolabelled with [ 3 H]substance P (final concentration 0.6 nM). Binding assays were performed in HEPES buffer (50 mM, pH 7.4) containing BSA (0.04%) leupeptin (16.8 ⁇ g/ml), MnCl 2 (3 mM) and phosphoramidon (2 ⁇ M).
  • Binding assays consisted of 250 ⁇ l of membrane suspension (approximately 1.5 ⁇ g/well in a 96 well plate), 0.125 ⁇ l of buffer of displacing agent and 125 ⁇ l of [ 3 H]substance P. Displacement curves were determined with at least seven concentrations of the compound.
  • the assay tubes were incubated for 60 min at room temperature after which time the tube contents were rapidly filtered under vacuum through GF/C filters presoaked for 60 min with PEI (0.3%) with 3 ⁇ 1 ml washes of HEPES buffer (50 mM, pH 7.4). The radioactivity retained on the filters was measured by scintillation counting. All assays were performed in duplicate in at least 2 separate experiments.
  • Recombinant human NK 3 (hNK 3 ) receptor affinity was determined in a 96 well plate assay, using [ 3 H]SR142801 (final concentration 0.3 nM) to radiolabel the hNK 3 receptor in the presence of 10 concentrations of competing compound or buffer. Non specific binding was determined using 10 ⁇ M SB222200. Assay buffer consisted of Tris-HCl (50 mM, pH 7.4), BSA (0.1%), MnCl 2 (4 mM) and phosphoramidon (1 ⁇ M). Membrane preparations of hNK3 receptors (approximately 2.5 ⁇ g/well in a 96 well plate) were used to initiate the incubation for 90 min at room temperature.
  • This assay was terminated by rapid filtration under vacuum through GF/C filters, presoaked for 90 min with PEI (0.3%), with 3 ⁇ 0.5 ml washes of ice-cold Tris buffer (50 mM, pH 7.4) containing 0.1% BSA. The radioactivity retained on the filters was measured by scintillation counting. All assays were performed in duplicate in at least two separate experiments.
  • the present invention also provides pharmaceutical compositions containing compounds of formula I or pharmaceutically usable acid addition salts thereof and a pharmaceutically acceptable carrier.
  • Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • compositions of the invention in addition to one or more compounds of formula I or a pharmaceutically usable acid addition salt thereof, contain a pharmaceutically acceptable excipient.
  • suitable pharmaceutically inert excipients include pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragées and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • compositions of the invention can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • Compounds of the present invention are dual NK-1/NK-3 antagonists. Therefore, the present invention also provides a method for the treatment of schizophrenia. Such method includes administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable addition salt thereof, to an individual. In particular, such method includes administering a therapeutically effective amount of a compound of formula I-1, or a pharmaceutically acceptable acid addition salt thereof, to an individual.
  • the present invention provides methods for the treatment of schizophrenia which comprise administering to an individual an effective amount of a compound of formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, or a pharmaceutically acceptable acid addition salt of any one or more of these compounds.
  • the compounds and compositions of the invention can be administered in a conventional manner, for example, orally, rectally, or parenterally.
  • the pharmaceutical compositions of the invention can be administered orally, for example, in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the pharmaceutical compositions also can be administered rectally, for example, in the form of suppositories or parenterally, for example, in the form of injectable solutions.
  • the dosage at which the compound of the invention is administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
  • reaction mixture was allowed to warm to room temperature and stirred at room temperature for 1 h.
  • the reaction mixture was treated with 220 ml 1 N sodium hydrogencarbonate solution and extracted with three 200-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate and triturated with 150 ml diethylether to give 34.6 g (82%) of the title compound as a white solid.
  • the title compound was obtained as a white foam in 52% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • the title compound was obtained as a light yellow foam in 87% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • the title compound was obtained as a light yellow foam in 57% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • the title compound was obtained as a light yellow foam in 45% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • the title compound was obtained as a light yellow oil in 76% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using ⁇ 4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl ⁇ -methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • a solution of 18.2 g (82.8 mmol) (3,5-dichloro-phenyl)-acetic acid methyl ester in 15 ml THF was added to a solution of lithium diisopropylamide in THF (obtained by adding 49.7 ml (99.4 mmol) of a 2 M solution of lithium diispropylamide in THF/heptane/ethylbenzene to 125 ml THF at ⁇ 20° C. After stirring for 45 min. 6.3 ml (99.4 mmol) methyl iodide in 12 ml THF was added at the same temperature over a period of 30 min.
  • the title compound was obtained as a white foam in 84% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (R)-1-amino-2-propanol instead of ethanolamine.
  • the title compound was obtained as a light brown foam in 79% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-1-amino-2-propanol instead of ethanolamine.
  • the title compound was obtained as a yellow foam in 55% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 1-amino-2-butanol instead of ethanolamine.
  • the title compound was obtained as a white foam in 24% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (R)-2-amino-1-propanol instead of ethanolamine.
  • the title compound was obtained as a white foam in 34% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-amino-1,3-propandiol instead of ethanolamine.
  • the title compound was obtained as a white foam in 30% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(methylthio)ethylamine instead of ethanolamine.
  • the title compound was obtained as a white foam in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using N-acetylethylenediamine instead of ethanolamine.
  • the title compound was obtained as a white foam in 76% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (2R,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of ethanolamine.
  • the title compound was obtained as a light yellow foam in 23% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of ethanolamine.
  • reaction mixture was stirred at room temperature for 18 h, followed by dilution with 10 ml ethyl acetate and washing with 10 ml saturated sodium carbonate solution. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 130 mg (87%) of the title compound as a white foam.
  • reaction mixture was diluted with 30 ml tert-butyl methyl ether and washed with 20 ml of water and 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate and concentrated. The residue was dissolved in 25 ml of a 2 N solution of ammonia in ethanol. The solution was stirred at room temperature for 18 h. The reaction mixture was concentrated and purified by flash chromatography to give 640 mg (60%) of the title compound as a light brown foam.
  • reaction mixture was stirred at room temperature for 18 h, followed by dilution with 10 ml tert-butyl methyl ether and washing with 20 ml water and with 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and purified by flash chromatography to give 86 mg (55%) of the title compound as an off-white foam.
  • reaction mixture was allowed to slowly warm to room temperature during 5 h, followed by dilution with 20 ml ethyl acetate, washing with 10 ml brine and extraction with 20 ml ethyl acetate.
  • the combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 480 mg (64%) of the title compound as a white foam.
  • the title compound was obtained as a white solid in 23% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N- ⁇ 4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl ⁇ -N-methyl-isobutyramide using 2-(ethylamino)ethanol instead of 2-(methylamino)ethanol.

Abstract

The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula
Figure US20050090533A1-20050428-C00001
 wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.

Description

    BACKGROUND OF THE INVENTION
  • Schizophrenia is one of the major neuropsychiatric disorders, characterized by severe and chronic mental impairment. This devastating disease affects about 1% of the world's population. Symptoms begin in early adulthood and are followed by a period of interpersonal and social dysfunction. Schizophrenia manifests as auditory and visual hallucinations, paranoia, delusions (positive symptoms), blunted affect, depression, anhedonia, poverty of speech, memory and attention deficits as well as social withdrawal (negative symptoms).
  • For decades scientists and clinicians have made efforts with the aim of discovering an ideal agent for the pharmacological treatment of schizophrenia. However, the complexity of the disorders, due to a wide array of symptoms, has hampered those efforts. There are no specific focal characteristics for the diagnosis of schizophrenia and no single symptom is consistently present in all patients. Consequently, the diagnosis of schizophrenia as a single disorder or as a variety of different disorders has been discussed but not yet resolved. The major difficulty in the development of a new drug for schizophrenia is the lack of knowledge about the cause and nature of this disease. Some neurochemical hypotheses have been proposed on the basis of pharmacological studies to rationalize the development of a corresponding therapy: the dopamine, the serotonin and the glutamate hypotheses. But taking into account the complexity of schizophrenia, an appropriate multireceptor affinity profile might be required for efficacy against positive and negative signs and symptoms. Furthermore, an ideal drug against schizophrenia would preferably have a low dosage allowing once-per-day dosage, due to the low adherence of schizophrenic patients.
  • In recent years clinical studies with selective NK1 and NK2 receptor antagonists appeared in the literature showing results for the treatment of emesis, depression, anxiety, pain and migraine (NK1) and asthma (NK2 and NK1). The most exciting data were produced in the treatment of chemotherapy-induced emesis, nausea and depression with NK1 and in asthma with NK2-receptor antagonists. In contrast, no clinical data on NK3 receptor antagonists have appeared in the literature until 2000. Osanetant (SR 142,801) from Sanofi-Synthelabo was the first identified potent and selective non-peptide antagonist described for the NK3 tachykinin receptor for the potential treatment of schizophrenia, which was reported in the literature (Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 and Psychiatric Disorders Study 4, Schizophrenia, June 2003, Decision Resources, Inc., Waltham, Mass.). The proposed drug SR 142,801 has been shown in a phase II trial as active on positive symptoms of schizophrenia, such as altered behavior, delusion, hallucinations, extreme emotions, excited motor activity and incoherent speech, but inactive in the treatment of negative symptoms, which are depression, anhedonia, social isolation or memory and attention deficits.
  • The neurokinin-3 receptor antagonists have been described as useful in pain or inflammation, as well as in schizophrenia, Exp. Opinion. Ther. Patents (2000), 10(6), 939-960 and Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 956 and Psychiatric Disorders Study 4, Schizophrenia, June 2003, Decision Resources, Inc., Waltham, Mass.).
  • In addition, EP 1 192 952 describes a pharmaceutical composition containing a combination of a NK3 receptor antagonist and a CNS penetrant NK1 receptor antagonist for the treatment of depression and anxiety.
  • Now it has been found that the combination of the antidepressant, mood enhancing properties of NK1 receptor antagonism and the antipsychotic symptoms of NK3 receptor antagonism are suitable to treat both positive and negative symptoms in schizophrenia.
  • This advantage may be realized in the administration of an ideal drug against schizophrenia.
  • Some of the compounds of formula I are described in EP 1035115, WO 02/08232 or WO 02/16324.
  • They have been described as active at the NK1 receptor for the treatment of diseases related to this receptor, such as inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's disease, anxiety, pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases.
  • The neurokinin-1 receptor antagonists are further useful for the treatment of motion sickness, for treatment induced vomiting or for the treatment of psychoimmunologic or psychosomatic disorders, see Neurosci. Res., 1996, 7, 187-214, Can. J. Phys., 1997, 75, 612-621, Science, 1998, 281, 1640-1645, Auton. Pharmacol., 13, 23-93, 1993, WO 95/16679, WO 95/18124 and WO 95/23798, The New England Journal of Medicine, Vol. 340, No. 3 190-195, 1999, U.S. Pat. No. 5,972,938.
    • SUMMARY OF THE INVENTION
  • The present invention relates to the use of compounds of formula I and pharmaceutically acceptable salts thereof for the treatment of positive and negative symptoms in schizophrenia, novel compounds of formulas I, pharmaceutically active acid-addition salts thereof, all sterioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof, the preparation of the above-mentioned novel compounds, medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier or in the manufacture of corresponding medicaments.
  • Thus, in one embodiment the invention provides a method of treating schizophrenia which comprises administering a compound of formula
    Figure US20050090533A1-20050428-C00002
  • wherein
    • R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
    •  is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently
    •  hydrogen,
    •  —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl,
    •  wherein R′ and R″ on each carbon atom may be the same or different from each other,
    •  —Cb-alkyl,
    •  —C(O)H,
    •  —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
    •  —(CH2)cNR′R″,
    •  —(CH2)cNR′C(O)-alkyl,
    •  —(CH2)cNR′S(O)2-alkyl,
    •  —(CH2)dS(O)-alkyl,
    •  —(CH2)dS-alkyl,
    •  —(CH2)dS(O)2-alkyl;
    •  —(CH2)dS(O)2—NR′R″
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl; or
    • R4 and R5 form together with the N-atom to which they are attached a ring
    •  with —(CH2)e-, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
    •  —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—S(O)f—(CH2)c—, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —CH2CH═CH—CH2—, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with
    •  —(CH2)2—S(O)2N(CH3)—CH2, or with
    •  —S(O)—O—(CH2)g— or
    • —NR4R5 is
      Figure US20050090533A1-20050428-C00003
    • a is 0 or 1;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3;
    • e is 3, 4, or 5;
    • f is 0, 1, or 2; and
    • g is 2 or 3;
      or a pharmaceutically active acid-addition salt thereof.
  • The compounds of formula I may contain some asymmetric carbon atoms. Accordingly, the present invention includes all stereioisomeric forms of the compounds of formula I, including each of the individual enantiomers and mixtures thereof.
  • The compounds of formula I and their salts are characterized by valuable therapeutic properties. It has surprisingly been found that the compounds of formula I show a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
  • As used herein, the term “lower alkyl” denotes a straight- or branched-chain alkyl group containing from 1-4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like. The term “alkyl” denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms.
  • The terms “lower alkoxy” and “alkoxy” denote a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom.
  • The term “halogen” denotes chlorine, iodine, fluorine and bromine.
  • The term “cycloalkyl” denotes a saturated carbocyclic group containing 3-6 carbon atoms.
  • The term “aryl” means a monovalent cyclic aromatic hydrocarbon group consisting of one or more fused rings in which at least one ring is aromatic in nature. Examples of aryl radicals include, but are not limited to, phenyl, naphthyl, biphenyl, indanyl, anthraquinolyl, and the like. The preferred aryl group is phenyl.
  • “Heteroaryl” means a monovalent aromatic carbocyclic group having one or more rings incorporating one, two, or three heteroatoms within the ring wherein the heteroatoms are chosen from nitrogen, oxygen, or sulfur. Examples of heteroaryl radicals include, but are not limited to, imidazolyl, isoxazolyl, thiazolyl, pyrazinyl, thiophenyl, furanyl, pyranyl, pyridinyl, quinolinyl, isoquinolinyl, benzofuryl, benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzothiazolyl, benzopyranyl, indazolyl, indolyl, isoindolyl, naphtyridinyl, and the like. Preferred heteroaryl groups are isoxazolyl and pyridinyl.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • The term “pharmaceutically acceptable acid addition salt” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • In one embodiment the invention provides a method of treating schizophrenia which comprises administering a compound of formula
    Figure US20050090533A1-20050428-C00004
    wherein
    • R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
    •  is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently
    •  hydrogen,
    •  —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl,
    •  wherein R′ and R″ on each carbon atom may be the same or different from each other,
    •  —Cb-alkyl,
    •  —C(O)H,
    •  —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
    •  —(CH2)cNR′R″,
    •  —(CH2)cNR′C(O)-alkyl,
    •  —(CH2)cNR′S(O)2-alkyl,
    •  —(CH2)dS(O)-alkyl,
    •  —(CH2)dS-alkyl,
    •  —(CH2)dS(O)2-alkyl, or
    •  —(CH2)dS(O)2—NR′R″;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl; or
    • R4 and R5 form together with the N-atom to which they are attached a ring
    •  with —(CH2)e-, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
    •  —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)r—O—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—S(O)f—(CH2)c-, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)cOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —CH2CH═CH—CH2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with —(CH2)2—S(O)2N(CH3)—CH2, or with —S(O)—O—(CH2)g—;
    • or —NR4R5 is
      Figure US20050090533A1-20050428-C00005
    • a is 0 or 1;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3;
    • e is 3, 4, or 5;
    • f is 0, 1, or 2; and
    • g is 2 or 3;
      or a pharmaceutically active acid-addition salt thereof.
  • In another embodiment, the invention provides a method of treating schizophrenia which comprises administering a compound of 1 formula
    Figure US20050090533A1-20050428-C00006
  • wherein
    • R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-lower alkyl, —S(O)2-lower alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-lower alkyl, and —NR′S(O)2-lower alkyl, or
    •  is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl, and oxazolyl, each of which is unsubstituted or substituted by lower alkyl, halogen or lower alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently
    •  hydrogen,
    •  —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-lower alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
    •  —Cb-alkyl,
    •  —C(O)H, —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
    •  —(CH2)cNR′C(O)-lower alkyl, —(CH2)cNR′S(O)2-lower alkyl, or
    •  —(CH2)dS(O)2-lower alkyl;
    • R′ is hydrogen, lower alkyl, —(CH2)dOH, —C(O)H, —C(O)-lower alkyl, —C(O)-cycloalkyl or S(O)2-lower alkyl;
    • R″ is hydrogen or lower alkyl; or
    • R4 and R5 form together with the N-atom to which they are attached a ring with
    •  —(CH2)e-, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, CF3, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
    •  —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—S(O)f—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —CH2CH═CH—CH2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
    • a is 0 or 1;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3;
    • e is 3, 4 or 5;
    • f is 0, 1, or 2; and
    • g is 2 or 3;
      or a pharmaceutically active acid-addition salts thereof as described above.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R1, R4 and R5 have the definitions as described in formula I-1 and R2 and R3 are both CF3.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e-, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, —NR′R″, —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl, and —C(O)NR′R″.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, wherein the ring is mono substituted by —CH2OH or disubstituted by hydroxy and —CH2OH. Examples of such compounds include
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, wherein the ring is disubstituted by NHC(O)CH3 and —CH2OH. An example of such compounds is
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, wherein the ring is disubstituted by ═O and —CH2OH. Examples of such compounds are
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1 wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, wherein the ring is di- or tri-substituted by halogen and —CH2OH. Examples of such compounds are
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 are each independently hydrogen, —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-lower alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other, or are —Cb-alkyl, —C(O)H, —(CH2)dcycloalkyl which is unsubstituted or substituted by hydroxy,
  • —(CH2)cNR′C(O)-lower alkyl, —(CH2)cNR′S(O)2-lower alkyl, —(CH2)dS(O)2-lower alkyl,
      • C(O)(CH2)dOH; R′ is hydrogen, lower alkyl, —(CH2)dOH, —C(O)-lower alkyl, —C(O)-cycloalkyl or S(O)2-lower alkyl; and R″ is hydrogen or lower alkyl.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 are each independently hydrogen, —CH(CH2OH)CH2OH or —(CH2)cOH. Examples of such compounds are
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, —NR′R″, —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl and —C(O)NR′R″.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)2—O—(CH2)2—, wherein the ring is substituted by —CH2OH.
  • Examples of such compounds are
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)C—S(O)f—(CH2)2—, which is unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, —NR′R″, —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl and —C(O)NR′R″.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)2—S(O)2—(CH2)2—, wherein the ring is mono-substituted by —CH2OH. Examples of such compounds are
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R1, R4 and R5 have the definitions as described above and R2 and R3 are other than di-CF3.
  • In another embodiment of the invention, the method employs a compound of formula I-1, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4— wherein the ring is mono substituted by —CH2OH or disubstituted by OH and
  • —CH2OH. Examples of such compounds are
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • (2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention provides a compound of formula
    Figure US20050090533A1-20050428-C00007
  • wherein
    • R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-lower alkyl, —S(O)2-lower alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-lower alkyl, and —NR′S(O)2-lower alkyl, or
    •  is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl, and oxazolyl, each of which is unsubstituted or substituted by lower alkyl, halogen or lower alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently
    •  hydrogen,
    •  —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-lower alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
    •  —Cb-alkyl,
    •  —C(O)H, —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
    •  —(CH2)cNR′C(O)-lower alkyl, —(CH2)cNR′S(O)2-lower alkyl, or
    •  —(CH2)dS(O)2-lower alkyl;
    • R′ is hydrogen, lower alkyl, —(CH2)dOH, —C(O)H, —C(O)-lower alkyl, —C(O)-cycloalkyl or S(O)2-lower alkyl;
    • R″ is hydrogen or lower alkyl; or
    • R4 and R5 form together with the N-atom to which they are attached a ring with
    •  —(CH2)e-, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, CF3, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
    •  —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alky, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —(CH2)c—S(O)f—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
    •  —CH2CH═CH—CH2—, which is unsubstituted or substituted
      • by one or more substituents, selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
    • a is 0 or 1;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3;
    • e is 3, 4 or 5;
    • f is 0, 1, or 2; and
    • g is 2 or 3;
      or a pharmaceutically active acid-addition salts thereof as described above.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 are each independently hydrogen,
  • —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH, or —(CR′R″)l—(CR′R″)l—(CR′R″)a-lower alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other, or are Cb-alkyl. Examples of these compounds are
    • N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[(2-hydroxy-ethyl)-propyl-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl, R4 is hydrogen and R5 is —(CH2)d-cycloalkyl, unsubstituted or substituted by hydroxy. Examples of these compounds are
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl, R4 is hydrogen and R5 is —(CH2)cNR′C(O)-lower alkyl or —(CH2)dS(O)2-lower alkyl. Examples of such compounds are
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • N-[6-(2-acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, which ring is substituted by one or two groups —(CR′R″)dOH. Examples of such compounds are
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3-fluoro-5′-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
    • (S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-benzamide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, which ring is substituted by one to three substituents selected from the group consisting of —NR′R″, —(CH2)d—C(O)-lower alkyl,
      • CH2OH, —(CH2)d-pyrrolidinyl, —(CH2)d—S(O)2-lower alkyl, ═O, halogen and —(CH2)dOC(O)NR′R″. Examples of such compounds are
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
    • (S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide or
    • (S)-dimethyl-carbamic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-pyrrolidin-2-ylmethyl ester.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)h—, which ring is mono- or di-substituted by —(CH2)dOH or —NR′R″, wherein h is 3 or 5. Examples of such compounds are
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-(2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[4-amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • N-[4-acetylamino-4′(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and
    • (2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with
  • —(CH2)g—NR′—(CH2)2—, which is unsubstituted or mono-or di-substituted by —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —NR′R″ or ═O. Examples of such compounds are
    • N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)2, —O—(CH2)2—, which is unsubstituted or mono- or -di-substituted by —(CR′R″)dOH. Examples of such compounds are
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl and R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—S(O)f—(CH2)2—, which is unsubstituted or mono-or di-substituted by —(CR′R″)dOH Examples of such compounds are
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted phenyl as described above and R4 and R5 form together with the N-atom to which they are attached a ring with —CH2CH═CH—CH2—, which is unsubstituted or mono-substituted by, —(CR′R″)dOH. One such compound is
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • In another embodiment, the invention is a compound of formula I-1, wherein R1 is unsubstituted or substituted heteroaryl as described above. Examples of such compounds are
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxazol-4-yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • N-{6′-[bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-4-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • N-{6′-[bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-{6′-[(2-hydroxy-ethyl)-methyl-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-N-methyl-isobutyramide.
  • Preferred is the use of compounds of formula I, wherein R1, R4 and R5 have the definitions as described above and R2 and R3 are both CF3.
  • Further preferred is the use of compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e—, which ring is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or substituted by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″.
  • Preferred is also the use of compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e-, wherein the ring is mono or di-substituted by hydroxy, —CH2OH or —C(O)H. Examples of such compounds are
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-formyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide.
  • Preferred are further compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e—, wherein the ring is mono or di-substituted by NH2, NHS(O)2CH3, NCH3S(O)2CH3, N(CH2CH3)S(O)2CH3, NHC(O)CH3 and —CH2OH. Examples of such compounds are
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-(methanesulfonyl-methyl-amino)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(ethyl-methanesulfonyl-amino)-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • A further preferred group of compounds are further those, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4— and wherein the ring is disubstituted by ═O and —CH2OH, for example the following compounds:
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)4—, wherein the ring is di- or tri-substituted by halogen and —CH2OH, are also preferred. The following compounds relate to this group:
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • A further preferred group of compounds are those, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e—, wherein the ring is substituted by CH2S(O)2CH3, CH2SCH3 or CH2S(O)CH3. Examples of such compounds are
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(RS)-3-((RS)-methanesulfinylmethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide and
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Other preferred compounds of formula 1 are those, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e-, wherein the ring is substituted by S(O)2CH3, SCH3, S(O)CH3 or S(O)2N(CH3)2, for example the following compounds:
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methylsulfanyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfinyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • Compounds, wherein —NR4R5 is
    Figure US20050090533A1-20050428-C00008
    and R′ is as described in claim 1, are further preferred, which compounds are
    • (1S,3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (rac)-(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-4λ6-thia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5λ6-thia-9-aza-spiro [5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,4,4-tetraoxo-lλ6,4λ6-dithia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,5,5-tetraoxo-lλ6,4λ6-dithia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-8-aza-spiro [4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl-phenyl)-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8%-thia-3-aza-bicyclo [3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (1R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Another group of preferred compounds of formula I are those wherein R4 and R5 are each independently hydrogen; —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other; —Cb-alkyl; —C(O)H; —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy; or is —(CH2)cNR′R″, —(CH2)cNR′C(O)-alkyl, —(CH2)cNR′S(O)2-alkyl, —(CH2)dS(O)-alkyl, —(CH2)dS-alkyl, —(CH2)fS(O)2-alkyl or —(CH2)dS(O)2—NR′R″.
  • Especially preferred compounds from this group are those, wherein R4 and R5 are each independently hydrogen, —CH(CH2OH)CH2OH or —(CH2)cOH, for example,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Compounds of formula I, wherein R4 and R5 are each independently hydrogen, (CH2)2SCH3, (CH2)2S(O)2CH3 or (CH2)2S(O)2NHCH3 are also preferred. Examples of such compounds are
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Other preferred compounds are those, wherein R4 and R5 are each independently hydrogen, (CH2)2NH2, (CH2)2NHS(O)2CH3 or (CH2)2NHC(O)CH3, for example,
    • N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • N-[6-(2-acetylamino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • Preferred are further compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with
  • —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted by one or more substituent selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″.
  • To this group relate compounds, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)2—O—(CH2)2—, wherein the ring is unsubstituted or substituted by —CH2OH, for example,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
  • Another preferred group are compounds of formula I, wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—S(O)f—(CH2)v—, which is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″.
  • Especially preferred compounds from this group are those wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)2—S(O)2—(CH2)2—, wherein the ring is unsubstituted or substituted by —CH2OH or methyl. Examples of such compounds are
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1RS,4RS)- or (1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 349),
    • (1RS,4SR)- or (1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 348),
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1,1-dioxo-lλ6-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (−)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methyl-1,1-dioxo-1%6-[1,2,4]thiadiazinan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Preferred are also compounds wherein R1, R4 and R5 have the definitions as describe above and R2 and R3 are other than di-CF3. Examples of such compounds are
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide and
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • A preferred group of compounds of formula I are compounds wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″.
  • Preferred from this group are those compounds wherein R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—NR′—(CH2)2—, and wherein R′ on the N-atom is hydrogen, lower alkyl, C(O)H, C(O)CH3, C(O)-cyclopropyl,
  • S(O)2-alkyl, S(O)2—CH2C1 or S(O)2—N(CH3)2. Examples of such compounds are
    • N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(4-acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide and
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • The following compounds of formulas IA to IJ, are novel.
  • Encompassed by formula I are compounds of formula IA
    Figure US20050090533A1-20050428-C00009
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently
    •  hydrogen,
    •  —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH, or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other and are hydrogen
    •  or Cb-alkyl;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
    • R″ is hydrogen or alkyl;
    • a is 0 or 1;
    • b is 1 or 2; and
    • d is 0, 1, 2 or 3;
      or a pharmaceutically active acid-addition salt thereof.
  • Some specific compounds of formula IA are
    • N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[(2-hydroxy-ethyl)-propyl-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide.
  • Other compounds of formula I are compounds of formula IB
    Figure US20050090533A1-20050428-C00010
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 are each independently hydrogen, —(CH2)2SCH3, —(CH2)2S(O)2CH3, —(CH2)2S(O)2NHCH3, —(CH2)2NH2, —(CH2)2NHS(O)2CH3 or —(CH2)2NHC(O)CH3;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2; and
    • d is 0, 1, 2, or 3;
      or a pharmaceutically active acid-addition salt thereof.
  • Some specific compounds of formula IB are
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Also encompassed by formula I are compounds of formula IC
    Figure US20050090533A1-20050428-C00011
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 is hydrogen;
    • R5 is —(CH2)0-cycloalkyl, unsubstituted or substituted by hydroxy;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2; and
    • d is 0, 1, 2, or 3;
      or a pharmaceutically active acid-addition salt thereof.
  • Some compounds of formula IC are trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Other compounds encompassed by formula I are compounds of formula-ID
    Figure US20050090533A1-20050428-C00012
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e-, which is unsubstituted or substituted by one or more substituents selected from the group consisting of —(CR′R″)dOH;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2;
    • d is 0, 1, 2, or 3; and
    • e is 3, 4, or 5;
      or a pharmaceutically active acid-addition salt thereof.
  • Examples of compounds of formula ID are
  • wherein the compounds are selected from the group consisting of
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(27-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
    • (S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-benzamide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and
    • (2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide.
  • Specific compounds of formula ID, encompassed by formula I, which ring is substituted by one to three substituents, selected from the group consisting of —NR′R″, —(CH2)d—C(O)-lower alkyl, —CH2OH, —(CH2)d-pyrrolidinyl, —(CH2)d—S(O)2-alkyl, ═O, halogen or —(CH2)dOC(O)NR′R″, are the followings
    • (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
    • (S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide or (S)-dimethyl-carbamic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-pyrrolidin-2-ylmethyl ester.
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-(2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[4-amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • N-[4-acetylamino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
    • (3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
    • (3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and
    • (2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • Other compounds of formula I are specific compounds of formula IE
    Figure US20050090533A1-20050428-C00013
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 form together with the N-atom to which they are attached a ring with
    •  —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3; and
    • e is 3, 4, or 5;
      or a pharmaceutically active acid-addition salt thereof.
  • Examples of compounds of formula IE are
    • N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (3S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-N-[6-(4-acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide and
    • 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • Additional compounds of formula I are compounds of formula IF
    Figure US20050090533A1-20050428-C00014
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl,
    •  or is heteroaryl selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3; and
    • R4 and R5 form together with the N-atom to which they are attached a ring with
    •  —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituent selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, or 3; and
    • e is 3, 4, or 5;
      or a pharmaceutically active acid-addition salt thereof.
  • Compounds of formula IF include
    • (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
  • Formula I also encompasses compounds of formula IG I
    Figure US20050090533A1-20050428-C00015
  • wherein
    • R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • R4 and R5 form together with the N-atom to which they are attached a ring with
    •  —(CH2)c—S(O)f—(CH2)2—, which is unsubstituted or substituted
      • by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)d, or
      • by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
    • R″ is hydrogen or alkyl;
    • b is 1 or 2;
    • c is 1, 2, or 3;
    • d is 0, 1, 2, 3 or 4; and
    • e is 3, 4, or 5; and
    • f is 0, 1, or 2;
      or a pharmaceutically active acid-addition salt thereof.
  • Examples of compounds of formula IG include
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1RS,4RS)- or (1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 349),
    • (1RS,4SR)- or (1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 348),
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1,1-dioxo-lλ6-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (−)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • The invention relates also to compounds of formula I, wherein R1 is unsubstituted or substituted phenyl as described above and R4 and R5 form together with the N-atom to which they are attached a ring with —CH2CH═CH—CH2—, which is unsubstituted or mono-substituted by —(CR′R″)dOH. An example of such a compound
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • Other compounds of formula I are compounds of formula IH
    Figure US20050090533A1-20050428-C00016
  • wherein
    • R1 is heteroaryl selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
      and the other substituents are as described in formula I above.
  • Examples for compounds of formula IH are
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxazol-4-yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • N-{6′ [bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
    • (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-4-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide,
    • N-{6′-[bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-{6′-[(2-hydroxy-ethyl)-methyl-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-N-methyl-isobutyramide.
  • Also encompassed by formula I are compounds of compounds of formula I J,
    Figure US20050090533A1-20050428-C00017
  • wherein
    • R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl,
    •  or is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
    • R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
    • —NR4R5 are
      Figure US20050090533A1-20050428-C00018
    • R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
    • R″ is hydrogen or alkyl;
    • b is 1 or 2;
    • d is 0, 1, 2, or 3; and
    • f is 0, 1, or 2;
      or a pharmaceutically active acid-addition salt thereof.
  • Examples of such compounds are
    • (1S,3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (rac)-(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-lλ6-thia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5λ6-thia-9-aza-spiro [5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,4,4-tetraoxo-lλ6,4λ6-dithia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,5,5-tetraoxo-lλ6,5λ6-dithia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-8-aza-spiro [4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl-phenyl)-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8%-thia-3-aza-bicyclo [3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
    • (1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
    • (1R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, described in schemes 1 to 14 and in specific examples 1 to 421 and, for example, by a process described below, which process comprises
    • a) reacting a compound of formula
      Figure US20050090533A1-20050428-C00019
    •  with a compound of formula
      NHR4R5  III
    •  to produce a compound of formula
      Figure US20050090533A1-20050428-C00020
    •  wherein R1, R2, R3, R4 and R5 have the significances given above, or
    • b) reacting a compound of formula
      Figure US20050090533A1-20050428-C00021
    •  with a compound of formula
      R1—B(OH)2 or
      Figure US20050090533A1-20050428-C00022
    •  or
      R1—ZnCl
    •  to produce a compound of formula
      Figure US20050090533A1-20050428-C00023
    •  wherein R1, R2, R3, R4 and R5 have the significances given above, and
    •  if desired, modifying one or more substituents R1-R5 within the definitions given above, and
    •  if desired, converting the compound obtained into a pharmaceutically acceptable acid addition salt.
  • In general, the compounds of formula I may be prepared as follows:
    • a) To a solution of a compound of formula II, for example N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and an amine of formula III, for example L-prolinol in dimethyl sulfoxide, Na2CO3 or K2CO3 is added, and the solution is stirred at 120-150° C. for about 22 h. After cooling to ambient temperature, the solution is worked up in conventional manner or
    • b) A mixture of a compound of formula IV, 2-chlorophenylboronic acid, palladium(II)acetate, triphenylphosphine, sodium carbonate and dimethoxyethane is heated at about 80° C. for 90 min. Then the reaction mixture is cooled to room temperature, worked up and purified.
  • The salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.
  • The following schemes 1-14 describe the processes for preparation of compounds of formula I in more detail. The starting materials are known compounds, described in EP 1035115, WO 02/08232 or WO 02/16324, or they may be prepared according to methods known in the art. Furthermore, the preparation of intermediates 1, 2, 3A-3L, 4A-4L and 5A-5I are described in more detail in the experimental part.
  • In the schemes the following abbreviations have been used:
    DMF N,N-dimethylformamide
    TFA trifluoroacetic acid
    DME ethylene glycol dimethyl ether
    KHMDS potassium hexamethyldisilazide
    DMSO di-methyl sulfoxide
    TBDMS tert-butyldimethylsilyl-protecting group
    THF tetrahydrofuran
    Oxone potassium peroxymonosulfate
    DEAD diethyl azodicarboxylate
    DIAD diisopropyl azodicarboxylate
    DMAP 4-(N,N-dimethylamine)pyridine
    RT room temperature
    DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
    MW microwave
    MCPBA 3-chloroperbenzoic acid
  • Figure US20050090533A1-20050428-C00024
    Figure US20050090533A1-20050428-C00025
    Figure US20050090533A1-20050428-C00026
    Figure US20050090533A1-20050428-C00027
    wherein R1, R2, R4 and R5 have the meaning as described above.
    Figure US20050090533A1-20050428-C00028
    wherein R1, R2, R3, R4 and R5 have the meaning as described above.
    Figure US20050090533A1-20050428-C00029
    wherein R1, R2, R3 and R5 have the meaning as described above.
    Figure US20050090533A1-20050428-C00030
    wherein R1, R2 and R3, have the meaning as described above.
    Figure US20050090533A1-20050428-C00031
    wherein R1, R2 and R3 have the meaning as described above.
    • Method 7
  • The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by
      • reacting a compound of formula
        Figure US20050090533A1-20050428-C00032
        wherein R4 or R5 contain an —OH substituent to form a compound of formula I in which the absolute configuration at the carbon center, to which the —OH group is attached, is reversed. This is effected by reacting the compound of formula I wherein R4 or R5 contain an —OH substituent with triphenylphosphine, diethyl or diisopropyl azodicarboxylate and benzoic acid in THF followed by treatment with sodium methylate or sodium hydroxide in methanol.
        Figure US20050090533A1-20050428-C00033
        Figure US20050090533A1-20050428-C00034
        Figure US20050090533A1-20050428-C00035
        Figure US20050090533A1-20050428-C00036
        Figure US20050090533A1-20050428-C00037
        Figure US20050090533A1-20050428-C00038
        Figure US20050090533A1-20050428-C00039
    Method 15
  • The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by
      • reacting a compound of formula
        Figure US20050090533A1-20050428-C00040
        wherein R4 or R5 contain an —OH substituent to form a compound of formula I in which the —OH group has been transformed into an —S-alkyl, —S(O)-alkyl or S(O)2-alkyl group under inversion of the absolute configuration at the carbon center to which the —OH group has been attached using the following procedure:
  • The —OH group is first transformed into a —OS(O)2CH3 group by reaction with methanesulfonyl chloride and triethylamine in dichloromethane. By treatment with the salt of a thioalkane such as sodium methanethiolate in methanol or DMF the —OS(O)2CH3 group is further transformed into the —S-alkyl group. The —S-alkyl group can be oxidized to an —S(O)-alkyl group by treatment with Oxone in methanol or MCPBA in dichloromethane. The compounds of formula I containing an —S(O)-alkyl group can be isolated or oxidized further without isolation to compounds containing an —S(O)2-alkyl group by treatment with Oxone in methanol or MCPBA in dichloromethane (Examples 331 and 388).
    • Method 16
  • The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by
      • reacting a compound of formula
        Figure US20050090533A1-20050428-C00041
        wherein R4 or R5 contain an —OH substituent to form a compound of formula I in which the —OH group has been transformed into an —S(O)2—NR′R″ group under inversion of the absolute configuration at the carbon center to which the —OH group has been attached using the following procedure:
  • The —OH group is transformed into a —SC(O)CH3 group by reaction with triphenylphosphine, diethyl azodicarboxylate and thioacetic acid in THF. The —SC(O)CH3 group is oxidized to an —SO3H group by reaction with an aqueous solution of hydrogen peroxide in acetic acid. Compounds containing the —SO3H are treated consecutively with oxalyl chloride and a catalytic amount of DMF in dichloromethane and an amine to form compounds of formula I wherein R or R5 contain an —S(O)2—NR′R″ group.
  • As mentioned earlier, the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are dual antagonists of the Neurokinin 1 and 3 receptors.
  • The compounds were investigated in accordance with the tests given hereinafter.
    • NK1
  • The affinity of test compounds for the NK1 receptor was evaluated at human NK1 receptors in CHO cells infected with the human NK1 receptor (using the Semliki virus expression system) and radiolabelled with [3H]substance P (final concentration 0.6 nM). Binding assays were performed in HEPES buffer (50 mM, pH 7.4) containing BSA (0.04%) leupeptin (16.8 μg/ml), MnCl2 (3 mM) and phosphoramidon (2 μM). Binding assays consisted of 250 μl of membrane suspension (approximately 1.5 μg/well in a 96 well plate), 0.125 μl of buffer of displacing agent and 125 μl of [3H]substance P. Displacement curves were determined with at least seven concentrations of the compound. The assay tubes were incubated for 60 min at room temperature after which time the tube contents were rapidly filtered under vacuum through GF/C filters presoaked for 60 min with PEI (0.3%) with 3×1 ml washes of HEPES buffer (50 mM, pH 7.4). The radioactivity retained on the filters was measured by scintillation counting. All assays were performed in duplicate in at least 2 separate experiments.
    • NK3
  • Recombinant human NK3 (hNK3) receptor affinity was determined in a 96 well plate assay, using [3H]SR142801 (final concentration 0.3 nM) to radiolabel the hNK3 receptor in the presence of 10 concentrations of competing compound or buffer. Non specific binding was determined using 10 μM SB222200. Assay buffer consisted of Tris-HCl (50 mM, pH 7.4), BSA (0.1%), MnCl2 (4 mM) and phosphoramidon (1 μM). Membrane preparations of hNK3 receptors (approximately 2.5 μg/well in a 96 well plate) were used to initiate the incubation for 90 min at room temperature. This assay was terminated by rapid filtration under vacuum through GF/C filters, presoaked for 90 min with PEI (0.3%), with 3×0.5 ml washes of ice-cold Tris buffer (50 mM, pH 7.4) containing 0.1% BSA. The radioactivity retained on the filters was measured by scintillation counting. All assays were performed in duplicate in at least two separate experiments.
  • The activity of the present compounds is described in the table below:
    Subst. pKi
    on R1 R2/R3 R4 R5 R1 NK1/NK3 Expl.
    2-Cl 3,5-di Cl —(CH2)2OH H phenyl 8.56/8.05 1
    2-Cl 3,5-di Cl are together with the N-atom phenyl 8.47/9.05 2
    Figure US20050090533A1-20050428-C00042
    2-Cl 3,5-di Cl are together with the N-atom phenyl 8.85/9.06 3
    Figure US20050090533A1-20050428-C00043
    2-Cl 3-F/5-CF3 are together with the N-atom phenyl 8.35/8.81 4
    Figure US20050090533A1-20050428-C00044
    2-Cl 3-F/5-CF3 are together with the N-atom phenyl 8.81/8.76 5
    Figure US20050090533A1-20050428-C00045
    2-Cl 3,5-di-F are together with the N-atom phenyl 8.14/8.31 6
    Figure US20050090533A1-20050428-C00046
    2-Cl 3-OCH3/ are together with the N-atom phenyl 8.32/8.75 7
    5-Cl
    Figure US20050090533A1-20050428-C00047
    2-Cl 3-OCH3/ are together with the N-atom phenyl 8.77/8.90 8
    5-Cl
    Figure US20050090533A1-20050428-C00048
    2-Cl 3,5-di- are together with the N-atom phenyl 8.19/8.44 9
    CH3
    Figure US20050090533A1-20050428-C00049
    2-Cl 3,5-di- are together with the N-atom phenyl 8.67/8.44 10
    Figure US20050090533A1-20050428-C00050
    2-CH3 3,5-di-Cl are together with the N-atom phenyl 8.75/8.96 11
    Figure US20050090533A1-20050428-C00051
    2-CH3 3,5-di-Cl are together with the N-atom phenyl 8.95/8.86 12
    Figure US20050090533A1-20050428-C00052
    2-CH3 3-CF3/ are together with the N-atom phenyl 8.66/8.81 13
    5-F
    Figure US20050090533A1-20050428-C00053
    2-CH3 3-F/5-CF3 are together with the N-atom phenyl 8.89/8.52 14
    Figure US20050090533A1-20050428-C00054
    2-CH3 3,5-di-F are together with the N atom phenyl 8.20/8.35 15
    Figure US20050090533A1-20050428-C00055
    2-CH3 3,5-di-F are together with the N-atom phenyl 8.58/8.39 16
    Figure US20050090533A1-20050428-C00056
    2-CH3 3-OCH3/ are together with the N-atom phenyl 8.41/8.50 17
    5-Cl
    Figure US20050090533A1-20050428-C00057
    2-CH3 3-OCH3/ are together with the N-atom phenyl 8.93/8.60 18
    5-Cl
    Figure US20050090533A1-20050428-C00058
    2-CH3 3,5-di-CH3 are together with the N-atom phenyl 8.53/8.29 19
    Figure US20050090533A1-20050428-C00059
    2-CH3 3,5-di-CH3 are together with the N-atom phenyl 8.94/8.21 20
    Figure US20050090533A1-20050428-C00060
    2-CH3/4-F 3,5-di-Cl —(CH2)2OH H phenyl 8.89/8.06 21
    2-CH3/4-F 3,5-di-Cl are together with the N-atom phenyl 8.29/8.93 22
    Figure US20050090533A1-20050428-C00061
    2-CH3/4-F 3,5-di-Cl are together with the N-atom phenyl 9.05/8.80 23
    Figure US20050090533A1-20050428-C00062
    2-CH3/4-F 3-CF3/5-F are together with the N-atom phenyl 8.88/9.05 24
    Figure US20050090533A1-20050428-C00063
    2-CH3/4-F 3-CF3/5-F are together with the N-atom phenyl 9.03/8.76 25
    Figure US20050090533A1-20050428-C00064
    2-CH3/4-F H/5-CF3 are together with the N-atom phenyl 8.52/8.24 26
    Figure US20050090533A1-20050428-C00065
    2-CH3/4-F H/5-CF3 are together with the N-atom phenyl 8.82/7.97 27
    Figure US20050090533A1-20050428-C00066
    2-CH3/4-F 3,5-di-F are together with the N-atom phenyl 8.55/8.40 28
    Figure US20050090533A1-20050428-C00067
    2-CH3/4-F 3,5-di-F are together with the N-atom phenyl 8.81/8.45 29
    Figure US20050090533A1-20050428-C00068
    2-CH3/4-F 3-OCH3/5-Cl are together with the N-atom phenyl 8.43/8.45 30
    Figure US20050090533A1-20050428-C00069
    2-CH3/4-F 3-OCH3/5-Cl are together with the N-atom phenyl 9.01/8.78 31
    Figure US20050090533A1-20050428-C00070
    2-CH3/4-F 3,5-di-CH3 are together with the N-atom phenyl 8.51/8.52 32
    Figure US20050090533A1-20050428-C00071
    2-CH3/4-F 3,5-di-CH3 are together with the N-atom phenyl 8.93/8.52 33
    Figure US20050090533A1-20050428-C00072
    2-Cl 3-OCHF2/ are together with the N-atom phenyl 8.41/9.08 34
    5-Cl
    Figure US20050090533A1-20050428-C00073
    2-Cl 3-OCHF2/ are together with the N-atom phenyl 8.71/9.26 35
    5-Cl
    Figure US20050090533A1-20050428-C00074
    2-CH3 3-OCHF2/ are together with the N-atom phenyl 8.37/9.15 36
    5-Cl
    Figure US20050090533A1-20050428-C00075
    2-CH3 3-OCHF2/ are together with the N-atom phenyl 8.92/9.21 37
    5-Cl
    Figure US20050090533A1-20050428-C00076
    2-CH3/4-F 3-OCHF2/ are together with the N-atom phenyl 8.45/8.65 38
    Figure US20050090533A1-20050428-C00077
    2-CH3/4-F 3-OCHF2/ are together with the N-atom phenyl 8.98/8.89 39
    Figure US20050090533A1-20050428-C00078
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.19/8.99 40
    Figure US20050090533A1-20050428-C00079
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.97/8.12 41
    Figure US20050090533A1-20050428-C00080
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.78/9.08 42
    Figure US20050090533A1-20050428-C00081
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.62/7.45 43
    Figure US20050090533A1-20050428-C00082
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.20/7.81 44
    Figure US20050090533A1-20050428-C00083
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.64/8.70 45
    Figure US20050090533A1-20050428-C00084
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.22/8.06 46
    Figure US20050090533A1-20050428-C00085
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.71/8.20 47
    Figure US20050090533A1-20050428-C00086
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.27/8.06 48
    Figure US20050090533A1-20050428-C00087
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.32/7.83 49
    Figure US20050090533A1-20050428-C00088
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.85/7.84 50
    Figure US20050090533A1-20050428-C00089
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.19/7.54 51
    Figure US20050090533A1-20050428-C00090
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.96/8.10 52
    Figure US20050090533A1-20050428-C00091
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.60/7.61 53
    Figure US20050090533A1-20050428-C00092
    2-Cl 3,5-di-CF3 —(CH2)2OH —CH3 phenyl 9.00/8.57 54
    2-Cl 3,5-di-CF3 —(CH2)2OH —CH2CH3 phenyl 8.48/7.95 55
    2-Cl 3,5-di-CF3 —(CH2)2OH —(CH2)2CH3 phenyl 8.34/8.28 56
    2-Cl 3,5-di-CF3 —(CH2)2OH —(CH2)3CH3 phenyl 8.00/7.56 57
    2-Cl 3,5-di-CF3 —CH2CH(OH) CH3 phenyl 8.62/8.24 58
    CH2OH
    2-Cl 3,5-di-CF3 CH(CH2OH) H phenyl 8.49/8.31 59
    CH2CH(CH3)2
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00093
         		H phenyl 8.90/8.10 60
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.38/7.85 61
    Figure US20050090533A1-20050428-C00094
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.99/8.18 62
    Figure US20050090533A1-20050428-C00095
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.74/8.93 63
    Figure US20050090533A1-20050428-C00096
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.00/8.54 64
    Figure US20050090533A1-20050428-C00097
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.94/8.56 65
    Figure US20050090533A1-20050428-C00098
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.83/8.89 66
    Figure US20050090533A1-20050428-C00099
    2-Cl 3,5-di-CF3 —(CH2)2OH H phenyl 9.14/7.94 67
    2-CH3/4-F 3,5-di-CF3 —(CH2)2OH H phenyl 8.84/8.49 68
    2-Cl/4-F 3,5-di-CF3 —(CH2)2OH H phenyl 8.95/7.84 69
    2-Cl/4-Cl 3,5-di-CF3 —(CH2)2OH H phenyl 8.70/8.39 70
    2-Cl/4-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00100
         		H phenyl 8.69/8.04 71
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00101
         		H phenyl 9.14/7.58 72
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00102
         		H phenyl 9.06/8.13 73
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00103
         		H phenyl 9.06/8.24 74
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00104
         		H phenyl 8.77/7.91 75
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00105
         		H phenyl 8.80/7.97 76
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00106
         		H phenyl 9.19/8.32 77
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00107
         		H phenyl 8.55/8.21 78
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00108
         		H phenyl 8.87/7.98 79
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00109
         		H phenyl 8.90/8.05 80
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00110
         		H phenyl 8.68/8.25 81
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00111
    Figure US20050090533A1-20050428-C00112
         		phenyl 9.03/9.09 82
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00113
    Figure US20050090533A1-20050428-C00114
         		phenyl 8.93/8.96 83
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00115
    Figure US20050090533A1-20050428-C00116
         		phenyl 8.47/8.76 84
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00117
    Figure US20050090533A1-20050428-C00118
         		phenyl 8.63/8.64 85
    2-Cl/4-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00119
    Figure US20050090533A1-20050428-C00120
         		phenyl 8.78/8.45 86
    3-Cl/4-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00121
    Figure US20050090533A1-20050428-C00122
         		phenyl 8.80/8.02 87
    4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00123
    Figure US20050090533A1-20050428-C00124
         		phenyl 8.87/8.03 88
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00125
         		H phenyl 9.31/8.49 89
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00126
         		H phenyl 8.75/8.22 90
    2-Cl/4-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00127
         		H phenyl 8.61/8.25 91
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00128
         		H phenyl 8.99/7.67 92
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.95/8.13 93
    Figure US20050090533A1-20050428-C00129
    2-Cl/4-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.37/7.83 94
    Figure US20050090533A1-20050428-C00130
    3-Cl/4-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.42/8.03 95
    Figure US20050090533A1-20050428-C00131
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.16/7.84 96
    Figure US20050090533A1-20050428-C00132
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.13/8.89 97
    Figure US20050090533A1-20050428-C00133
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.16/8.46 98
    Figure US20050090533A1-20050428-C00134
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.09/7.26 99
    Figure US20050090533A1-20050428-C00135
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.74/7.70 100
    Figure US20050090533A1-20050428-C00136
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.77/8.03 101
    Figure US20050090533A1-20050428-C00137
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.71/7.88 102
    Figure US20050090533A1-20050428-C00138
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/7.80 103
    Figure US20050090533A1-20050428-C00139
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.79/8.17 104
    Figure US20050090533A1-20050428-C00140
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.99/8.28 105
    Figure US20050090533A1-20050428-C00141
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.23/8.33 106
    Figure US20050090533A1-20050428-C00142
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.63/7.93 107
    Figure US20050090533A1-20050428-C00143
    2-CH3/4-F 3,5-di-CF3 are together with the N atom phenyl 8.61/8.05 108
    Figure US20050090533A1-20050428-C00144
    2-CH3/4-F 3,5-di-CF3 are together with the N atom phenyl 8.69/7.87 109
    Figure US20050090533A1-20050428-C00145
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.58/7.86 110
    Figure US20050090533A1-20050428-C00146
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.68/8.39 111
    Figure US20050090533A1-20050428-C00147
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.25/8.26 112
    Figure US20050090533A1-20050428-C00148
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.24/8.46 113
    Figure US20050090533A1-20050428-C00149
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.22/7.79 114
    Figure US20050090533A1-20050428-C00150
    4-F 3,5-di-CF3 —(CH2)2OH CH3 phenyl 8.73/7.52 115
    4-F 3,5-di-CF3 —(CH2)2OH CH2CH3 phenyl 8.41/7.49 116
    2-CH3 3,5-di-CF3 —(CH2)2OH CH3 phenyl 8.68/8.51 117
    2-CH3 3,5-di-CF3 —(CH2)2OH CH2CH3 phenyl 8.44/8.34 118
    2-CH3 3,5-di-CF3 —(CH2)2OH CH2CH2CH3 phenyl 8.40/8.64 119
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00151
         		H phenyl 8.86/8.00 120
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00152
    Figure US20050090533A1-20050428-C00153
         		phenyl 8.54/7.96 121
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00154
         		H phenyl 8.72/7.71 122
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00155
         		H phenyl 8.60/7.90 123
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00156
    Figure US20050090533A1-20050428-C00157
         		phenyl 8.58/7.86 124
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00158
         		H phenyl 8.55/7.86 125
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00159
         		H phenyl 8.60/8.11 126
    2-CH3/3-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00160
    Figure US20050090533A1-20050428-C00161
         		phenyl 8.66/8.82 127
    2-CH3/5-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00162
    Figure US20050090533A1-20050428-C00163
         		phenyl 8.58/8.25 128
    2-Br 3,5-di-CF3 are together with the N-atom phenyl 9.07/8.58 129
    Figure US20050090533A1-20050428-C00164
    2-Br 3,5-di-CF3 are together with the N-atom phenyl 8.78/8.64 130
    Figure US20050090533A1-20050428-C00165
    2-Br 3,5-di-CF3
    Figure US20050090533A1-20050428-C00166
         		H phenyl 8.97/8.37 131
    2-Br 3,5-di-CF3
    Figure US20050090533A1-20050428-C00167
         		H phenyl 8.88/8.14 132
    2-Br 3,5-di-CF3 are together with the N-atom phenyl 9.10/8.70 133
    Figure US20050090533A1-20050428-C00168
    2-Br 3,5-di-CF3
    Figure US20050090533A1-20050428-C00169
    Figure US20050090533A1-20050428-C00170
         		phenyl 8.65/8.66 134
    3,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.37/7.50 135
    Figure US20050090533A1-20050428-C00171
    2,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.79/8.84 136
    Figure US20050090533A1-20050428-C00172
    2,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.55/8.87 137
    Figure US20050090533A1-20050428-C00173
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.78/9.00 138
    Figure US20050090533A1-20050428-C00174
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.17/7.90 139
    Figure US20050090533A1-20050428-C00175
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.11/8.83 140
    Figure US20050090533A1-20050428-C00176
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.19/7.73 141
    Figure US20050090533A1-20050428-C00177
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00178
         		H phenyl 8.89/8.59 142
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00179
         		H phenyl 8.52/8.44 143
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00180
         		H phenyl 8.44/8.92 144
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00181
         		H phenyl 9.08/8.10 145
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00182
         		H phenyl 9.05/7.93 146
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00183
         		H phenyl 9.14/7.98 147
    2-Cl 3,5-di-CF3 (CH2)2OH (CH2)5CH3 phenyl 8.68/7.92 148
    2-Cl 3,5-di-CF3 (CH2)2OH (CH2)4CH3 phenyl 8.89/8.21 149
    2-Cl 3,5-di-CF3 (CH2)3OH (CH2)2OH phenyl 8.88/9.01 150
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00184
         		H phenyl 8.94/7.56 151
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00185
         		H phenyl 9.12/8.11 152
    2-Cl 3,5-di-CF3
    Figure US20050090533A1-20050428-C00186
         		H phenyl 9.31/8.39 153
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00187
         		H phenyl 8.50/8.24 154
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.76/9.06 155
    Figure US20050090533A1-20050428-C00188
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.76/8.80 156
    Figure US20050090533A1-20050428-C00189
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.60/8.80 157
    Figure US20050090533A1-20050428-C00190
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/9.02 158
    Figure US20050090533A1-20050428-C00191
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.75/8.02 159
    Figure US20050090533A1-20050428-C00192
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.69/7.52 160
    Figure US20050090533A1-20050428-C00193
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 7.94/8.17 161
    Figure US20050090533A1-20050428-C00194
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.68/7.73 162
    Figure US20050090533A1-20050428-C00195
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.74/7.55 163
    Figure US20050090533A1-20050428-C00196
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.79/7.80 164
    Figure US20050090533A1-20050428-C00197
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.68/8.96 165
    Figure US20050090533A1-20050428-C00198
    2-CH3/5-F 3,5-di-CF3 are together with the N-atom phenyl 8.42/8.92 166
    Figure US20050090533A1-20050428-C00199
    2-CH3/3-F 3,5-di-CF3 are together with the N-atom phenyl 8.35/9.01 167
    Figure US20050090533A1-20050428-C00200
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.68/8.00 168
    Figure US20050090533A1-20050428-C00201
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.85/7.67 169
    Figure US20050090533A1-20050428-C00202
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.71/8.04 170
    Figure US20050090533A1-20050428-C00203
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.43/7.61 171
    Figure US20050090533A1-20050428-C00204
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.15/7.89 172
    Figure US20050090533A1-20050428-C00205
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00206
         		H phenyl 8.72/8.73 173
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/8.59 174
    Figure US20050090533A1-20050428-C00207
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.79/8.67 175
    Figure US20050090533A1-20050428-C00208
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.68/7.58 176
    Figure US20050090533A1-20050428-C00209
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.92/8.58 177
    Figure US20050090533A1-20050428-C00210
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 9.03/8.46 178
    Figure US20050090533A1-20050428-C00211
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.82/8.39 179
    Figure US20050090533A1-20050428-C00212
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.79/8.49 180
    Figure US20050090533A1-20050428-C00213
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.70/8.47 181
    Figure US20050090533A1-20050428-C00214
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 9.03/7.49 182
    Figure US20050090533A1-20050428-C00215
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.96/7.57 183
    Figure US20050090533A1-20050428-C00216
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.91/7.70 184
    Figure US20050090533A1-20050428-C00217
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.81/7.49 185
    Figure US20050090533A1-20050428-C00218
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.85/7.91 186
    Figure US20050090533A1-20050428-C00219
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.78/7.59 187
    Figure US20050090533A1-20050428-C00220
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.88/7.81 188
    Figure US20050090533A1-20050428-C00221
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.82/8.40 189
    Figure US20050090533A1-20050428-C00222
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.80/8.39 190
    Figure US20050090533A1-20050428-C00223
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.69/7.61 191
    Figure US20050090533A1-20050428-C00224
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.52/7.46 192
    Figure US20050090533A1-20050428-C00225
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.84/7.92 193
    Figure US20050090533A1-20050428-C00226
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.78/7.76 194
    Figure US20050090533A1-20050428-C00227
    2-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.74/7.54 195
    Figure US20050090533A1-20050428-C00228
    2-CH3/4-F 3,5-di-CF3
    Figure US20050090533A1-20050428-C00229
         		CH3 phenyl 8.76/8.34 196
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.54/8.41 197
    Figure US20050090533A1-20050428-C00230
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.75/8.96 198
    Figure US20050090533A1-20050428-C00231
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.60/7.81 199
    Figure US20050090533A1-20050428-C00232
    4-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.63/7.74 200
    Figure US20050090533A1-20050428-C00233
    — 3,5-di-CF3 are together with the N-atom phenyl 8.83/8.06 201
    Figure US20050090533A1-20050428-C00234
    4-F 3,5-di-CF3 are together with the N-atom phenyl 8.92/8.13 202
    Figure US20050090533A1-20050428-C00235
    4-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.69/7.98 203
    Figure US20050090533A1-20050428-C00236
    4-N(CH3)2 3,5-di-CF3 are together with the N-atom phenyl 7.82/7.83 204
    Figure US20050090533A1-20050428-C00237
    3-Br 3,5-di-CF3 are together with the N-atom phenyl 8.71/8.07 205
    Figure US20050090533A1-20050428-C00238
    3-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.73/7.80 206
    Figure US20050090533A1-20050428-C00239
    3-F 3,5-di-CF3 are together with the N-atom phenyl 8.86/8.33 207
    Figure US20050090533A1-20050428-C00240
    3,5-di-F 3,5-di-CF3 are together with the N-atom phenyl 8.87/8.21 208
    Figure US20050090533A1-20050428-C00241
    3,4-di-F 3,5-di-CF3 are together with the N-atom phenyl 8.87/8.46 209
    Figure US20050090533A1-20050428-C00242
    3-F/4-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.64/7.86 210
    Figure US20050090533A1-20050428-C00243
    3-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/7.81 211
    Figure US20050090533A1-20050428-C00244
    3-Cl/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.09/8.60 212
    Figure US20050090533A1-20050428-C00245
    2-NH2 3,5-di-CF3 are together with the N-atom phenyl 9.18/8.49 213
    Figure US20050090533A1-20050428-C00246
    2-OCH3 3,5-di-CF3 are together with the N-atom phenyl 8.99/8.56 214
    Figure US20050090533A1-20050428-C00247
    2-OH 3,5-di-CF3 are together with the N-atom phenyl 8.99/8.35 215
    Figure US20050090533A1-20050428-C00248
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.87/9.10 216
    Figure US20050090533A1-20050428-C00249
    2-SCH3 3,5-di-CF3 are together with the N-atom phenyl 8.98/8.62 217
    Figure US20050090533A1-20050428-C00250
    2-SO2CH3 3,5-di-CF3 are together with the N-atom phenyl 8.58/8.14 218
    Figure US20050090533A1-20050428-C00251
    2-CONH2 3,5-di-CF3 are together with the N-atom phenyl 8.84/7.69 219
    Figure US20050090533A1-20050428-C00252
    2,4-di-F 3,5-di-CF3 are together with the N-atom phenyl 8.82/8.18 220
    Figure US20050090533A1-20050428-C00253
    2-Cl/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.03/8.28 221
    Figure US20050090533A1-20050428-C00254
    2-CHO/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.98/8.99 222
    Figure US20050090533A1-20050428-C00255
    2-CH2OH/ 3,5-di-CF3 are together with the N-atom phenyl 9.15/8.51 223
    4-F
    Figure US20050090533A1-20050428-C00256
    2-CHO 3,5-di-CF3 are together with the N-atom phenyl 8.95/8.82 224
    Figure US20050090533A1-20050428-C00257
    2-CH2OH 3,5-di-CF3 are together with the N-atom phenyl 8.78/8.59 225
    Figure US20050090533A1-20050428-C00258
    2,5-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.11/7.78 226
    Figure US20050090533A1-20050428-C00259
    2-CH3/5-F 3,5-di-CF3 are together with the N-atom phenyl 8.96/8.86 227
    Figure US20050090533A1-20050428-C00260
    2-CH3/3-F 3,5-di-CF3 are together with the N-atom phenyl 8.93/8.85 228
    Figure US20050090533A1-20050428-C00261
    2,3-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.53/8.73 229
    Figure US20050090533A1-20050428-C00262
    3,5-di-CH3 3,5-di-CF3 are together with the N-atom Isoxazol-4-yl 9.13/8.57 230
    Figure US20050090533A1-20050428-C00263
    2,4-di-OCH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 8.61/7.85 231
    Figure US20050090533A1-20050428-C00264
    2-Cl 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 9.24/8.87 232
    Figure US20050090533A1-20050428-C00265
    2-CH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 9.37/8.41 233
    Figure US20050090533A1-20050428-C00266
    3-Cl 3,5-di-CF3 are together with the N-atom Pyridin-2-yl 8.66/7.96 234
    Figure US20050090533A1-20050428-C00267
    2-Cl/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/8.90 235
    Figure US20050090533A1-20050428-C00268
    2,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.75/8.75 236
    Figure US20050090533A1-20050428-C00269
    2,4-di-F 3,5-di-CF3 are togethet with the N-atom phenyl 8.99/8.11 237
    Figure US20050090533A1-20050428-C00270
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.91/8.99 238
    Figure US20050090533A1-20050428-C00271
    2-CHO/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.79/8.83 239
    Figure US20050090533A1-20050428-C00272
    2-CH2OH/ 3,5-di-CF3 are together with the N-atom phenyl 9.10/8.52 240
    4-F
    Figure US20050090533A1-20050428-C00273
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.84/8.79 241
    Figure US20050090533A1-20050428-C00274
    2-F 3,5-di-CF3 are together with the N-atom phenyl 8.88/8.16 242
    Figure US20050090533A1-20050428-C00275
    2-CF3 3,5-di-CF3 are together with the N-atom phenyl 8.41/8.33 243
    Figure US20050090533A1-20050428-C00276
    2-OCH3 3,5-di-CF3 are together with the N-atom phenyl 9.00/8.15 244
    Figure US20050090533A1-20050428-C00277
    2-CN 3,5-di-CF3 are together with the N-atom phenyl 8.92/8.96 245
    Figure US20050090533A1-20050428-C00278
    2-Br 3,5-di-CF3 are together with the N-atom phenyl 8.72/8.83 246
    Figure US20050090533A1-20050428-C00279
    — 3,5-di-CF3 are together with the N-atom phenyl 8.82/7.80 247
    Figure US20050090533A1-20050428-C00280
    3-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.66/7.56 248
    Figure US20050090533A1-20050428-C00281
    2-CH3/3-F 3,5-di-CF3 are together with the N-atom phenyl 8.70/8.99 249
    Figure US20050090533A1-20050428-C00282
    2-CH3/5-F 3,5-di-CF3 are together with the N-atom phenyl 8.71/8.70 250
    Figure US20050090533A1-20050428-C00283
    3-F 3,5-di-CF3 are together with the N-atom phenyl 8.88/8.05 251
    Figure US20050090533A1-20050428-C00284
    3,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.78/8.21 252
    Figure US20050090533A1-20050428-C00285
    2,3-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.54/8.50 253
    Figure US20050090533A1-20050428-C00286
    2-Cl 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 9.01/8.51 254
    Figure US20050090533A1-20050428-C00287
    2-CH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 9.02/7.97 255
    Figure US20050090533A1-20050428-C00288
    6-Cl 3,5-di-CF3 are together with the N-atom Pyridin-2-yl 8.62/7.70 256
    Figure US20050090533A1-20050428-C00289
    2CH3 3,5-di-CF3 are together with the N-atom phenyl 257
    Figure US20050090533A1-20050428-C00290
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.70/8.00 258
    Figure US20050090533A1-20050428-C00291
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.78/7.82 259
    Figure US20050090533A1-20050428-C00292
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.85/7.75 260
    Figure US20050090533A1-20050428-C00293
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.89/9.04 261
    Figure US20050090533A1-20050428-C00294
    2-CF3 3,5-di-CF3 are together with the N-atom phenyl 8.10/8.01 262
    Figure US20050090533A1-20050428-C00295
    2-OCH3 3,5-di-CF3 are together with the N-atom phenyl 8.99/8.87 263
    Figure US20050090533A1-20050428-C00296
    2-F 3,5-di-CF3 are together with the N-atom phenyl 8.83/8.67 264
    Figure US20050090533A1-20050428-C00297
    — 3,5-di-CF3 are together with the N-atom phenyl 8.84/8.31 265
    Figure US20050090533A1-20050428-C00298
    4-F 3,5-di-CF3 are together with the N-atom phenyl 8.92/8.42 266
    Figure US20050090533A1-20050428-C00299
    4-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.44/7.54 267
    Figure US20050090533A1-20050428-C00300
    3,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.64/8.62 268
    Figure US20050090533A1-20050428-C00301
    3-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.73/8.45 269
    Figure US20050090533A1-20050428-C00302
    2,5-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.58/8.66 270
    Figure US20050090533A1-20050428-C00303
    2,3-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.52/8.86 271
    Figure US20050090533A1-20050428-C00304
    2-Cl/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.70/8.96 272
    Figure US20050090533A1-20050428-C00305
    2-CHO/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.84/8.81 273
    Figure US20050090533A1-20050428-C00306
    2-CH2OH/ 3,5-di-CF3 are together with the N-atom phenyl 8.89/8.82 274
    4-F
    Figure US20050090533A1-20050428-C00307
    2-CH3/3-F 3,5-di-CF3 are together with the N-atom phenyl 8.83/9.24 275
    Figure US20050090533A1-20050428-C00308
    2-CH3/5-F 3,5-di-CF3 are together with the N-atom phenyl 8.84/8.86 276
    Figure US20050090533A1-20050428-C00309
    2,5-di-F 3,5-di-CF3 are together with the N-atom phenyl 8.83/8.61 277
    Figure US20050090533A1-20050428-C00310
    2-CH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 9.09/8.57 278
    Figure US20050090533A1-20050428-C00311
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.55/8.93 279
    Figure US20050090533A1-20050428-C00312
    2-OCH3 3,5-di-CF3 are together with the N-atom phenyl 8.74/8.73 280
    Figure US20050090533A1-20050428-C00313
    2-Br 3,5-di-CF3 are together with the N-atom phenyl 8.46/8.74 281
    Figure US20050090533A1-20050428-C00314
    2-F 3,5-di-CF3 are together with the N-atom phenyl 8.51/8.65 282
    Figure US20050090533A1-20050428-C00315
    2,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.55/8.83 283
    Figure US20050090533A1-20050428-C00316
    2,5-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.83/8.84 284
    Figure US20050090533A1-20050428-C00317
    2,3-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.80/8.73 285
    Figure US20050090533A1-20050428-C00318
    3,4-di-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.87/8.43 286
    Figure US20050090533A1-20050428-C00319
    4-Cl 3,5-di-CF3 are together with the N-atom phenyl 8.20/8.13 287
    Figure US20050090533A1-20050428-C00320
    4-F 3,5-di-CF3 are together with the N-atom phenyl 8.58/8.60 288
    Figure US20050090533A1-20050428-C00321
    — 3,5-di-CF3 are together with the N-atom phenyl 8.52/8.30 289
    Figure US20050090533A1-20050428-C00322
    2-CH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 8.84/8.75 290
    Figure US20050090533A1-20050428-C00323
    2-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00324
    Figure US20050090533A1-20050428-C00325
         		Pyridin-3-yl 8.48/8.11 291
    6-CH3 3,5-di-CF3 are together with the N-atom Pyridin-3-yl 8.44/9.11 292
    Figure US20050090533A1-20050428-C00326
    6-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00327
    Figure US20050090533A1-20050428-C00328
         		Pyridin-3-yl 8.42/8.79 293
    6-CH3 3,5-di-CF3
    Figure US20050090533A1-20050428-C00329
         		CH3 Pyridin-3-yl 8.29/8.37 294
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.81/8.78 295
    Figure US20050090533A1-20050428-C00330
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.60/8.76 296
    Figure US20050090533A1-20050428-C00331
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.54/8.88 297
    Figure US20050090533A1-20050428-C00332
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.81/915 298
    Figure US20050090533A1-20050428-C00333
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.59/8.97 299
    Figure US20050090533A1-20050428-C00334
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 9.02/9.31 300
    Figure US20050090533A1-20050428-C00335
    2-CH3 3,5-di-CF3 are together with the N-atom phenyl 8.67/8.64 301
    Figure US20050090533A1-20050428-C00336
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.60/7.69 302
    Figure US20050090533A1-20050428-C00337
    2-CH3/4-F 3,5-di-CF3 are together with the N-atom phenyl 8.88/7.82 303
    Figure US20050090533A1-20050428-C00338
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .77/8.73
    Figure US20050090533A1-20050428-P00899
    04
    Figure US20050090533A1-20050428-C00339
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .65/8.18
    Figure US20050090533A1-20050428-P00899
    05
    Figure US20050090533A1-20050428-C00340
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .76/7.92
    Figure US20050090533A1-20050428-P00899
    06
    Figure US20050090533A1-20050428-C00341
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .06/7.66
    Figure US20050090533A1-20050428-P00899
    07
    Figure US20050090533A1-20050428-C00342
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .65/8.25
    Figure US20050090533A1-20050428-P00899
    08
    Figure US20050090533A1-20050428-C00343
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .67/7.88
    Figure US20050090533A1-20050428-P00899
    09
    Figure US20050090533A1-20050428-C00344
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .83/7.70
    Figure US20050090533A1-20050428-P00899
    10
    Figure US20050090533A1-20050428-C00345
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .93/7.94
    Figure US20050090533A1-20050428-P00899
    11
    Figure US20050090533A1-20050428-C00346
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .65/8.18
    Figure US20050090533A1-20050428-P00899
    12
    Figure US20050090533A1-20050428-C00347
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .93/8.32
    Figure US20050090533A1-20050428-P00899
    13
    Figure US20050090533A1-20050428-C00348
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .90/8.14
    Figure US20050090533A1-20050428-P00899
    14
    Figure US20050090533A1-20050428-C00349
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .99/8.51
    Figure US20050090533A1-20050428-P00899
    15
    Figure US20050090533A1-20050428-C00350
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .88/7.76
    Figure US20050090533A1-20050428-P00899
    16
    Figure US20050090533A1-20050428-C00351
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .97/8.40
    Figure US20050090533A1-20050428-P00899
    17
    Figure US20050090533A1-20050428-C00352
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .11/8.50
    Figure US20050090533A1-20050428-P00899
    18
    Figure US20050090533A1-20050428-C00353
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .12/8.34
    Figure US20050090533A1-20050428-P00899
    19
    Figure US20050090533A1-20050428-C00354
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .90/7.80
    Figure US20050090533A1-20050428-P00899
    20
    Figure US20050090533A1-20050428-C00355
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .81/7.98
    Figure US20050090533A1-20050428-P00899
    21
    Figure US20050090533A1-20050428-C00356
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .75/7.61
    Figure US20050090533A1-20050428-P00899
    22
    Figure US20050090533A1-20050428-C00357
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .15/8.07
    Figure US20050090533A1-20050428-P00899
    23
    Figure US20050090533A1-20050428-C00358
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .67/7.93
    Figure US20050090533A1-20050428-P00899
    24
    Figure US20050090533A1-20050428-C00359
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .05/8.05
    Figure US20050090533A1-20050428-P00899
    25
    Figure US20050090533A1-20050428-C00360
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .87/8.58
    Figure US20050090533A1-20050428-P00899
    26
    Figure US20050090533A1-20050428-C00361
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .91/7.89
    Figure US20050090533A1-20050428-P00899
    27
    Figure US20050090533A1-20050428-C00362
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .70/8.34
    Figure US20050090533A1-20050428-P00899
    28
    Figure US20050090533A1-20050428-C00363
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .63/7.70
    Figure US20050090533A1-20050428-P00899
    29
    Figure US20050090533A1-20050428-C00364
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .92/7.83
    Figure US20050090533A1-20050428-P00899
    30
    Figure US20050090533A1-20050428-C00365
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .02/8.60
    Figure US20050090533A1-20050428-P00899
    31
    Figure US20050090533A1-20050428-C00366
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .70/8.04
    Figure US20050090533A1-20050428-P00899
    32
    Figure US20050090533A1-20050428-C00367
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .82/8.06
    Figure US20050090533A1-20050428-P00899
    33
    Figure US20050090533A1-20050428-C00368
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .01/8.56
    Figure US20050090533A1-20050428-P00899
    34
    Figure US20050090533A1-20050428-C00369
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .59/8.25
    Figure US20050090533A1-20050428-P00899
    35
    Figure US20050090533A1-20050428-C00370
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .00/8.67
    Figure US20050090533A1-20050428-P00899
    36
    Figure US20050090533A1-20050428-C00371
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .79/7.99
    Figure US20050090533A1-20050428-P00899
    37
    Figure US20050090533A1-20050428-C00372
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .05/8.74
    Figure US20050090533A1-20050428-P00899
    38
    Figure US20050090533A1-20050428-C00373
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .97/7.98
    Figure US20050090533A1-20050428-P00899
    39
    Figure US20050090533A1-20050428-C00374
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .88/7.81
    Figure US20050090533A1-20050428-P00899
    40
    Figure US20050090533A1-20050428-C00375
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .92/8.18
    Figure US20050090533A1-20050428-P00899
    41
    Figure US20050090533A1-20050428-C00376
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .65/8.93
    Figure US20050090533A1-20050428-P00899
    42
    Figure US20050090533A1-20050428-C00377
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .78/7.70
    Figure US20050090533A1-20050428-P00899
    43
    Figure US20050090533A1-20050428-C00378
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .99/7.69
    Figure US20050090533A1-20050428-P00899
    44
    Figure US20050090533A1-20050428-C00379
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2SCH3 phenyl
    Figure US20050090533A1-20050428-P00899
    .00/7.95
    Figure US20050090533A1-20050428-P00899
    45
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2S(O)2 phenyl
    Figure US20050090533A1-20050428-P00899
    .81/8.08
    Figure US20050090533A1-20050428-P00899
    46
    CH3
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .93/7.93
    Figure US20050090533A1-20050428-P00899
    47
    Figure US20050090533A1-20050428-C00380
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .97/8.55
    Figure US20050090533A1-20050428-P00899
    48
    Figure US20050090533A1-20050428-C00381
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .85/.65
    Figure US20050090533A1-20050428-P00899
    49
    Figure US20050090533A1-20050428-C00382
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .80/8.31
    Figure US20050090533A1-20050428-P00899
    50
    Figure US20050090533A1-20050428-C00383
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .39/8.27
    Figure US20050090533A1-20050428-P00899
    51
    Figure US20050090533A1-20050428-C00384
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .07/8.33
    Figure US20050090533A1-20050428-P00899
    52
    Figure US20050090533A1-20050428-C00385
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .08/8.81
    Figure US20050090533A1-20050428-P00899
    53
    Figure US20050090533A1-20050428-C00386
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .65/7.70
    Figure US20050090533A1-20050428-P00899
    54
    Figure US20050090533A1-20050428-C00387
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .63/7.72
    Figure US20050090533A1-20050428-P00899
    55
    Figure US20050090533A1-20050428-C00388
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .95/7.92
    Figure US20050090533A1-20050428-P00899
    56
    Figure US20050090533A1-20050428-C00389
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2NH2 phenyl
    Figure US20050090533A1-20050428-P00899
    .74/7.65
    Figure US20050090533A1-20050428-P00899
    57
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2 phenyl
    Figure US20050090533A1-20050428-P00899
    .47/7.77
    Figure US20050090533A1-20050428-P00899
    58
    NHS(O)2CH3
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .90/8.00
    Figure US20050090533A1-20050428-P00899
    59
    Figure US20050090533A1-20050428-C00390
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2 phenyl
    Figure US20050090533A1-20050428-P00899
    .78/7.84
    Figure US20050090533A1-20050428-P00899
    60
    NHC(O)2CH3
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .42/7.89
    Figure US20050090533A1-20050428-P00899
    61
    Figure US20050090533A1-20050428-C00391
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .03/8.32
    Figure US20050090533A1-20050428-P00899
    62
    Figure US20050090533A1-20050428-C00392
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .13/8.57
    Figure US20050090533A1-20050428-P00899
    63
    Figure US20050090533A1-20050428-C00393
    Figure US20050090533A1-20050428-P00899
    -CH3/3-Cl
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .15/7.78
    Figure US20050090533A1-20050428-P00899
    64
    Figure US20050090533A1-20050428-C00394
    Figure US20050090533A1-20050428-P00899
    -CH3/3-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .03/8.42
    Figure US20050090533A1-20050428-P00899
    65
    Figure US20050090533A1-20050428-C00395
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .22/8.67
    Figure US20050090533A1-20050428-P00899
    66
    Figure US20050090533A1-20050428-C00396
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .11/8.44
    Figure US20050090533A1-20050428-P00899
    67
    Figure US20050090533A1-20050428-C00397
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .98/8.39
    Figure US20050090533A1-20050428-P00899
    68
    Figure US20050090533A1-20050428-C00398
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .16/8.67
    Figure US20050090533A1-20050428-P00899
    69
    Figure US20050090533A1-20050428-C00399
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .03/8.55
    Figure US20050090533A1-20050428-P00899
    70
    Figure US20050090533A1-20050428-C00400
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .03/8.91
    Figure US20050090533A1-20050428-P00899
    71
    Figure US20050090533A1-20050428-C00401
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .05/8.68
    Figure US20050090533A1-20050428-P00899
    72
    Figure US20050090533A1-20050428-C00402
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .16/8.80
    Figure US20050090533A1-20050428-P00899
    73
    Figure US20050090533A1-20050428-C00403
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .21/9.22
    Figure US20050090533A1-20050428-P00899
    74
    Figure US20050090533A1-20050428-C00404
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .09/8.95
    Figure US20050090533A1-20050428-P00899
    75
    Figure US20050090533A1-20050428-C00405
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .14/9.06
    Figure US20050090533A1-20050428-P00899
    76
    Figure US20050090533A1-20050428-C00406
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .93/8.44
    Figure US20050090533A1-20050428-P00899
    77
    Figure US20050090533A1-20050428-C00407
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .24/8.76
    Figure US20050090533A1-20050428-P00899
    78
    Figure US20050090533A1-20050428-C00408
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .79/8.32
    Figure US20050090533A1-20050428-P00899
    79
    Figure US20050090533A1-20050428-C00409
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .06/8.67
    Figure US20050090533A1-20050428-P00899
    80
    Figure US20050090533A1-20050428-C00410
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .01/7.90
    Figure US20050090533A1-20050428-P00899
    81
    Figure US20050090533A1-20050428-C00411
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .07/7.96
    Figure US20050090533A1-20050428-P00899
    82
    Figure US20050090533A1-20050428-C00412
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .89/9.31
    Figure US20050090533A1-20050428-P00899
    83
    Figure US20050090533A1-20050428-C00413
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .74/8.99
    Figure US20050090533A1-20050428-P00899
    84
    Figure US20050090533A1-20050428-C00414
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .84/9.19
    Figure US20050090533A1-20050428-P00899
    85
    Figure US20050090533A1-20050428-C00415
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .77/9.18
    Figure US20050090533A1-20050428-P00899
    86
    Figure US20050090533A1-20050428-C00416
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .58/8.67
    Figure US20050090533A1-20050428-P00899
    87
    Figure US20050090533A1-20050428-C00417
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		—(CH2)2 phenyl
    Figure US20050090533A1-20050428-P00899
    .65/8.04
    Figure US20050090533A1-20050428-P00899
    88
    S(O)2NHCH3
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .03/8.13
    Figure US20050090533A1-20050428-P00899
    89
    Figure US20050090533A1-20050428-C00418
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .09/8.22
    Figure US20050090533A1-20050428-P00899
    90
    Figure US20050090533A1-20050428-C00419
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .85/8.26
    Figure US20050090533A1-20050428-P00899
    91
    Figure US20050090533A1-20050428-C00420
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .72/8.77
    Figure US20050090533A1-20050428-P00899
    92
    Figure US20050090533A1-20050428-C00421
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .79/8.90
    Figure US20050090533A1-20050428-P00899
    93
    Figure US20050090533A1-20050428-C00422
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .22/8.64
    Figure US20050090533A1-20050428-P00899
    94
    Figure US20050090533A1-20050428-C00423
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .12/8.31
    Figure US20050090533A1-20050428-P00899
    95
    Figure US20050090533A1-20050428-C00424
    Figure US20050090533A1-20050428-P00899
    -CH2OH/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .85/8.04
    Figure US20050090533A1-20050428-P00899
    96
    Figure US20050090533A1-20050428-C00425
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .26/8.24
    Figure US20050090533A1-20050428-P00899
    97
    Figure US20050090533A1-20050428-C00426
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-CF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .85/7.73
    Figure US20050090533A1-20050428-P00899
    98
    Figure US20050090533A1-20050428-C00427
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .05/8.15
    Figure US20050090533A1-20050428-P00899
    99
    Figure US20050090533A1-20050428-C00428
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .48/8.22
    Figure US20050090533A1-20050428-P00899
    00
    Figure US20050090533A1-20050428-C00429
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		—(CH2)2OH phenyl
    Figure US20050090533A1-20050428-P00899
    .59/7.70
    Figure US20050090533A1-20050428-P00899
    01
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .44/8.33
    Figure US20050090533A1-20050428-P00899
    02
    Figure US20050090533A1-20050428-C00430
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .82/8.24
    Figure US20050090533A1-20050428-P00899
    03
    Figure US20050090533A1-20050428-C00431
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCH3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .40/8.28
    Figure US20050090533A1-20050428-P00899
    04
    Figure US20050090533A1-20050428-C00432
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		—(CH2)2OH phenyl
    Figure US20050090533A1-20050428-P00899
    .72/8.30
    Figure US20050090533A1-20050428-P00899
    05
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .98/9.04
    Figure US20050090533A1-20050428-P00899
    06
    Figure US20050090533A1-20050428-C00433
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .53/9.06
    Figure US20050090533A1-20050428-P00899
    07
    Figure US20050090533A1-20050428-C00434
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		—(CH2)2OH phenyl
    Figure US20050090533A1-20050428-P00899
    .71/8.25
    Figure US20050090533A1-20050428-P00899
    08
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .51/8.99
    Figure US20050090533A1-20050428-P00899
    09
    Figure US20050090533A1-20050428-C00435
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .86/9.14
    Figure US20050090533A1-20050428-P00899
    10
    Figure US20050090533A1-20050428-C00436
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .46/9.17
    Figure US20050090533A1-20050428-P00899
    11
    Figure US20050090533A1-20050428-C00437
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		—(CH2)2OH phenyl
    Figure US20050090533A1-20050428-P00899
    .59/8.41
    Figure US20050090533A1-20050428-P00899
    12
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .05/9.05
    Figure US20050090533A1-20050428-P00899
    13
    Figure US20050090533A1-20050428-C00438
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    -OCF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .10/8.23
    Figure US20050090533A1-20050428-P00899
    14
    Figure US20050090533A1-20050428-C00439
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    -OCF3     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .39/8.24
    Figure US20050090533A1-20050428-P00899
    15
    Figure US20050090533A1-20050428-C00440
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .83/7.64
    Figure US20050090533A1-20050428-P00899
    16
    Figure US20050090533A1-20050428-C00441
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .13/7.63
    Figure US20050090533A1-20050428-P00899
    17
    Figure US20050090533A1-20050428-C00442
    Figure US20050090533A1-20050428-P00899
    -Cl/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .01/8.45
    Figure US20050090533A1-20050428-P00899
    18
    Figure US20050090533A1-20050428-C00443
    Figure US20050090533A1-20050428-P00899
    -CH3/4-F
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .18/8.42
    Figure US20050090533A1-20050428-P00899
    19
    Figure US20050090533A1-20050428-C00444
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .13/8.49
    Figure US20050090533A1-20050428-P00899
    20
    Figure US20050090533A1-20050428-C00445
    Figure US20050090533A1-20050428-P00899
    -CH3/H
    Figure US20050090533A1-20050428-P00899
    ,5-di-OCHF2     		are together with the N-atom phenyl
    Figure US20050090533A1-20050428-P00899
    .10/7.61
    Figure US20050090533A1-20050428-P00899
    21
    Figure US20050090533A1-20050428-C00446
  • The present invention also provides pharmaceutical compositions containing compounds of formula I or pharmaceutically usable acid addition salts thereof and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • The pharmaceutical compositions of the invention, in addition to one or more compounds of formula I or a pharmaceutically usable acid addition salt thereof, contain a pharmaceutically acceptable excipient. Suitable pharmaceutically inert excipients include pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragées and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules.
  • Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • Moreover, the pharmaceutical compositions of the invention can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • Compounds of the present invention are dual NK-1/NK-3 antagonists. Therefore, the present invention also provides a method for the treatment of schizophrenia. Such method includes administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable addition salt thereof, to an individual. In particular, such method includes administering a therapeutically effective amount of a compound of formula I-1, or a pharmaceutically acceptable acid addition salt thereof, to an individual.
  • In individual embodiments, the present invention provides methods for the treatment of schizophrenia which comprise administering to an individual an effective amount of a compound of formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, or a pharmaceutically acceptable acid addition salt of any one or more of these compounds.
  • The compounds and compositions of the invention can be administered in a conventional manner, for example, orally, rectally, or parenterally. The pharmaceutical compositions of the invention can be administered orally, for example, in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The pharmaceutical compositions also can be administered rectally, for example, in the form of suppositories or parenterally, for example, in the form of injectable solutions.
  • The dosage at which the compound of the invention is administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
  • The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.
    • Intermediate 1 (6-Chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid tert-butyl ester
  • Figure US20050090533A1-20050428-C00447
  • To a solution of 1.00 g (2.82 mmol) (6-chloro-4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester in 10 ml DMF were added 0.12 g (3.1 mmol) sodium hydride (60% in mineral oil) at −10° C. (The preparation of (6-chloro-4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester has been described in US 2002/0022624 A1.) The reaction mixture was allowed to warm to room temperature. After 1 h, the mixture was cooled back to −10° C., and 0.44 ml (7.1 mmol) iodomethane were added during 5 min. The reaction mixture was allowed to warm to room temperature. After 2.5 h at room temperature, the reaction was quenched by addition of 10 ml of a saturated aqueous solution of NaHCO3 and the mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (silica gel, hexanes/ethyl acetate=4:1) to give 1.06 g (100%) of the title compound as a colorless oil.
  • MS m/e (%): 368 (M+, 1)
    • Intermediate 2 (6-Chloro-4-iodo-pyridin-3-yl)-methyl-amine
  • Figure US20050090533A1-20050428-C00448
  • To a solution of 8.65 g (19.6 mmol) (6-chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid tert-butyl ester in 20 ml dichloromethane were added 20.0 ml (261 mmol) trifluoroacetic acid at 0° C. After stirring for 2 h at room temperature the reaction mixture was concentrated in vacuo. The residue was treated with 50 ml saturated sodium carbonate solution and extracted three times with 75 ml ethyl acetate. The combined organic layers were washed with 50 ml brine, dried over sodium sulfate and concentrated in vacuo to give 6.1 g (87%) of the title compound as a light brown solid.
  • MS m/e (%): 268 (M+, 1)
    • Intermediate 3A [6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00449
  • A mixture of 6.05 g (19.3 mmol) (6-chloro-4-iodo-pyridin-3-yl)-methyl-amine, 23.6 g (23.6 mmol) 2-chlorophenylboronic acid, 441 mg (1.96 mmol) palladium(II) acetate, 1.03 g (3.93 mmol) triphenylphosphine, 47.1 ml 2 N sodium carbonate solution and 50 ml 1,2-dimethoxyethane was heated at 80° C. for 90 min. The reaction mixture was cooled to room temperature and diluted with 100 ml ethyl acetate. The aqueous layer was separated and extracted with 100 ml ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 4.1 g (83%) of the title compound as a light brown solid.
  • MS m/e (%): 253 (M+H+, 100)
    • Intermediate 3B [4-(2-Bromo-phenyl)-6-chloro-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00450
  • The title compound was obtained as a brown solid in 86% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 2-bromophenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 297 (M+H+, 85)
    • Intermediate 3C [6-Chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00451
  • The title compound was obtained as a light brown solid in 69% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 2-chloro-4-fluorophenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 271 (M+H+, 100)
    • Intermediate 3D [6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00452
  • The title compound was obtained as a orange solid in 80% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 4-fluoro-2-methyl-phenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 251 (M+H+, 100)
    • Intermediate 3E [6-Chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00453
  • The title compound was obtained as an off-white solid in comparable yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 3-fluoro-2-methyl-phenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 251 (M+H+, 100)
    • Intermediate 3F [6-Chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00454
  • The title compound was obtained as an off-white solid in comparable yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 5-fluoro-2-methyl-phenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 251 (M+H+, 100)
    • Intermediate 3G (6-Chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine
  • Figure US20050090533A1-20050428-C00455
  • The title compound was obtained as a light brown solid in 92% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using o-tolylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 233 (M+H+, 100)
    • Intermediate 3H [6-Chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00456
  • The title compound was obtained as a light brown solid in 70% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 2,4-dichlorophenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 287 (M+H+, 100)
    • Intermediate 31 [6-Chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00457
  • The title compound was obtained as a light brown solid in 68% yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 3,4-dichlorophenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 287 (M+H+, 100)
    • Intermediate 3J [6-Chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine
  • Figure US20050090533A1-20050428-C00458
  • The title compound was obtained as an off-white solid in comparable yield according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 4-fluorophenylboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 237 (M+H+, 100)
    • Intermediate 3K [6-Chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
  • a) 3-Chloro-2-methyl-phenylboronic acid
    Figure US20050090533A1-20050428-C00459
  • To a solution of 10.0 g (48.7 mmol) 2-bromo-6-chlorotoluene and 11.3 ml (48.7 mmol) triisopropyl borate in 90 ml dry THF were added dropwise 30 ml (49 mmol) of a 1.6 M solution on n-butyllithium in hexanes at −78° C. under argon. After 45 min the reaction mixture was allowed to warm to room temperature. The reaction was quenched by addition of 5 ml water and the solvent was evaporated in vacuo. Addition of 1 M aqueous hydrochloric acid solution was followed by extraction with four portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Crystallisation from heptane gave 5.08 g (61%) of the title compound as a white solid.
    b) [6-Chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
    Figure US20050090533A1-20050428-C00460
  • The title compound was obtained as an off-white solid in comparable yield after flash chromatography according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine (Intermediate 3A) using 3-chloro-2-methyl-phenylboronic acid instead of 2-chlorophenylboronic acid.
    • Intermediate 3L {4-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl}-methyl-amine
  • a) [2-(2-Chloro-5-methylamino-pyridin-4-yl)-phenyl]-methanol
    Figure US20050090533A1-20050428-C00461
  • The title compound was obtained as a yellow oil in comparable yield according to the procedure described above for the preparation of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using 2-(hydroxymethyl)benzeneboronic acid instead of 2-chlorophenylboronic acid.
  • MS m/e (%): 249 (M+H+, 100)
    b) [4-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl]-methyl-amine
    Figure US20050090533A1-20050428-C00462
  • The crude title compound was obtained as a yellow oil in quantitative yield after extraction according to the procedure described above for the preparation of (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine (Example 174 a)) using [2-(2-chloro-5-methylamino-pyridin-4-yl)-phenyl]-methanol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
  • MS m/e (%): 363 (M+H+, 100)
    • Intermediate 4A 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00463
  • To a solution of 20 g (79 mmol) [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine in 200 ml tetrahydrofuran were added dropwise at 0° C. 113 ml (94.8 mmol) of a 0.91 M solution of potassium bis(trimethylsilyl)amide in tetrahydrofuran. The reaction mixture was stirred at room temperature for 30 min. After cooling to 0° C. 27.7 g (86.9 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride were added dropwise. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 1 h. The reaction mixture was treated with 220 ml 1 N sodium hydrogencarbonate solution and extracted with three 200-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate and triturated with 150 ml diethylether to give 34.6 g (82%) of the title compound as a white solid.
  • MS m/e (%): 535 (M+H+, 100)
    • Intermediate 4B 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00464
  • The title compound was obtained as a light yellow solid in 68% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 579 (M+H+, 98)
    • Intermediate 4C 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00465
  • The title compound was obtained as a white foam in 52% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 553 (M+H+, 100)
    • Intermediate 4D 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00466
  • The title compound was obtained as a light yellow foam in 87% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 533 (M+H+, 100)
    • Intermediate 4E 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00467
  • The title compound was obtained as a light brown solid in 78% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 533 (M+H+, 100)
    • Intermediate 4F 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00468
  • The title compound was obtained as a light yellow solid in comparable yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 533 (M+H+, 100)
    • Intermediate 4G 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00469
  • The title compound was obtained as a white solid in 78% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 514 (M+, 5)
    • Intermediate 4H 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00470
  • The title compound was obtained as a light yellow foam in 57% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 569 (M+H+, 100)
    • Intermediate 41 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00471
  • The title compound was obtained as a light yellow foam in 45% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 569 (M+H+, 100)
    • Intermediate 4J 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00472
  • The title compound was obtained as a light brown solid in 92% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using [6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 519 (M+H+, 100)
    • Intermediate 4K 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00473
  • The title compound was obtained as a white solid in 49% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4A) using [6-chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 549 (M+H+, 100)
    • Intermediate 4L 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl}-N-methyl-isobutyramide
  • Figure US20050090533A1-20050428-C00474
  • The title compound was obtained as a light yellow oil in 76% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using {4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl}-methyl-amine instead of [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
  • MS m/e (%): 645 (M+H+, 100)
    • Intermediate 5A 2-(3,5-Dichloro-phenyl)-2-methyl-propionyl chloride
  • a) 2-(3,5-Dichloro-phenyl)-2-methyl-propionic acid methyl ester
  • A solution of 18.2 g (82.8 mmol) (3,5-dichloro-phenyl)-acetic acid methyl ester in 15 ml THF was added to a solution of lithium diisopropylamide in THF (obtained by adding 49.7 ml (99.4 mmol) of a 2 M solution of lithium diispropylamide in THF/heptane/ethylbenzene to 125 ml THF at −20° C. After stirring for 45 min. 6.3 ml (99.4 mmol) methyl iodide in 12 ml THF was added at the same temperature over a period of 30 min. To this solution another 49.7 ml (99.4 mmol) lithium diisopropylamide solution (2 M) in THF/heptane/ethylbenzene was added at −20° C. followed by 6.3 ml (99.4 mmol) methyl iodide in 12 ml THF. After stirring for 2 h at ambient temperature the solution was poured into 500 ml 2 N hydrochloric acid solution and extracted three times with 300 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/hexanes 1:2) to yield 17.0 g (83%) 2-(3,5-dichloro-phenyl)-2-methyl-propionic acid methyl ester as a light yellow oil.
  • MS m/e (%): 246 (M+, 38), 187 (100).
  • b) 2-(3,5-Dichloro-phenyl)-2-methyl-propionic acid
  • To a solution of 9.0 g (36 mmol) 2-(3,5-dichloro-phenyl)-2-methyl-propionic acid methyl ester in 40 ml ethanol 40 ml 2 N sodium hydroxide solution was added. After stirring for 4 hrs at RT 150 ml water was added and the solution washed twice with 200 ml Et2O. The aqueous phase was acidified with 25% hydrochloric acid solution and three times extracted with 150 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated to yield 8.3 g (97%) 2-(3,5-dichloro-phenyl)-2-methyl-propionic acid as a off-white solid.
  • MS m/e (%): 232 (M+, 28), 187 (100).
  • c) 2-(3,5-Dichloro-phenyl)-2-methyl-propionyl chloride
  • To a solution of 8.3 g (35.6 mmol) 2-(3,5-dichloro-phenyl)-2-methyl-propionic acid in 80 ml CH2Cl2 and 4 drops DMF 6.1 ml (71.2 mmol) oxalyl chloride was added at 0° C. and the resulting mixture stirred for 12 h After evaporation of the solvent 8.3 g (93%) 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride was obtained as a light yellow oil, which was used without further purification.
    • Intermediate 5B 2-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride
  • The title compound was obtained as a yellow oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3-fluoro-5-trifluoromethyl-phenyl)-acetic acid methyl ester in step a).
    • Intermediate 5C 2-Methyl-2-(3-trifluoromethyl-phenyl)-propionyl chloride
  • The title compound was obtained as a yellow oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3-trifluoromethyl-phenyl)-acetic acid methyl ester in step a).
    • Intermediate 5D 2-(3,5-Difluoro-phenyl)-2-methyl-propionyl chloride
  • The title compound was obtained as a yellow oil in analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3,5-difluoro-phenyl)-acetic acid methyl ester in step a).
    • Intermediate 5E 2-(3-Chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride
  • The title compound was obtained as a yellow oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3-chloro-5-methoxy-phenyl)-acetic acid methyl ester in step a).
    • Intermediate 5F 2-(3,5-Dimethyl-phenyl)-2-methyl-propionyl chloride
  • The title compound was obtained as a yellow oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3,5-dimethyl-phenyl)-acetic acid methyl ester in step a).
    • Intermediate 5G 2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride
  • The title compound is obtained according to the procedure described in WO 0279134 A1.
    • Intermediate 5H 2-(3,5-Dimethoxy-phenyl)-2-methyl-propionyl chloride
  • The title compound was obtained as a light red oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3,5-dimethoxy-phenyl)-acetic acid ethyl ester in step a).
    • Intermediate 5I 2-Methyl-2-(3-trifluoromethoxy-phenyl)-propionyl chloride
  • The title compound was obtained as a light yellow oil in an analogous manner to that described for 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using (3-trifluoromethoxy-phenyl)-acetic acid ethyl ester in step a).
    • EXAMPLE 1 N-[4-(2-Chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • To a solution of 1.20 g (4.74 mmol) [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 1.43 g (5.68 mmol) 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride in 20 ml toluene 1.27 g (10.42 mmol) 4-dimethylaminopyridine was added and the resulting solution stirred at 120° for 48 h. After cooling to ambient temperature, the solution was poured into 100 ml 0.5 N NaHCO3-solution and extracted three times with 50 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, hexanes/ethyl acetate 4:1) to give 1.90 g (85%) of the title compound as a white solid.
  • MS m/e (%): 469.1 (M+H+, 100).
  • b) N-[4-(2-Chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • A solution of 0.14 g (0.29 mmol) N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and 4 ml ethanolamine was stirred at 0.130° for 9 h. After cooling to ambient temperature, the solution was poured into 20 ml 0.5N NaHCO3-solution and extracted three times with 30 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate 1:3) to give 0.08 g (54%) of the title
  • compound as a white foam.
  • MS m/e (%): 492.2 (M+H+, 100).
    • EXAMPLE 2 (S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • To a solution of 0.15 g (0.32 mmol) N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and 0.25 g (2.47 mmol) L-prolinol in 2 ml dimethyl sulfoxide 0.2 g (1.55 mmol) Na2CO3 was added and the solution was stirred at 130° C. for 22 h. After cooling to ambient temperature, the solution was poured into 20 ml 0.5 N NaHCO3-solution and extracted three times with 30 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate 1:2) to give 0.15 g (87%) of the title compound as a white foam.
  • MS m/e (%): 532.2 (M+H+, 100).
    • EXAMPLE 3 (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • To a solution of 0.15 g (0.32 mmol) N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and 0.25 g (2.13 mmol) (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine in 2 ml dimethyl sulfoxide 0.2 g (1.55 mmol) Na2CO3 was added and the solution was stirred at 130° C. for 9 h After cooling to ambient temperature, the solution was poured into 20 ml 0.5 N NaHCO3-solution and extracted three times with 30 ml CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate 1:2) to give 0.05 g (31%) of the title compound as a white foam.
  • MS m/e (%): 548.3 (M+H+, 100).
    • EXAMPLE 4 (S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride as a white solid.
  • MS m/e (%): 485.3 (M+H+, 100).
  • b) (S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 550.3 (M+H+, 100).
    • EXAMPLE 5 (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 566.3 (M+H+, 100).
    • EXAMPLE 6 (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a light yellow solid.
  • MS m/e (%): 435.2 (M+H+, 100).
  • b) (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 516.3 (M+H+, 100).
    • EXAMPLE 7 (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3-chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride as a light yellow solid.
  • MS m/e (%): 463.2 (M+H+, 100).
  • b) (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 528.2 (M+H+, 100).
    • EXAMPLE 8 (2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 544.3 (M+H+, 100).
    • EXAMPLE 9 (S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a white solid.
  • MS m/e (%): 427.1 (M+H+, 100).
  • b) (S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 492.3 (M+H+, 100).
    • EXAMPLE 10 (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 508.3 (M+H+, 100).
    • EXAMPLE 11 (S)-2-(3,5-Dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-6-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride as a white solid. MS m/e (%): 449.2 (M+H+, 100).
  • b) (S)-2-(3,5-Dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 512.4 (M+H+, 100).
    • EXAMPLE 12 (2S,4R)-2-(3,5-Dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 528.3 (M+H+, 100).
    • EXAMPLE 13 (S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analougous manner to that described in Example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride as a white foam.
  • MS m/e (%): 465.2 (M+H+, 100).
  • b) (S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 530.2 (M+H+, 100).
    • EXAMPLE 14 (2R,4S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a orange foam.
  • MS m/e (%): 546.3 (M+H+, 100).
    • EXAMPLE 15 (S)-2-(3,5-Difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a light yellow solid.
  • MS m/e (%): 415.2 (M+H+, 100).
  • b) (S)-2-(3,5-Difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and L-prolinol as a light yellow foam.
  • MS m/e (%): 480.2 (M+H+, 100).
    • EXAMPLE 16 (2S,4R)-2-(3,5-Difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a orange foam.
  • MS m/e (%): 496.4 (M+H+, 100).
    • EXAMPLE 17 (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3-Chloro-5-methoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3-chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride as a light yellow solid.
  • MS m/e (%): 443.1 (M+H+, 100).
  • b) (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3-chloro-5-methoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 508.2 (M+H+, 100).
    • EXAMPLE 18 (2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3-chloro-5-methoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 524.3 (M+H+, 100).
    • EXAMPLE 19 (S)-2-(3,5-Dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained to that described in example 1a) from (6-Chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a light yellow foam.
  • MS m/e (%): 407.1 (M+H+, 100).
  • b) (S)-2-(3,5-Dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 472.3 (M+H+, 100).
    • EXAMPLE 20 (2S,4R)-2-(3,5-Dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 488.3 (M+H+, 100)
    • EXAMPLE 21 2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride as a white foam.
  • MS m/e (%): 464.1 (M+, 5).
  • b) 2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1b) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and ethanolamine as a white foam.
  • MS m/e (%): 490.2 (M+H+, 100).
    • EXAMPLE 22 (S)-2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 530.2 (M+H+, 100).
    • EXAMPLE 23 (2S,4R)-2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 546.2 (M+H+, 100).
    • EXAMPLE 24 (S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride as a white foam.
  • MS m/e (%): 483.2 (M+H+, 100).
  • b) (S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 548.4 (M+H+, 100).
    • EXAMPLE 25 (2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 564.4 (M+H+, 100).
    • EXAMPLE 26 (S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-methyl-2-(3-trifluoromethyl-phenyl)-propionyl chloride as a white solid.
  • MS m/e (%): 465.4 (M+H+, 100).
  • b) (S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 530.3 (M+H+, 100).
    • EXAMPLE 27 (2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 546.3 (M+H+, 100).
    • EXAMPLE 28 (S)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a white solid.
  • MS m/e (%): 433.3 (M+H+, 100).
  • b) (S)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and L-prolinol as a light yellow foam.
  • MS m/e (%): 498.3 (M+H+, 100).
    • EXAMPLE 29 (2S,4R)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 513.2 (M+), 482.2 (100).
    • EXAMPLE 30 (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3-chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride as a waxy solid.
  • MS m/e (%): 461.1 (M+H+, 100).
  • b) (S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 526.2 (M+H+, 100).
    • EXAMPLE 31 (2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 542.2 (M+H+, 100).
    • EXAMPLE 32 (S)-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a white foam.
  • MS m/e (%): 425.2 (M+H+, 100).
  • b) (S)-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 490.4 (M+H+, 100).
    • EXAMPLE 33 (2S,4R)-2-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 506.3 (M+H+, 100).
    • EXAMPLE 34 (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-hydroxy-phenyl)-N-methyl-isobutyramide
  • To a solution of 1.10 g (2.37 mmol) N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide in 20 ml CH2Cl2 4.74 ml (4.74 mmol) BBr3 (1 M in CH2Cl2) was added at 0° C. The reaction mixture was allowed to reach ambient temperature and stirred for 6 h After addition of 50 ml water the mixture was extracted three times with 60 ml CH2Cl2. The combined organic solvents were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate 4:1) to give 0.70 g (65%) of the title compound as a white foam.
  • MS m/e (%): 449.1 (M+H+, 100).
  • b) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-difluoromethoxy-phenyl)-N-methyl-isobutyramide
  • To a solution of 0.700 g (1.56 mmol) N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-hydroxy-phenyl)-N-methyl-isobutyramide in 10 ml N,N-Dimethylformamide 0.215 g (1.56 mmol) K2CO3 and 0.2 ml (1.56 mmol) ethyl chlordifluoroacetate was added and the resulting suspension heated at 65° C. for 15 h. After cooling to ambient temperature, the reaction mixture was poured into 75 ml water and extracted three times with 80 ml CH2Cl2. The combined organic solvents were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate 4:1) to give 0.38 g (49%) of the title compound as a white solid.
  • MS m/e (%): 499.1 (M+H+, 100).
  • c) (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2 from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-difluoromethoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 564.2 (M+H+, 100).
    • EXAMPLE 35 (2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-difluoromethoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 580.5 (M+H+, 100).
    • EXAMPLE 36 (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3-Chloro-5-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 34a), b) from 2-(3-chloro-5-methoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide as a white foam.
  • MS m/e (%): 479.1 (M+H+, 100).
  • b) (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin 1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3-chloro-5-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 544.3 (M+H+, 100).
    • EXAMPLE 37 (2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3-chloro-5-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 560.3 (M+H+, 100).
    • EXAMPLE 38 (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 34a), b) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide as a white foam.
  • MS m/e (%): 497.1 (M+H+, 100).
  • b) (S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2S-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 562.2 (M+H+, 100).
    • EXAMPLE 39 (2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light brown foam.
  • MS m/e (%): 578.3 (M+H+, 100).
    • EXAMPLE 40 (2S,4S)-N-[6-(4-Acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 30 mg (0.056 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 200 mg (1.27 mmol) (2S,4S)-4-acetylamino-2-hydroxymethyl-pyrrolidine and 0.2 ml dimethyl sulfoxide was heated at 130° C. for 24 h. After cooling to room temperature, 22 mg (59%) of the title compound were isolated as a white solid by automated, preparative HPLC (YMC CombiPrep C18 column 50×20 mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0 min, λ=230 nm, flow rate 40 ml/min). (2S,4S)-4-Acetylamino-2-hydroxymethyl-pyrrolidine can be obtained by the method described by Terry Rosen, Daniel T. W. Chu, Isabella M. Lico, Isabella M. Lico, Prabhavathi B. Fernandes, Kennan Marsh, Linus Shen, Valerie G. Cepa, André G. Pernet, J. Med. Chem. 1988, 31, 1598.
  • MS m/e (%): 657 (M+H+)
    • EXAMPLE 41 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from D-prolinol as a light grey solid in 8% yield according to to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 600 (M+H+)
    • EXAMPLE 42 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from L-prolinol as a white solid in 49% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 600 (M+H+)
    • EXAMPLE 43 (S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained from (S)-3-acetamidopyrrolidine as a white solid in 42% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 627 (M+H+)
    • EXAMPLE 44 (R)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained from (R)-3-acetamidopyrrolidine as a white solid in 56% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 627 (M+H+)
    • EXAMPLE 45 (RS)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained from (RS)-3-(N-acetyl-N-ethylamino)pyrrolidine as a white solid in 54% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 655 (M+H+)
    • EXAMPLE 46 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (S)-3-pyrrolidinol as a light grey solid in 7% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 586 (M+H+)
    • EXAMPLE 47 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (R)-3-pyrrolidinol as an off-white solid in 30% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 586 (M+H+)
    • EXAMPLE 48 (3R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (3R,4S)-pyrrolidin-3,4-diol as a white solid in 47% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide. 3R,4S)-Pyrrolidine-3,4-diol can be obtained by the method described by Albert Defoin, Joaquim Pires, Jaques Streith, Helv. Chim. Acta 1991, 74, 1653.
  • MS m/e (%): 602 (M+H+)
    • EXAMPLE 49 (3R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (3R,4R)-pyrrolidin-3,4-diol as a white solid in 61% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 602 (M+H+)
    • EXAMPLE 50 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (RS)-3-piperidinol as a white solid in 55% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 600 (M+H+)
    • EXAMPLE 51 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained from 4-hydroxypiperidine as a white solid in 47% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 600 (M+H+)
    • EXAMPLE 52 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained from 4-(hydroxmethyl)-piperidine as a white foam in 43% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 614 (M+H+)
    • EXAMPLE 53 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-(2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (RS)-2-piperidin-2-yl-ethanol as a light yellow solid in 5% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 628 (M+H+)
    • EXAMPLE 54 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained from N-methylethanolamine as a white solid in 54% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 574 (M+H+)
    • EXAMPLE 55 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[ethyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained from 2-ethylamino-ethanol as a white solid in 50% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 588 (M+H+)
    • EXAMPLE 56 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-propyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained from N-propylethanolamine as a white solid in 34% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 602 (M+H+)
    • EXAMPLE 57 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from N-butylethanolamine as a colorless waxy solid in 37% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 616 (M+H+)
    • EXAMPLE 58 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained from (RS)-2,3-dihydroxy-N-methylpropylamine as a white solid in 48% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 604 (M+H+)
    • EXAMPLE 59 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from L-leucinol as a white solid in 42% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 616 (M+H+)
    • EXAMPLE 60 trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from trans-4-aminocyclohexanol as a white solid in 42% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 614 (M+H+)
    • EXAMPLE 61 N-[6-(4-Acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained from 1-acetylpiperazine as a white solid in 52% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 627 (M+H+)
    • EXAMPLE 62 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from 1-cyclopropylcarbonylpiperazine as a white solid in 32% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 653 (M+H+)
    • EXAMPLE 63 N-[6-(4-Acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained from 1-acetylhomopiperazine as a white solid in 50% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 641 (M+H+)
    • EXAMPLE 64 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (S)-(+)-1-(2-pyrrolidinyl-methyl)pyrrolidine as a white solid in 54% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 653 (M+H+)
    • EXAMPLE 65 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (S)-(−)-3-(dimethylamino)pyrrolidine as a white solid in 56% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 613 (M+H+)
    • EXAMPLE 66 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained from (RS)-3-methylsulfonylpyrrolidine as a white solid in 57% yield according to the procedure described above for the preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 648 (M+H+)
    • EXAMPLE 67 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 28.6 g (56 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 50 ml dimethyl sulfoxide and 50 ml (830 mmol) ethanolamine was stirred at 140° C. for 24 h. The reaction mixture was cooled to room temperature, diluted with 200 ml ethyl acetate and washed with 200 ml 1 N sodium carbonate solution and 100 ml water. The aqueous layers were extracted with two 200-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was crystallized from a mixture of 150 ml diisopropyl ether and 150 ml heptane to give 29.1 g (93%) of the title compound as white crystals. M.p. 117-118° C.
  • MS m/e (%): 560 (M+H+, 100)
    • EXAMPLE 68 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 28% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 558 (M+H+, 100)
    • EXAMPLE 69 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 48% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 578 (M+H+, 100)
    • EXAMPLE 70 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 91% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 594 (M+H+, 100)
    • EXAMPLE 71 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 78% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (S)-1-amino-2-propanol instead of ethanolamine.
  • MS m/e (%): 608 (M+H+, 100)
    • EXAMPLE 72 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-1-amino-2-propanol instead of ethanolamine.
  • MS m/e (%): 574 (M+H+, 100)
    • EXAMPLE 73 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 84% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (R)-1-amino-2-propanol instead of ethanolamine.
  • MS m/e (%): 574 (M+H+, 100)
    • EXAMPLE 74 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 79% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-1-amino-2-propanol instead of ethanolamine.
  • MS m/e (%): 574 (M+H+, 100)
    • EXAMPLE 75 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 457 mg (3.60 mmol) oxalyl chloride in 17 ml dichloromethane was added dropwise during 5 minutes at −75° C. a solution of 562 mg (7.20 mmol) dimethyl sulfoxide in 5 ml dichloromethane. After stirring for 5 minutes a solution of 1.72 g (3.00 mmol) (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide in 5 ml dichloromethane was added dropwise at −65° C. Stirring was continued at −70° C. for 1 h, followed by addition of 2.6 ml (15 mmol) ethyldiisopropylamine. After stirring at room temperature for 3 h the reaction mixture was diluted with 20 ml dichloromethane and washed with 20 ml water, 20 ml 1 N hydrochloric acid solution and 20 ml saturated sodium carbonate solution. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 1.45 g (85%) of the title compound as a white foam.
  • MS m/e (%): 572 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 100 mg (0.175 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide in 1 ml tetrahydrofuran was added a 3 N solution of methylmagnesium bromide in diethyl ether at room temperature. The reaction mixture was stirred at room temperature for 1 h and at 65° C. for 3 h. After cooling to room temperature few drops of a 1 N aqueous solution of hydrochloric acid were added to the reaction mixture, followed by extraction with dichloromethane and washing with saturated sodium carbonate solution. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 51 mg (50%) of the title compound as a white foam.
  • MS m/e (%): 588 (M+H+, 100)
    • EXAMPLE 76 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 55% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 1-amino-2-butanol instead of ethanolamine.
  • MS m/e (%): 588 (M+H+, 100)
    • EXAMPLE 77 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 59% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-1-amino-2-propanol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 572 (M+H+, 100)
    • EXAMPLE 78 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 100% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-3-amino-1,2-propandiol instead of ethanolamine.
  • MS m/e (%): 590 (M+H+, 100)
    • EXAMPLE 79 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 14% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using L-alaninol instead of ethanolamine.
  • MS m/e (%): 574 (M+H+, 100)
    • EXAMPLE 80 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 24% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (R)-2-amino-1-propanol instead of ethanolamine.
  • MS m/e (%): 574 (M+H+, 100)
    • EXAMPLE 81 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 34% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-amino-1,3-propandiol instead of ethanolamine.
  • MS m/e (%): 590 (M+H+, 100)
    • EXAMPLE 82 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 41% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine.
  • MS m/e (%): 604 (M+H+, 100)
    • EXAMPLE 83 N-{6-[Bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 55% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 584 (M+H+, 100)
    • EXAMPLE 84 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 52% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 602 (M+H+, 100)
    • EXAMPLE 85 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 15% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 3-(2-hydroxyethylamino)-1-propanol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 86 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 48% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide. and diethanolamine instead of ethanolamine.
  • MS m/e (%): 638 (M+H+, 100)
    • EXAMPLE 87 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and diethanolamine instead of ethanolamine.
  • MS m/e (%): 638 (M+H+, 100)
    • EXAMPLE 88 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 68% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 588 (M+H+, 100)
    • EXAMPLE 89 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 30% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(methylthio)ethylamine instead of ethanolamine.
  • MS m/e (%): 590 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 50 mg (0.087 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide and 130 mg (0.212 mmol) potassium monopersulfate triple salt in 1 ml methanol was stirred at room temperature for 3 days. The reaction was quenched with 1 ml sodium hydrogen sulfite solution 38%. The mixture was treated with 3 ml saturated sodium carbonate solution and extracted with three 5-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 29 mg (55%) of the title compound as a white foam.
  • MS m/e (%): 622 (M+H+, 100)
    • EXAMPLE 90 N-[6-(2-Acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using N-acetylethylenediamine instead of ethanolamine.
  • MS m/e (%): 601 (M+H+, 100)
    • EXAMPLE 91 trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 42% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and trans-4-aminocyclohexanol instead of ethanolamine.
  • MS m/e (%): 648 (M+H+, 100)
    • EXAMPLE 92 trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 23% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using trans-4-aminocyclohexanol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 612 (M+H+, 100).
    • EXAMPLE 93 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 58% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using D-prolinol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 94 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 96% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide. and D-prolinol instead of ethanolamine.
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 95 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 97% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and D-prolinol instead of ethanolamine.
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 96 (2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 76% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (2R,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of ethanolamine.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 97 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 62% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of ethanolamine.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 98 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 23% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of ethanolamine.
  • MS m/e (%): 572 (M+H+, 100)
    • EXAMPLE 99 (S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 58% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-3-acetamidopyrrolidine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 625 (M+H+, 100)
    • EXAMPLE 100 (R)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 75% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (R)-3-acetamidopyrrolidine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 625 (M+H+, 100)
    • EXAMPLE 101 (R)-N-[6-[3-(Acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • To a solution of 146 mg (0.234 mmol) (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 5 ml tetrahydrofuran were added dropwise at room temperature 0.31 ml (0.28 mmol) of a 0.91 N potassium bis(trimethylsilyl)amide solution in tetrahydrofuran. After stirring at room temperature for 30 min. 43 mg (30 mmol) iodomethane were added. The reaction mixture was stirred at room temperature for 18 h, followed by dilution with 10 ml ethyl acetate and washing with 10 ml saturated sodium carbonate solution. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 130 mg (87%) of the title compound as a white foam.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE 102 (R)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 41% yield after flash chromatography according to the procedure described above for the preparation of (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using iodoethane instead of iodomethane.
  • MS m/e (%): 653 (M+H+, 100)
    • EXAMPLE 103 (S)-N-[6-(3-Amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 975 mg (1.83 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 1.26 g (9.15 mmol) potassium carbonate and 800 mg (3.66 mmol) (S)-3-(trifluoro-acetamido)pyrrolidine hydrochloride in 10 ml dimethyl sulfoxide was stirred at 130° C. for 52 h. After cooling to room temperature the reaction mixture was diluted with 30 ml tert-butyl methyl ether and washed with 20 ml of water and 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate and concentrated. The residue was dissolved in 25 ml of a 2 N solution of ammonia in ethanol. The solution was stirred at room temperature for 18 h. The reaction mixture was concentrated and purified by flash chromatography to give 640 mg (60%) of the title compound as a light brown foam.
  • MS m/e (%): 583 (M+H+, 100)
    • EXAMPLE 104 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 600 mg (1.03 mmol) (S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 6 ml dichloromethane were added 6 mg (0.05 mmol) 4-(N,N-dimethylamino)pyridine, 266 mg (2.06 mmol) N,N-diisopropylethylamine and 153 mg (1.34 mmol) methanesulfonyl chloride. After stirring at room temperature for 18 h the reaction mixture was diluted with 20 ml dichloromethane and washed with 20 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and purified by flash chromatography to give 553 mg (81%) of the title compound as an off-white foam.
  • MS m/e (%): 659 ([M−H+]-, 100)
    • EXAMPLE 105 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 48% yield after flash chromatography according to the procedure described above for the preparation of (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 106 (S)-(2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 150 mg (0.227 mmol) (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 1 ml dimethylformamide were added 14 mg (0.35 mmol) sodium hydride (60% dispersion in mineral oil). After stirring at room temperature for 30 min. 22 mg (0.27 mmol) iodoethane were added. The reaction mixture was stirred at room temperature for 18 h, followed by dilution with 10 ml tert-butyl methyl ether and washing with 20 ml water and with 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and purified by flash chromatography to give 86 mg (55%) of the title compound as an off-white foam.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 107 (S)-N-[6-[3-(Acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 62% yield after flash chromatography according to the procedure described above for the preparation of (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE 108 (S)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 59% yield after flash chromatography according to the procedure described above for the preparation of (R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using (S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and iodoethane instead of iodomethane.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE 109 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 62% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-3-hydroxypyrrolidine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 584 (M+H+, 100)
    • EXAMPLE 110 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 73% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-3-pyrrolidinol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 584 (M+H+, 100)
    • EXAMPLE 111 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a off-white foam in 73% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 582 (M+H+, 100)
    • EXAMPLE 112 N-[4-Amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-1,2′ 1 bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 72% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 598 (M+H+, 100)
  • b) N-[4-Amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • To a solution of 752 mg (1.26 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in 7 ml methanol 970 mg (12.6 mmol) ammonium acetate were added at room temperature. The mixture was stirred 5 minutes at this temperature, cooled to 0° C. and treated with 119 mg (1.89 mmol) sodium cyanoborohydride. The reaction mixture was allowed to slowly warm to room temperature during 5 h, followed by dilution with 20 ml ethyl acetate, washing with 10 ml brine and extraction with 20 ml ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 480 mg (64%) of the title compound as a white foam.
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 113 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 16% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using N-[4-amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 677 (M+H+, 100)
    • EXAMPLE 114 N-[4-Acetylamino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 93% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 4-hydroxy-piperidine instead of ethanolamine.
  • MS m/e (%): 598 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 96% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 596 (M+H+, 100)
  • c) N-[4-Amino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 45% yield after flash chromatography according to the procedure described above for the preparation of N-[4-amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 597 (M+H+, 100)
  • d) N-[4-Acetylamino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • To a solution of 80 mg (0.13 mmol) N-[4-amino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and 26 mg (0.20 mmol) N,N-diisopropylethylamine in 3 ml dichloromethane were added 12 mg (0.15 mmol) acetyl chloride at 0° C. The reaction mixture was stirred at room temperature for 18 h. The mixture was diluted with 10 ml dichloromethane and washed with 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and purified by flash chromatography to give 82 mg (95%) of the title compound as a white foam.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE 115 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • A mixture of 0.10 g (0.20 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 0.45 g (6.0 mmol) 2-(methylamino)ethanol was stirred 6 h at 140° C. After cooling to room temperature the reaction mixture was partitioned between water and tert-butyl methyl ether and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were washed with a saturated aqueous solution of ammonium chloride and water, dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 87 mg (78%) of the title compound as a light yellow solid.
  • MS m/e (%): 558 (M+H+, 100)
    • EXAMPLE 116 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 23% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(ethylamino)ethanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 572 (M+H+, 100)
    • EXAMPLE 117 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[(2-hydroxy-ethyl)-methyl-amino]-4-o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 87% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 554 (M+H+, 100)
    • EXAMPLE 118 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[ethyl-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 91% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 2-(ethylamino)ethanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 568 (M+H+, 100)
    • EXAMPLE 119 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[(2-hydroxy-ethyl)-propyl-amino]-4-o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 72% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 2-(propylamino)ethanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 568 (M+H+, 100)
    • EXAMPLE 120 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 55% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (S)-1-amino-2-propanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 554 (M+H+, 100)
    • EXAMPLE 121 N-{6-[Bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 51% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and bis-(2-hydroxypropyl)amine instead of 2-(methylamino)ethanol.
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 122 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 76% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (S)-3-amino-1,2-propandiol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 570 (M+H+, 100)
    • EXAMPLE 123 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 74% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (R)-3-amino-1,2-propandiol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 570 (M+H+, 100)
    • EXAMPLE 124 N-[6-[Bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 71% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and bis-(2-hydroxypropyl)amine instead of 2-(methylamino)ethanol.
  • MS m/e (%): 632 (M+H+, 100)
    • EXAMPLE 125 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 73% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (S)-3-amino-1,2-propandiol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 590 (M+H+, 100)
    • EXAMPLE 126 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (R)-3-amino-1,2-propandiol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 590 (M+H+, 100)
    • EXAMPLE 127 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 34% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 2-(2-hydroxy-ethylamino)-ethanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 602 (M+H+, 100)
    • EXAMPLE 128 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 9% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 2-(2-hydroxy-ethylamino)-ethanol instead of 2-(methylamino)ethanol.
  • MS m/e (%): 602 (M+H+, 100)
    • EXAMPLE 129 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 800 mg (1.38 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide, 4 ml dimethyl sulfoxide and 1.15 g (6.9 mmol) (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine was stirred at 130° C. for 24 h. The reaction mixture was cooled to room temperature, diluted with 100 ml ethyl acetate and washed with 200 ml 1 N sodium carbonate solution and 100 ml water. The combined aqueous layers were extracted twice with 100 ml ethyl acetate. The combined organic layers were dried over sodium sulfate and evaporated. Purification by flash chromatography gave 434 mg (48%) of the title compound as a yellow foam.
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 130 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 27% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 131 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 52% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-1-amino-2-propanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 618 (M+H+, 89)
    • EXAMPLE 132 trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 39% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using trans-4-aminocyclohexanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 658 (M+H+, 83)
    • EXAMPLE 133 (S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 67% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-acetamidopyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 671 (M+H+, 100)
    • EXAMPLE 134 N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 23% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 648 (M+H+, 100)
    • EXAMPLE 135 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 61% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 136 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 50% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 137 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 45% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and (2R,3S)-2-hydroxymethyl-pyrrolidin-3-ol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 138 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 26% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 139 (2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 67% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and (2R,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 140 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 50% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and (2S,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 141 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 45% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and (RS)-2-piperidinemethanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 142 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy 1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 23% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and 2-amino-1,3-propandiol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 588 (M+H+, 100)
    • EXAMPLE 143 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 55% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 2-amino-1,3-propandiol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 570 (M+H+, 100)
    • EXAMPLE 144 (1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 32% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and L-threoninol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 604 (M+H+, 100)
    • EXAMPLE 145 (1R,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 23% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and L-allo-threoninol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 604 (M+H+, 100)
    • EXAMPLE 146 (1S,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 18% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and D-allo-threoninol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 604 (M+H+, 100)
    • EXAMPLE 147 (1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 4% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and D-threoninol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 604 (M+H+, 100)
    • EXAMPLE 148 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[hexyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 39% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 2-(hexylamino)ethanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 149 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-pentyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 38% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 2-(N-amylamino)ethanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 150 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 26% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 3-(hydroxyethylamino)-1-propanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 151 (1RS,2RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 46% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and (1RS,2RS)-2-aminocyclohexanol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 152 (1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(1R,2R)-N-[6-(2-Benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a brown solid in 58% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-% 4-(N,N-dimethylamino)pyridine and (1R,2R)-2-benzyloxy-cyclopentylamine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • b) (1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.15 g (0.22 mmol) (1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 2 ml dichloromethane were added 0.87 ml (0.87 mmol) of a 1 M boron trichloride solution in dichloromethane at room temperature. After 2 h the reaction was quenched by addition of 2 ml of a 1 M aqueous hydrochloric acid solution. Neutralisation with 1 M aqueous NaOH solution was followed by extraction with 3 portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 60 mg (46%) of the title compound as an off-white solid.
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 153 (1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 8% yield over two steps according to the procedures described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (1S,2S)-2-benzyloxy-cyclopentylamine instead of (1R,2R)-2-benzyloxy-cyclopentylamine in step a).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 154 (1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 15% yield over two steps according to the procedures described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (1S,2S)-2-benzyloxy-cyclopentylamine instead of (1R,2R)-2-benzyloxy-cyclopentylamine in step a).
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 155 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 11.0 g (20.6 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 14.3 g (103 mmol) potassium carbonate and 12.2 g (75.7 mmol) (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine in 110 ml dimethyl sulfoxide was stirred at 130° C. for 68 h. The reaction mixture was diluted with 800 ml ethyl acetate and washed with 800 ml saturated sodium carbonate solution, 500 ml water and 750 ml brine. The combined aqueous layers were extracted with two 800-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Purification by flash chromatography gave 8.48 g (67%) of the title compound as a light yellow foam.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 156 (2R,3R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and EXAMPLE 157 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 400 mg (0.65 mmol) (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 6.5 ml tetrahydrofuran were added at 0° C. 0.67 ml (3.26 mmol) diisopropyl azodicarboxylate and 398 mg (3.26 mmol) benzoic acid. The reaction mixture was cooled to −78° C., followed by addition of 855 mg (3.26 mmol) triphenylphosphine. The reaction mixture was allowed to slowly warm to room temperature over night. Addition of 75 ml of a saturated sodium carbonate solution was followed by extraction with two 75-ml portions of tert-butyl methyl ether. The organic layers were washed with 75 ml brine, dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography. The residue was dissolved in 20 ml methanol and treated with 0.1 ml of a 5.5 M sodium methylate solution in methanol. After stirring 3 h at room temperature the reaction mixture was concentrated in vacuo. The residue was dissolved in 75 ml dichloromethane and washed with 60 ml water, dried over sodium sulfate and purified by flash chromatography to give 117 mg (29%) of (2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white foam and 155 mg (40%) of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white foam.
    • (2R,3R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide:
  • MS m/e (%): 614 (M+H+, 100)
    • (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide:
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 158 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white foam in 66% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 159 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a light brown amorphous material in 36% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-2-pyrrolidin-2-yl-propan-2-ol instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 626 (M+H+, 100)
    • EXAMPLE 160 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown gum in 14% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (R)-piperidine-2-ylmethanol instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 161 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown oil in 15% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-piperidine-2-yl-methanol instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 162 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 65% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 570 (M+H+, 100)
    • EXAMPLE 163 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 62% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 552 (M+H+, 100)
    • EXAMPLE 164 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 36% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,3,6,7-tetrahydro-(1H)-1,4-diazepin-5-(4H)-one instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 611 (M+H+, 100)
    • EXAMPLE 165 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.20 g (0.38 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.23 g (2.3 mmol) L-prolinol and 0.15 g (1.1 mmol) potassium carbonate in 0.5 ml dimethyl sulfoxide was heated at 180° C. under microwave irradiation for 30 min. in a sealed tube. After cooling to room temperature the reaction mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were washed with water and brine, dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.18 g (78%) of the title compound as an off-white solid.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 166 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 47% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 167 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 40% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 168 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 45% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and D-prolinol instead of L-prolinol.
  • MS m/e (%): 580 (M+H+, 100)
    • EXAMPLE 169 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 57% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine instead of L-prolinol.
  • MS m/e (%): 651 (M+H+, 100)
    • EXAMPLE 170 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 48% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 3-(methylsulfonyl)pyrrolidine instead of L-prolinol.
  • MS m/e (%): 646 (M+H+, 100)
    • EXAMPLE 171 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 84% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (RS)-pyrrolidin-3-yl-methanol instead of L-prolinol.
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 172 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 54% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 4-(hydroxymethyl)piperidine instead of L-prolinol.
  • MS m/e (%): 594 (M+H+, 100)
    • EXAMPLE 173 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 30% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (R)-1-amino-2-propanol instead of L-prolinol.
  • MS m/e (%): 554 (M+H+, 100)
    • EXAMPLE 174 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-4-Benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine
  • A solution of 1.00 g (4.82 mmol) (R)-(4-benzyl-morpholin-3-yl)-methanol, 0.80 g (5.3 mmol) tert-butyl-chloro-dimethyl-silane and 0.72 g (0.11 mmol) imidazole in 10 ml N,N-dimethylformamide was stirred at room temperature for 90 min. Consecutive addition of water and 1 M aqueous sodium hydroxide solution was followed by extraction with three portions of tert-butyl methyl ether. The combined organic layers were washed with 1 M aqueous sodium hydroxide solution, dried over sodium sulphate and concentrated in vacuo to give 1.54 g (99.3%) of the crude title compound as a colorless oil.
  • MS m/e (%): 322 (M+H+, 100)
  • b) (S)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-morpholine
  • A solution of 1.54 g (4.79 mmol) (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine in 24 ml ethanol was deoxygenated by three cycles of evacuation and flushing with argon. After addition of 0.5 g palladium on charcoal (10%) the reaction vessel was evacuated and filled with hydrogen gas. The reaction mixture was stirred at room temperature under an atmosphere of hydrogen over night. Filtration over decalite and evaporation of the solvent in vacuo gave 1.08 g (97.4%) of the crude title compound as a colorless oil.
  • MS m/e (%): 232 (M+H+, 100)
  • c) (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.30 g (0.56 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.17 g (0.73 mmol) (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine, 0.01 g (0.03 mmol) cetyltrimethylammonium bromide, 0.029 g (0.056 mmol) bis(tri-t-butylphosphine)palladium(0), 0.07 ml NaOH 50% and 3 ml toluene was degassed by two freeze-thaw cycles. The reaction mixture was heated under argon at 90° C. for 3 h. After cooling to room temperature the mixture was diluted with water and extracted with three portions of toluene. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. The residue was dissolved in a mixture of 10 ml methanol and 0.5 ml concentrated aqueous hydrochloric acid solution. After stirring at room temperature for 90 min. the reaction mixture was neturalized with 0.5 M aqueous sodium hydroxide solution and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.10 g (30%) of the title compound as an off-white solid.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 175 (R)-(2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 61% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 176 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-(4-benzyl-morpholin-2-yl)-methanol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 177 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(RS)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-thiomorpholine
  • The crude title compound was obtained as an orange oil in 92% yield according to the procedure described above for the preparation of (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine using (RS)-thiomorpholin-3-yl-methanol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
  • MS m/e (%): 248 (M+H+, 100)
  • b) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 55% yield after flash chromatography according to step c) of the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-3-(tert-butyl-dimethyl-silanyloxymethyl)-thiomorpholine instead of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine.
  • MS m/e (%): 630 (M+H+, 100)
  • c) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 80% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 662 (M+H+, 100)
    • EXAMPLE 178 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 179 (3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3R,5R)-1-benzyl-piperidine-3,5-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 180 (3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide, using (3R,5R)-1-benzyl-piperidine-3,5-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 181 (3S,5R)-5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a)(3R,5R)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol
  • The title compound was obtained as a light brown oil in 38% yield after flash chromatography according to the procedure described above for the preparation of (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine using (3R,5R)-1-benzyl-piperidine-3,5-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
  • MS m/e (%): 322 (M+H+, 100)
  • b) (3S,5R)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol
  • To a solution of 1.8 g (5.6 mmol) (3R,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol in 50 ml tetrahydrofuran were added at 0° C. 0.97 ml (6.2 mmol) diethyl azodicarboxylate and 0.75 g (6.2 mmol) benzoic acid. The reaction mixture was cooled to 0° C., followed by addition of 1.6 g (6.2 mmol) triphenylphosphine. The reaction mixture was stirred at 0° C. for 6 h. Addition of a saturated sodium carbonate solution was followed by extraction with three portions of tert-butyl methyl ether. The combined organic layers were washed with saturated sodium carbonate solution and brine, dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography. The residue was dissolved in a mixture of 50 ml dioxane and 18 ml 1 N aqueous sodium hydroxide solution. After stirring at 70° C. for 5 h the reaction mixture was diluted with tert-butyl methyl ether. The layers were separated and the organic layer was washed with a saturation aqueous sodium carbonate solution. The combined aqueous layers were extracted with two portions of tert-butyl methyl ether. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated in vacuo. Flash chromatography gave 0.1 g (6%) of the title compound as a light brown oil.
  • MS m/e (%): 322 (M+H+, 100)
  • c) (3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine
  • The title compound was obtained as a white solid in comparable yields according to the procedures described above for the preparation of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine using (3S,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
  • MS m/e (%): 346 (M+H+, 100)
  • d) (3S,5R)-5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3S,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-piperidine instead of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 182 (3S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3S,4S)-1-benzyl-pyrrolidine-3,4-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 602 (M+H+, 100)
    • EXAMPLE 183 (3S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3S,4S)-1-benzyl-pyrrolidine-3,4-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 582 (M+H+, 100)
    • EXAMPLE 184 (3R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3R,4S)-3,4-dihydroxy-pyrrolidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 582 (M+H+, 100)
    • EXAMPLE 185 (3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3 hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3RS,4SR)-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 186 (3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3RS,4SR)-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 187 (3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3RS,4SR)-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 188 (3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3RS,4SR)-3,4-dihydroxy-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 189 (2RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and (2RS,4SR)-1-benzyl-2-hydroxymethyl-piperidin-4-ol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (2RS,4SR)-1-Benzyl-2-hydroxymethyl-piperidin-4-ol is obtained by reduction of (1RS,5SR)-2-benzyl-6-oxa-2-aza-bicyclo[3.2.1]octan-7-one with lithium aluminum hydride in tetrahydrofuran at room temperature for 1 h.
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 190 (2RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and (2RS,4SR)-1-benzyl-2-hydroxymethyl-piperidin-4-ol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
  • MS m/e (%): 610 (M+H+, 100)
    • EXAMPLE 191 (3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and 1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett. 1999,9,1403-1408.) instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (3RS,4SR)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine was separated from (3RS,4RS)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine by flash column chromatography and used in step b).
  • MS m/e (%): 610 (M+H+, 100)
    • EXAMPLE 192 (3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and 1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett. 1999,9,1403-1408.) instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (3RS,4RS)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine was separated from (3RS,4SR)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine by flash column chromatography and used in step b).
  • MS m/e (%): 610 (M+H+, 100)
    • EXAMPLE 193 (3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and 1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett. 1999,9,1403-1408.) instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (3RS, 4SR)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine was separated from (3RS,4RS)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine by flash column chromatography and used in step b).
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 194 (3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and 1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett. 1999,9,1403-1408.) instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (3RS,4RS)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine was separated from (3RS,4SR)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimethyl-silanyloxymethyl)-piperidine by flash column chromatography and used in step b).
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 195 (2RS,3RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a)(2RS,3RS)-3-Hydroxy-2-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester
  • A mixture of 20.0 g (105 mmol) 3-hydroxy-2-(hydroxymethyl)-pyridine hydrochloride, 4.0 g (18 mmol) platinum(IV) oxide, 4 g charcoal (Norit SX1) and 300 ml acetic acid was stirred at room temperature for 20 h under a hydrogen pressure of 10 bar in an autoclave. The catalyst was filtered off and washed with acetic acid. The filtrate was concentrated in vacuo, redissolved in isopropanol and treated with 29.0 g (210 mmol) potassium carbonate. After stirring for 30 min. the mixture was filtered, and the solvent was evaporated in vacuo to give 15.7 g of crude (2RS,3RS)-2-hydroxymethyl-piperidin-3-ol. A portion of 2.0 g of the crude intermediate was dissolved in 50 ml dichloromethane and treated with 5.2 ml (30 mmol) N,N-diisopropylethylamine and 2.4 ml (16 mmol) benzyl chloroformate at 0° C. After 45 min. water and saturated ammonium chloride solution were added. The mixture was extracted with four portions of dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash chromatography gave 0.82 g (23% based on 3-hydroxy-2-(hydroxymethyl)-pyridine hydrochloride) of the title compound as an off-white oil.
  • MS m/e (%): 266 (M+H+, 92)
  • b) (2RS,3RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and (2RS,3RS)-3-hydroxy-2-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 196 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
  • a)[2-(tert-Butyl-dimethyl-silanyloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-methyl-amine
  • To 26 ml (0.21 mmol) of a 8 M solution of methylamine in ethanol were added dropwise at 0° C. 31 ml (0.11 mmol) titanium(IV) isopropoxide. The mixture was allowed to warm to room temperature over a period of 15 min. A solution of 17 g (0.52 mmol) 1,3-bis-(tert-butyl-dimethyl-silanyloxy)-propan-2-one in 10 ml ethanol was added. The reaction mixture was stirred at room temperature over night, followed by addition of 6.6 g (0.11 mmol) sodium cyanoborohydride. After stirring for 24 h the reaction was quenched by the addition of silica gel. The mixture was concentrated in vacuo, and the residue was transfered to a silica gel chromatography column. Flash chromatography and Kugelrohr distillation (120° C./2 mbar) gave 5.2 g (30%) of the title compound as a light yellow viscous oil.
  • MS m/e (%): 334 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino 1-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in comparable yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using [2-(tert-butyl-dimethyl-silanyloxy)-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-methyl-amine instead of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine in step c).
  • MS m/e (%): 602 (M+H+, 100)
    • EXAMPLE 197 (2R,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and EXAMPLE 198 (2S,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 0.30 g (0.56 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.11 g (0.68 mmol) (2S,5S)-(−)-2,5-bis(methoxymethyl)pyrrolidine, 5 mg (0.01 mmol) cetyltrimethylammonium bromide, 0.014 g (0.027 mmol) bis(tri-t-butylphosphine)palladium(0), 0.07 ml NaOH 50% and 2 ml toluene was degassed by two freeze-thaw cycles. The reaction mixture was heated under argon at 90° C. over night. After cooling to room temperature the mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. Flash column chromatography gave 0.09 g of the crude coupling product. This material was dissolved in 2 ml dichloromethane and treated with 1.1 ml (1.1 mmol) of a 1 M solution of boron tribromide in dichloromethane at 0° C. After 15 min. the reaction was quenched by the addition of water, followed by extraction with three portions of dichloromethane. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. Flash column chromatography gave 7 mg (2%) of (2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide as a light brown solid and 6 mg (2%) of (2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide as a light brown solid.
    • (2R,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • MS m/e (%): 628 (M+H+, 100)
    • (2S,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 199 (2R,5R)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in comparable yield after flash chromatography according to the procedure described above for the preparation of (2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using (2R,5R)-(+)-2,5-bis(methoxymethyl)pyrrolidine instead of (2S,5S)-(−)-2,5-bis(methoxymethyl)pyrrolidine.
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 200 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4R)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • A mixture of 26.5 g (71.8 mmol) (6-chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid tert-butyl ester and 25.4 g (144 mmol) (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine in 260 ml dimethyl sulfoxide was stirred at 130° C. for 32 h. The reaction mixture was concentrated in vacuo, treated with 200 ml 2 N sodium carbonate solution and extracted with three 200-ml portions of ethyl acetate. The organic layers were washed with 200 ml 2 N sodium carbonate solution and 200 ml brine and dried over sodium sulfate. Flash chromatography gave 15.5 g (48%) of the title compound as a white foam.
  • MS m/e (%): 450 (M+H+, 100)
  • b) (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 8.94 g (19.9 mmol) (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester in 85 ml dichloromethane were added 50 ml of a 2 M solution of hydrogen chloride in diethylether at 0° C. The reaction mixture was stirred at room temperature for 22 h and concentrated in vacuo. The residue was re-dissolved in 85 ml dichloromethane and treated with 17 ml (99.4 mmol) N-ethyldiisopropylamine. At 0° C. 19.0 g (59.7 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride were added dropwise. The reaction mixture was stirred at room temperature for 4 h and concentrated in vacuo. After addition of 250 ml methanol and 70 ml 3 N potassium hydroxide solution the mixture was stirred at room temperature for 2 h. The mixture was concentrated to remove methanol and extracted with four 750 ml-portions of dichloromethane. The combined organic layers were washed with 500 ml 1 N sodium hydroxide solution and 500 ml brine, dried over sodium sulfate and evaporated. Flash-chromatography gave 11 g (87%) of the title compound as a light yellow foam.
  • MS m/e (%): 632 (M+H+, 100)
  • c) (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 150 mg (0.238 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide, 38.7 mg (0.284 mmol) 4-tolylboronic acid, 0.75 ml 2 N sodium carbonate solution, 5.3 mg (0.024 mmol) palladium acetate and 12 mg (0.048 mmol) triphenylphosphine in 1.5 ml 1,2-dimethoxyethane was stirred at 80° C. for 2 h. The reaction mixture was treated with 10 ml 2 N sodium carbonate solution and extracted with two 15-ml portions of ethyl acetate. The combined organic layers were dried over sodium sulfate and evaporated. Flash chromatography gave 112 mg (79%) of the title compound as a yellow foam.
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 201 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 72% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using phenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 202 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 62% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 203 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 41% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-chlorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 204 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 76% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-dimethylaminophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 625 (M+H+, 73)
    • EXAMPLE 205 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 59% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-bromophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 660 (M+H+, 45)
    • EXAMPLE 206 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 68% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-chlorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 207 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 97% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 208 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 74% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3,5-difluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 209 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a solid in 85% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3,4-difluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 210 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 60% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluoro-4-methylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 211 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 60% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-3-methylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 212 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 97% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-chloro-4-fluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 213 (2S,4R)-N-[4-(2-Amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 82% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 597 (M+H+, 100)
    • EXAMPLE 214 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 88% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-methoxyphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 215 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 61% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 216 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 79% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 217 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 86% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2-methylthio)phenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 218 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 150 mg (0.239 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in 1.5 ml methanol were added 250 mg (0.406 mmol) potassium monopersulfate triple salt. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was treated with 0.5 ml sodium hydrogen sulfite solution (38%) and stirred for 30 minutes. Addition of 5 ml 2 N sodium carbonate solution was followed by extraction with two 10-ml portions of dichloromethane. The combined organic layers were dried over sodium sulfate and purified by flash chromatography to give 131 mg (83%) of the title compound as a white foam.
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 219 (2S,4R)-2-[5-{[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-benzamide
  • The title compound was obtained as a light brown foam in 33% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2-aminocarbonyl)phenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 625 (M+H+, 100)
    • EXAMPLE 220 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 78% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,4-difluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 221 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 76% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-chloro-4-fluorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 222 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(2-Bromo-5-fluoro-phenyl)-[1,3]dioxolane
  • To a solution of 2.0 g (9.9 mmol) 2-bromo-5-fluorobenzaldehyde in 20 ml toluene were added 0.722 ml (13.0 mmol) ethane-1,2-diol and 5 mg (0.03 mmol) toluene-4-sulfonic acid monohydrate. The reaction mixture was heated in a rotary evaporator at 60° C. and 200 mbar during 4 h. After evaporation of the solvent and flash chromatography 2.32 g (95%) of the title compound were obtained as a colorless liquid.
  • MS m/e (%): 246 (M+, 13)
  • b) 4-Fluoro-2-formylphenylboronic acid
  • To a solution of 2.30 g (9.31 mmol) 2-(2-bromo-5-fluoro-phenyl)-[1,3]dioxolane in 15 ml tetrahydrofuran was added dropwise at −70° C. 6.11 ml (9.77 mmol) of a 1.6 M solution of n-butyllithium in hexane. The reaction mixture was stirred at −74° C. for 1 h. After dropwise addition of 2.65 ml (11.2 mmol) triisopropyl borate at −70° C. the reaction mixture was allowed to warm to 15° C. during a period of 2 h. Water (7 ml) was added, and the mixture was acidified to pH 1 by addition of 37% hydrochloric acid solution. After heating at 60° C. for 1 h, the mixture was cooled to room temperature and extracted with three 50-ml portions of diethyl ether. The combined organic layers were washed with 50 ml brine, dried over sodium sulfate and concentrated. Flash chromatography gave 1.2 g (77%) of the title compound as a light yellow liquid.
  • MS m/e (%): 167 (M+, 1)
  • c) (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 80% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-formylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 223 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 24 mg (0.637 mmol) sodium borohydride in 1 ml methanol were added 100 mg (0.159 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide at room temperature. After stirring for 1 h the reaction mixture was concentrated in vacuo and partitioned between ethyl acetate and saturated sodium carbonate solution. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 78 mg (78%) of the title compound as a white foam.
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 224 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 68% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-formylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 610 (M+H+, 100)
    • EXAMPLE 225 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 52% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 226 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 60% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,5-dichlorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 49)
    • EXAMPLE 227 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 67% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 5-fluoro-2-methylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 228 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 100% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluoro-2-methylphenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 229 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 20% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,3-dichlorophenylboronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 230 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxazol-4-yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 80% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3,5-dimethylisoxazole-4-boronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 601 (M+H+, 100)
    • EXAMPLE 231 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 67% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,6-dimethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 643 (M+H+, 100)
    • EXAMPLE 232 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 49% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2-chloro-3-pyridyl)boronic acid instead of 4-tolylboronic acid in step c).
  • MS m/e (%): 617 (M+H+, 100)
    • EXAMPLE 233 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridilyl-3′-yl]-N-methyl-isobutyramide
  • A mixture of 0.12 g (0.48 mmol) trifluoro-methanesulfonic acid 2-methyl-pyridin-3-yl ester, 0.13 g (0.52 mmol) bis(pinacolato)diboron, 0.14 g (1.4 mmol) potassium acetate and 0.02 g (0.02 mmol) dichloro[1,1′-bis(diphenylphosphino) ferrocene]palladium(II) dichloromethane adduct in 2.5 ml N,N-dimethylformamide was heated at 80° C. over night under argon. After cooling to room temperature 0.10 g (0.16 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide and 1.3 ml of a deoxygenated 2 M aqueous solution of sodium carbonate were added. The reaction mixture was heated at 80° C. for 6 h. After cooling to room temperature the mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 37 mg (39%) of the title compound as an off-white solid.
  • MS m/e (%): 597 (M+H+, 100)
    • EXAMPLE 234 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • To a solution of 0.500 g (2.09 mmol) 3-chloro-2-iodo-pyridine in 6 ml tetrahydrofuran 1.04 ml (2.09 mmol) of a 2 M solution of isopropylmagnesium chloride in tetrahydrofuran was added dropwise at −40° C. under an atmosphere of argon. After 30 min. 2.3 ml (4.2 mmol) of an anhydrous 1.8 M solution of zinc chloride in tetrahydrofuran was added slowly. The cooling bath was removed after completed addition, and the reaction mixture was stirred at room temperature for 90 min. A portion of 1.6 ml of this solution was added to a solution of 0.15 g (0.24 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide and 14 mg (0.012 mmol) tetrakis(triphenylphosphine)palladium(0) in 1 ml tetrahydrofuran. The mixture was heated at 100° C. under microwave irradiation for 30 min. After cooling to room temperature a 0.5 M solution of sodium hydroxide was added, and the mixture was extracted with three portions of dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 58 mg (40%) of the title compound as a light yellow solid.
  • MS m/e (%): 617 (M+H+, 100)
    • EXAMPLE 235 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4S)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • The title compound was obtained as a light yellow foam in 60% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using (2S,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 450 (M+H+, 100)
  • b) (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 87% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4S)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester.
  • MS m/e (%): 632 (M+H+, 100)
  • c) (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 58% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-chloro-4-fluorophenylboronic acid instead of 4-tolylboronic acid and (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 236 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 56% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,4-dichlorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 237 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 78% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,4-difluorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 238 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 84% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-methylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 239 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 71% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-formylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 240 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 47% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 241 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 90% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 242 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 47% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-fluorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 243 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 79% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-trifluoromethylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 244 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 84% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-methoxyphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 245 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 10% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 607 (M+H+, 100)
    • EXAMPLE 246 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 68% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-bromophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 247 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 80% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using phenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 582 (M+H+, 100)
    • EXAMPLE 248 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 92% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-3-methylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 249 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 87% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluoro-2-methylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 250 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 48% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 5-fluoro-2-methylphenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 251 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 87% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 252 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 64% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 3,4-dichlorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 253 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 77% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,3-dichlorophenylboronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 254 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 48% yield after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2-chloro-3-pyridyl)boronic acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
  • MS m/e (%): 617 (M+H+, 100)
    • EXAMPLE 255 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 48% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide using (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 597 (M+H+, 100)
    • EXAMPLE 256 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 24% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide using (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 617 (M+H+, 100)
    • EXAMPLE 257 (2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2R,4R)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • The title compound was obtained as a light brown foam in 28% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using (2R,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 450 (M+H+, 100)
  • b) (2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown foam in 82% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide using (2R,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester.
  • MS m/e (%): 632 (M+H+, 100)
  • c) (2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 78% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 4-tolylboronic acid and (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 258 (2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 85% yield after flash chromatography according to the procedures described above for the preparation of (2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-methylphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 259 (2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2R,4S)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • The title compound was obtained as a light brown foam in 14% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using (2R,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 450 (M+H+, 100)
  • b) (2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 71% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide using (2R,4S)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester.
  • MS m/e (%): 632 (M+H+, 100)
  • c) (2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 78% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-methylphenylboronic acid instead of 4-tolylboronic acid and (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 260 (2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 94% yield after flash chromatography according to the procedures described above for the preparation of (2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 4-fluoro-2-methylphenylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 261 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2R,3S)-[6-(3-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • The title compound was obtained as a light yellow foam in 29% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 450 (M+H+, 100)
  • b) (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 53% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide using (2R,3S)-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester.
  • MS m/e (%): 632 (M+H+, 100)
  • c) (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 85% yield after flash chromatography according to the procedure described above for the preparation of (2S, 4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 4-tolylboronic acid and (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 262 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 58% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(trifluoromethyl)phenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 263 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 89% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-methoxyphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 264 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 70% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-fluorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 265 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a brown foam in 79% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using phenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 582 (M+H+, 100)
    • EXAMPLE 266 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 77% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 267 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 53% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-tolylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 268 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 45% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3,4-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 269 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 79% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-chlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 270 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 50% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,5 dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 271 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 54% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,3-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 272 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 77% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-chloro-4-fluorobenzeneboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 273 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 60% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluoro-2-formylphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 274 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 48% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 275 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a off white foam in 78% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3-fluoro-2-methylphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 276 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 83% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 5-fluoro-2-methylphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 614 (M+H+, 100)
    • EXAMPLE 277 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow foam in 52% yield after flash chromatography according to the procedures described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,5-difluorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 618 (M+H+, 100)
    • EXAMPLE 278 (2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 46% yield after flash chromatography according to the procedures described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide using (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 597 (M+H+, 100)
    • EXAMPLE 279 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-[6-(2-Hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester
  • The title compound was obtained as a light yellow foam in 15% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using L-prolinol instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
  • MS m/e (%): 434 (M+H+, 100)
  • b) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 74% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide using (S)-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester.
  • MS m/e (%): 616 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 43% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of 4-tolylboronic acid and (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 580 (M+H+, 100)
    • EXAMPLE 280 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 28% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-methoxyphenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 596 (M+H+, 100)
    • EXAMPLE 281 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 23% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-bromophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 282 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 68% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-fluorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 283 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 29% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,4-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 284 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow foam in 32% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,5-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 285 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 18% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2,3-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 286 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a orange foam in 34% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 3,4-dichlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 287 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a yellow oil in 50% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-chlorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 288 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 45% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 4-fluorophenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 289 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 48% yield after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using phenylboronic acid instead of 2-tolylboronic acid in step c).
  • MS m/e (%): 566 (M+H+, 100)
    • EXAMPLE 290 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • a)(6′-Chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-methyl-amine
  • The title compound was obtained as a light yellow solid in 60% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide using (6-chloro-4-iodo-pyridin-3-yl)-methyl-amine instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6′-chloro-2-methyl-[3,4]bipyridinyl-3′-yl)-N-methyl-isobutyramide
  • To a solution of 2.77 g (11.9 mmol) (6′-chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-methyl-amine in 120 ml tetrahydrofuran 7.8 ml (12 mmol) of a 1.6 M solution of n-butyllithium in hexanes was added dropwise at −78° C. After 30 min. 4.2 g (13 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride were added. The reaction mixture was stirred at −78° C. for 5 min. and allowed to warm to room temperature during a period of 1 h. Dilution with 2 M aqueous sodium carbonate solution was followed by extraction with three portions of tert-butyl methyl ether. The combined organic layers were washed with 2 M aqueous sodium carbonate solution and brine, dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 4.8 g (78%) of the title compound as an off-white solid.
  • MS m/e (%): 516 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 65% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 581 (M+H+, 100)
    • EXAMPLE 291 N-{6′-[Bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 43% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 585 (M+H+, 100)
    • EXAMPLE 292 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-4-methyl-[3,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • a)(6′-Chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-methyl-amine
  • The title compound was obtained as a light yellow solid in comparable yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6′-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4′]bipyridinyl-3′-yl]-N-methyl-isobutyramide using (6-chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid tert-butyl ester instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide and 3-bromo-4-methylpyridine instead of 3-chloro-2-iodo-pyridine.
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6′-chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 65% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide using (6′-chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-methyl-amine instead of (6′-chloro-2-methyl-[3,4′]bipyridinyl-3′-yl)-methyl-amine.
  • MS m/e (%): 585 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6′-(2-hydroxymethyl-pyrrolidin-1-yl)-4-methyl-[3,4′bipyridinyl-3′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 39% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 581 (M+H+, 100)
    • EXAMPLE 293 N-{6′-[Bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 34% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using diethanolamine instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 585 (M+H+, 100)
    • EXAMPLE 294 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6′-[(2-hydroxy-ethyl)-methyl-amino]-4-methyl-[3,4′]bipyridinyl-3′-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 66% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(methylamino)ethanol instead of ethanolamine and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6′-chloro-4-methyl-[3,4′]bipyridinyl-3′-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 555 (M+H+, 100)
    • EXAMPLE 295 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4R)-Acetic acid 1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino 1-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester
  • To a solution of 1.5 g (2.4 mmol) (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and 0.4 ml (5 mmol) pyridine in 24 ml dichloromethane were added dropwise at room temperature 0.22 ml (2.4 mmol) acetic anhydride. After stirring at room temperature for 20 h the reaction mixture was diluted with a 0.1 M aqueous hydrochloric acid solution and extracted with 3 portions of dichloromethane. The combined organic extracts were washed with a 2 M aqueous sodium carbonate solution, dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 1.1 g (71%) of the title compound as an off-white solid.
  • MS m/e (%): 638 (M+H+, 100)
  • b) (S)-Acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester
  • To a solution of 0.08 ml (0.9 mmol) oxalyl chloride in 2 ml dichloromethane were added dropwise at −78° C. 0.13 ml (1.9 mmol) dimethyl sulfoxide and after a period of 3 min. a solution of 0.50 g (0.78 mmol) (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester in 2 ml dichloromethane. After stirring at −78° C. for 30 min. 0.7 ml (4 mmol) N,N-diisopropylethylamine were added. The reaction mixture was allowed to warm to room temperature during 1 h, diluted with tert-butyl methyl ether and washed with an aqueous ammonium chloride solution. The aqueous layer was extracted with two portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.47 g (94%) of the title compound as a white solid.
  • MS m/e (%): 636 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • A solution of 60 mg (0.094 mmol) (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester and a catalytic amount of sodium methylate in 2 ml methanol was stirred at room temperature for 30 min. The reaction mixture was diluted with water and brine and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 13 mg (23%) of the title compound as a light brown solid.
  • MS m/e (%): 594 (M+H+, 100)
    • EXAMPLE 296 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4R)-Acetic acid 1-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino 1-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-hydroxy-pyrrolidin-2-ylmethyl ester
  • The title compound was obtained as a white solid in 52% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester using (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 656 (M+H+, 100)
  • b) (S)-Acetic acid 1-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino 1-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-oxo-pyrrolidin-2-ylmethyl ester
  • The title compound was obtained as a white solid in 77% yield after flash chromatography according to the procedure described above for the preparation of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester using (2S,4R)-acetic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-hydroxy-pyrrolidin-2-ylmethyl ester instead of (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 654 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in 37% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (S)-acetic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-oxo-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 297 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4S)-Acetic acid 1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-ylmethyl ester
  • To a solution of 0.14 g (0.21 mmol) (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester in 2 ml dichloromethane were added dropwise at 0° C. 0.03 ml (0.2 mmol) (diethylamino)sulfur trifluoride. After 1 h the reaction mixture was diluted with a 0.5 M aqueous sodium hydroxide solution and extracted with four portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 47 mg (35%) of the title compound as a white solid.
  • MS m/e (%): 640 (M+H+, 100)
  • b) (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 91% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4S)-acetic acid 1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 298 (2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4R)-acetic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-hydroxy-pyrrolidin-2-ylmethyl ester instead of (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester in step a).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 299 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-Acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4,4-difluoro-pyrrolidin-2-ylmethyl ester
  • To a solution of 0.20 g (0.31 mmol) (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester in 3 ml dichloromethane were added at room temperature 0.19 ml (1.5 mmol) (diethylamino)sulfur trifluoride. After 36 h the reaction mixture was partitioned between water and tert-butyl methyl ether. The layers were separated and the organic layer was washed with 0.5 M aqueous sodium hydroxide solution. The combined aqueous layers were extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 93 mg (45%) of the title compound as an off-white solid.
  • MS m/e (%): 658 (M+H+, 100)
  • b) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 83% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4,4-difluoro-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 300 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (S)-acetic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-oxo-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester in step a).
  • MS m/e (%): 634 (M+H+, 100)
    • EXAMPLE 301 (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2S,4S)-Acetic acid 1-(5-f [2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester
  • The title compound was obtained as a white solid in 60% yield after flash chromatography according to the procedure described above for the preparation of (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester using (2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide instead of (2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 638 (M+H+, 100)
  • b) (2S,4R)-Acetic acid 1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-ylmethyl ester
  • The title compound was obtained as an off-white solid in 69% yield after flash chromatography according to the procedure described above for the preparation of (2S,4S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-ylmethyl ester using (2S,4S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester instead of (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 640 (M+H+, 100)
  • c) (2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 78% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using (2S,4R)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid 1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 302 (S)-N-[6-[2-(Acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • a)(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.20 g (0.33 mmol) (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and 54 mg (0.37 mmol) phthalimide in 3 ml tetrahydrofuran were added 71 mg (0.37 mmol) diethyl azodicarboxylate (90%) and 97 mg (0.37 mmol) triphenylphosphine at 0° C. After stirring for 90 min. the reaction mixture was allowed to warm to room temperature over night. The mixture was diluted with a 0.1 M aqueous sodium hydroxide solution and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 70 mg (29%) of the title compound as a light yellow solid.
  • MS m/e (%): 727 (M+H+, 100)
  • b) (S)-N-[6-[2-(Acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A solution of 65 mg (0.089 mmol) (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 7.0 mg (0.14 mmol) hydrazine hydrate in 1 ml ethanol was stirred at room temperature over night. The reaction mixture was diluted with a 1 M aqueous sodium hydroxide solution and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated to give 55 mg of crude (S)-N-[6-(2-aminomethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide. This material was dissolved in 2 ml dichloromethane, followed by the addition of 0.013 ml (0.092 mmol) triethylamine and 0.009 ml (0.09 mmol) acetic anhydride at 0° C. The cooling bath was removed 5 min. after completed addition, and stirring was continued at room temperature over night. The reaction mixture was diluted with a 0.5 M aqueous sodium hydroxide solution and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Flash chromatography gave 44 mg (77%) of the title compound as an off-white solid.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE 303 (S)-Dimethyl-carbamic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-pyrrolidin-2-ylmethyl ester
  • To a solution of 44 mg (0.33 mmol) 1,1,3,3-tetramethyl-2-thiourea in 1.5 ml N,N-dimethylformamide were added 0.027 ml iodomethane at room temperature. After stirring for 50 min. 0.20 g (0.33 mmol) (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and a suspension of 45 mg (0.90 mmol) sodium hydride (ca. 50% dispersion in mineral oil) in 0.5 ml n-hexane were added. After stirring at room temperature for 1 h the reaction mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 90 mg (40%) of the title compound as an off-white solid.
  • MS m/e (%): 669 (M+H+, 100)
    • EXAMPLE 304 (3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a)(5R,3S)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol
  • To a solution of 1.8 g (5.6 mmol) (3R,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol in 50 ml THF were consecutively added 0.75 g (6.2 mmol) benzoic acid, 1.1 g (6.2 mmol) diethyl azodicarboxylate and 1.6 g (6.2 mmol) triphenylphosphine at 0° C. After 6 h the reaction mixture was diluted with tert-butyl methyl ether washed with a 2N aqueous solution of sodium carbonate. The aqueous layer was extracted with 3 portions of tert-butyl methyl ether. The combined organic extracts were washed with a 2N aqueous solution of sodium carbonate and brine and dried over sodium sulfate. Flash chromatography gave 0.80 g (3S,5R)-benzoic acid 1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-yl ester as a light brown oil. The ester was dissolved in a mixture of 50 ml dioxane and 18 ml 1N aqueous sodium hydroxide solution. The reaction mixture was heated at 70° C. for 5 h. After cooling to room temperature the mixture was extracted with tert-butyl methyl ether. The organic extract was washed with a 2N aqueous solution of sodium carbonate. The combined aqueous layers were extracted with two portions of tert-butyl methyl ether. The combined organic extracts were washed with brine and dried over sodium sulfate. Flash chromatography gave 0.10 g (17%) of the title compound as a light brown oil.
  • MS m/e (%): 322 (M+H+, 100)
  • b) (3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (5R,3S)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
  • MS m/e (%): 614.7 (M+H+, 100)
    • EXAMPLE 305 (3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a)(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine
  • The title compound was obtained as a light brown solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine (Example 174b)) using (3R,5R)-1-benzyl-piperidine-3,5-diol instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
  • MS m/e (%): 346 (M+H+, 100)
  • b) (3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 0.50 g (1.4 mmol) (3R,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-piperidine and 0.15 g (1.5 mmol) triethylamine in 30 ml of THF was added dropwise a solution of 0.26 g (1.5 mmol) benzyl chloroformate in 2 ml of THF at 0° C. After completed addition, the mixture was allowed to warm to room temperature during 30 min. Quenching with a saturated aqueous solution of sodium hydrogencarbonate was followed by extraction with three portions of dichloromethane. The combined organic extracts were washed with brine and dried over sodium sulfate. Flash chromatography gave 0.62 g (90%) of the title compound as a colorless oil.
  • MS m/e (%): 480 (M+H+, 100)
  • c) (3R,5R)-3-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 8.7 g (18 mmol) (3R,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester in 200 ml THF were added 18 ml (18 mmol) of a 1M solution of tetrabutyl ammoniumfluoride in THF at 0° C. After completed addition, the mixture was allowed to warm to room temperature over night. Addition of water was followed by extraction with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate. Flash chromatography gave 1.1 g (16%) of the title compound as a pale yellow oil.
  • MS m/e (%): 366 (M+H+, 98)
  • d) (3S,5R)-3-Benzoyloxy-5-(tert-butyl-dimethyl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 2.8 g (7.8 mmol) (3R,5R)-3-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-piperidine-1-carboxylic acid benzyl ester in 70 ml dry THF were consecutively added 1.0 g (8.5 mmol) benzoic acid, 1.7 g (8.5 mmol) diethyl azodicarboxylate and 2.2 g (8.5 mmol) triphenylphosiphine at 0° C. After 6 h the reaction mixture was diluted with tert-butyl methyl ether washed with a 2N aqueous solution of sodium carbonate. The aqueous layer was extracted with 3 portions of tert-butyl methyl ether. The combined organic extracts were washed with a 2N aqueous solution of sodium carbonate and brine and dried over sodium sulfate. Flash chromatography gave 2.8 g (78%) of the title compound as a yellow oil.
  • MS m/e (%): 470 (M+H+, 100)
  • e) (3S,5R)-3-Benzoyloxy-5-hydroxy-piperidine-1-carboxylic acid benzyl ester
  • To a solution of 2.3 g (5.0 mmol) (3S,5R)-3-benzoyloxy-5-(tert-butyl-dimethyl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester in 20 ml dry THF were added 5.5 ml (5.5 mmol) of a 1M solution of tetrabutyl ammoniumfluoride in THF at 0° C. After completed addition, the mixture was allowed to warm to room temperature over 30 min. Addition of water was followed by extraction with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate. Kugelrohr distillation gave 1.7 g (95%) of the title compound as a light yellow oil.
  • MS m/e (%): 356 (M+H+, 100)
  • f) (3S,5S)-3,5-Dihydroxy-piperidine-1-carboxylic acid benzyl ester
  • The title compound was obtained as a light brown oil in 4% yield after flash chromatography according to the procedure described above for the preparation of (5R,3S)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol (Example 304a)) using (3S,5R)-3-benzoyloxy-5-hydroxy-piperidine-1-carboxylic acid benzyl ester instead of (3R,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol.
  • MS m/e (%): 252 (M+H+, 63)
  • g) (3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (3S,5S)-3,5-dihydroxy-piperidine-1-carboxylic acid benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 616 (M+H+, 100)
    • EXAMPLE 306 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-formyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a colorless viscous oil in comparable yields after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 75a)) using (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 578 (M+H+, 100)
    • EXAMPLE 307 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-2-Methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl ester
  • To a suspension of 1.81 g (25.8 mmol) sodium methanethiolate in 25 ml methanol was added a solution of 1.35 g (4.31 mmol) 2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid benzyl ester in 25 ml methanol. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with ethyl acetate and washed with two portions of water. The organic layer was dried over sodium sulfate. Flash chromatography gave 0.89 g (3.4 mmol, 78%) (S)-2-methylsulfanylmethyl-pyrrolidine-1-carboxylic acid benzyl ester as a light yellow oil.
  • This material was dissolved in 25 ml of methanol and treated with 3.1 g (5.1 mmol) Oxone at room temperature. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with water and extracted with three portions of ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo to give 0.86 g (86%) of the crude title compound as a colorless oil.
  • MS m/e (%): 297 (M+, 3)
  • b) (S)-2-Methanesulfonylmethyl-pyrrolidine
  • A solution of 0.86 g (2.9 mmol) (S)-2-methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl ester in 15 ml ethanol was deoxygenated by three cycles of evacuation and flushing with argon. After addition of 0.15 g palladium on charcoal (10%) the reaction vessel was evacuated and filled with hydrogen gas. The reaction mixture was stirred at room temperature under an atmosphere of hydrogen over night. Filtration over decalite and evaporation of the solvent in vacuo gave 0.44 g (93%) of the crude title compound as a light yellow oil.
  • MS m/e (%): 164 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2 methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid after preparative thin layer chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-2-methanesulfonylmethyl-pyrrolidine instead of L-prolinol.
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 308 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • A mixture of 0.50 g (0.94 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.32 g (2.8 mmol) 4-(hydroxymethyl)piperidine, 0.12 g (2.8 mmol) lithium chloride and 0.39 g (2.8 mmol) potassium carbonate in 5 ml DMSO was heated at 140° C. for 24 h. After cooling to room temperature the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.42 g (74%) of the title compound as a white solid.
  • MS m/e (%): 612 (M+H+, 100)
    • EXAMPLE 309 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a) Methanesulfonic acid 5′-f [2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-ylmethyl ester
  • To a solution of 0.42 g (0.69 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in 7 ml dichloromethane were added 83 mg (0.72 mmol) methanesulfonyl chloride and 73 mg (0.72 mmol) triethylamine at 0° C. After 30 min the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.29 g (63%) of the title compound as a white solid.
  • MS m/e (%): 690 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • A solution of 0.29 g (0.42 mmol) methanesulfonic acid 5′-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-ylmethyl ester and 44 mg (0.63 mmol) sodium methanethiolate in 8 ml DMF was heated at 80° C. for 30 min. After cooling to room temperature the reaction mixture was treated with a 1 N aqueous sodium hydroxide solution and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.25 g (92%) of the title compound as a white solid.
  • MS m/e (%): 642 (M+H+, 100)
    • EXAMPLE 310 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • To a solution of 0.25 g (0.39 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in 10 ml dichloromethane were added 95 mg (70%, 0.39 mmol) 3-chloroperbenzoic acid at 0° C. After completed addition, the reaction mixture was allowed to warm to room temperature and stirred over night. An aqueous solution of sodium hydrogensulfite was added and the mixture was stirred for 10 min. Basification with 1 N aqueous sodium hydroxide solution was followed by extraction with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.23 g (89%) of the title compound as a white solid.
  • MS m/e (%): 658 (M+H+, 100)
    • EXAMPLE 311 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • To a solution of 0.22 g (0.33 mmol) (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in 5 ml dichloromethane were added 142 mg (70%, 0.58 mmol) 3-chloroperbenzoic acid at 0° C. After completed addition, the reaction mixture was allowed to warm to room temperature and stirred over night. An aqueous solution of sodium hydrogensulfite was added and the mixture was stirred for 10 min. Basification with 1 N aqueous sodium hydroxide solution was followed by extraction with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.13 g (55%) of the title compound as a white solid.
  • MS m/e (%): 674 (M+H+, 100)
    • EXAMPLE 312 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 70% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (RS)-3-(hydroxymethyl)pyrrolidine instead of 4-(hydroxymethyl)piperidine.
  • MS m/e (%): 598 (M+H+, 100)
    • EXAMPLE 313 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 66% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 628 (M+H+, 100)
    • EXAMPLE 314 2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(RS)-3-((RS)-methanesulfinylmethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 86% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 315 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 31% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(RS)-3-((RS)-methanesulfinylmethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 316 (R)-N-[6-(3-Amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 939 mg (1.76 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 1.22 g (8.81 mmol) potassium carbonate and 770 mg (3.52 mmol) (R)-3-(trifluoro-acetamido)pyrrolidine hydrochloride in 20 ml dimethyl sulfoxide was stirred at 130° C. for 52 h. After cooling to room temperature the reaction mixture was diluted with 30 ml tert-butyl methyl ether and washed with 20 ml of water and 10 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and dissolved in 25 ml of a 2 N solution of ammonia in ethanol. The solution was stirred at room temperature for 18 h. The reaction mixture was concentrated and purified by flash chromatography to give 670 mg (65%) of the title compound as a light brown foam.
  • MS m/e (%): 583 (M+H+, 100)
    • EXAMPLE 317 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 620 mg (1.06 mmol) (R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 6 ml dichloromethane were added 7 mg (0.05 mmol) 4-(N,N-dimethylamino)pyridine, 275 mg (2.13 mmol) N,N-diisopropylethylamine and 158 mg (1.38 mmol) methanesulfonyl chloride at room temperature. After stirring for 18 h the reaction mixture was diluted with 20 ml dichloromethane and washed with 20 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated and purified by flash chromatography to give 618 mg (88%) of the title compound as an off-white foam.
  • MS m/e (%): 659 (M+H+, 66)
    • EXAMPLE 318 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide
  • To a solution of 150 mg (0.227 mmol) (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 1 ml dimethylformamide were added 15 mg (0.34 mmol) sodium hydride (55% dispersion in mineral oil) at room temperature. After stirring at room temperature for 30 min 39 mg (27 mmol) iodomethane were added. The reaction mixture was stirred at room temperature for 18 h, followed by dilution with 10 ml ethyl acetate and washing with 10 ml saturated sodium carbonate solution. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 120 mg (78%) of the title compound as a white foam.
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 319 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 84% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide using iodoethane instead of iodomethane.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 320 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 93% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using N-[4-amino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide (Example 114c)) instead of (R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 673 ([M−H+]−, 90)
    • EXAMPLE 321 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-(methanesulfonyl-methyl-amino)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 98% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 322 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(ethyl-methanesulfonyl-amino)-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 95% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and iodoethane instead of iodomethane.
  • MS m/e (%): 703 (M+H+, 100)
    • EXAMPLE 323 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • A mixture of 150 mg (0.28 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 0.16 g (0.84 mmol) 4-(trifluoromethyl)piperidine hydrochloride in 2 ml 1,8-diazabicyclo[5.4.0]undec-7-ene was heated at 140° C. for 20 h. After cooling to room temperature the reaction mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 62 mg (34%) of the title compound as a light yellow solid.
  • MS m/e (%): 650 (M+H+, 100)
    • EXAMPLE 324 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 38% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 309) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 162) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 600 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.25 g (0.42 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 10 ml dichloromethane were added 206 mg (70%, 0.84 mmol) 3-chloroperbenzoic acid at 0° C. After completed addition, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. An aqueous solution of sodium hydrogensulfite was added and the mixture was stirred for 10 min. Basification with 1 N aqueous sodium hydroxide solution was followed by extraction with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.16 g (60%) of the title compound as a white solid.
  • MS m/e (%): 632 (M+H+, 100)
    • EXAMPLE 325 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a)(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 60% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (RS)-3-hydroxypiperidine instead of 4-(hydroxymethyl)piperidine.
  • MS m/e (%): 598 (M+H+, 100)
  • b) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 5% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 324) using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 326 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 35% yield after flash column chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 114a)) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 660 (M+H+, 100)
    • EXAMPLE 327 (1S,3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 57% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using nortropine instead of 4-(hydroxymethyl)piperidine.
  • MS m/e (%): 624 (M+H+, 100)
    • EXAMPLE 328 (1R,3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 37% yield after flash chromatography according to the procedure described above for the preparation of (5R,3S)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol (Example 304a)) using (1S,3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (3R,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol.
  • MS m/e (%): 624 (M+H+, 100)
    • EXAMPLE 329 (rac)-(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-8-aza-bicylo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 45% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (1R,3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 654 (M+H+, 100)
  • b) (rac)-(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 78% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′ ]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 670 (M+H+, 100)
    • EXAMPLE 330 (1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 60% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (rac)-(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 686 (M+H+, 100)
    • EXAMPLE 331 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • a) Thioacetic acid 5′-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-yl ester
  • A solution of 0.22 g (0.84 mmol) triphenylphosphine and 0.15 g (0.84 mmol) diethyl azodicarboxylate in 3.33 ml THF was stirred for 15 min at 0° C. This solution was added to a solution of 0.25 g (0.42 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and 64 mg (0.84 mmol) thoacetic acid in 10 ml THF at 0° C. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material a 2 N aqueous solution of sodium carbonate was added. The mixture was extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.16 g (59%) of the title compound as a white solid.
  • MS m/e (%): 656 (M+H+, 100)
  • b) 5′-[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino 1-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-sulfonic acid
  • To a suspension of 0.16 g (0.24 mmol) thioacetic acid 5′-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-yl ester in 1 ml acetic acid were added 0.12 ml (1.2 mmol) of a 30% aqueous solution of hydrogen peroxide at room temperature. After heating to 60° C., a clear solution was obtained. Stirring was continued at this temperature for 20 h. After cooling to room temperature an aqueous solution of sodium hydrogensulfite was added and the mixture was stirred for 10 min. Acidifcation with 1 N aqueous hydrochloride solution to pH 1 was followed by extraction with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 0.13 g (83%) of the title compound as a light yellow solid.
  • MS m/e (%): 660 ([M−H+]−, 100)
  • c) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • To a solution of 0.13 g (0.19 mmol) 5′-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-sulfonic acid in 2 ml dichloromethane were added 0.33 ml (0.39 mmol) oxalyl chloride and one drop of DMF at 0° C. After 30 min the reaction mixture was allowed to warm to room temperature during 2 h. To the yellow reaction mixture were added 1.8 ml (20 mmol) of an aqueous solution of dimethylamine (60%). After 1 h the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 92 mg (69%) of the title compound as a white solid.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 332 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methylsulfanyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 59% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 51) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 630 (M+H+, 100)
    • EXAMPLE 333 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfinyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 84% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methylsulfanyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 646 (M+H+, 100)
    • EXAMPLE 334 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 86% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfinyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 662 (M+H+, 100)
    • EXAMPLE 335 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.20 g (0.34 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide in 5 ml dichloromethane were added 0.03 g (0.4 mmol) 2-mercaptoethanol and 0.11 g (0.34 mmol) boron trifluoride etherate at 0° C. After 1 h the reaction mixture was allowed to warm to room temperature and stirred over night. Dilution with a 2 N aqueous sodium hydroxide solution was followed by extraction with 3 portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.22 g (98%) of the title compound as a white solid.
  • MS m/e (%): 656 (M+H+, 100)
    • EXAMPLE 336 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-4%6-thia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 55% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro [4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 688 (M+H+, 100)
    • EXAMPLE 337 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 84% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 3-mercapto-1-propanol instead of 2-mercaptoethanol.
  • MS m/e (%): 670 (M+H+, 100)
    • EXAMPLE 338 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5λ6-thia-9-aza-spiro [5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 70% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-5-thia-9-aza-spiro [5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 702 (M+H+, 100)
    • EXAMPLE 339 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,4,4-tetraoxo-lλ6,4λ6-dithia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,4-dithia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 41% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 1,2-ethanedithiol instead of 2-mercaptoethanol.
  • MS m/e (%): 672 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,4,4-tetraoxo-lλ6,4λ6-dithia-8-aza-spiro[4.51 dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 33% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,4-dithia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and 4 instead of 2 equivalents of 3-chloroperbenzoic acid.
  • MS m/e (%): 736 (M+H+, 100)
    • EXAMPLE 340 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,5,5-tetraoxo-lλ6,5λ6-dithia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,5-dithia-9-aza-spiro[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 41% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 1,3-propanedithiol instead of 2-mercaptoethanol.
  • MS m/e (%): 686 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,5,5-tetraoxo-lλ6,5λ6-dithia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 4% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,5-dithia-9-aza-spiro[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide and 4 instead of 2 equivalents of 3-chloroperbenzoic acid.
  • MS m/e (%): 750 (M+H+, 100)
    • EXAMPLE 341 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxa-8-aza-spiro [4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 12% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using 1-oxa-8-azaspiro[4.5]decane trifluoroacetic acid salt instead of 4-(trifluoromethyl)piperidine hydrochloride.
  • MS m/e (%): 638 (M+H+, 100)
    • EXAMPLE 342 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.10 g (0.17 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 142), 12 mg (0.39 mmol) paraformaldehyde and 61 mg (0.51 mmol) magnesium sulfate in 2 ml 1,2-dichloromethane was heated at 85° C. until complete consumption of starting material. After cooling to room temperature the reaction mixture was diluted with water and extracted with 3 portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 60 mg (59%) of the title compound as an off-white solid.
  • MS m/e (%): 600 (M+H+, 100)
    • EXAMPLE 343 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 67% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide (Example 115) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and morpholine instead of 2-(methylamino)ethanol.
  • MS m/e (%): 584 (M+H+, 100)
    • EXAMPLE 344 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl-phenyl)-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.15 g (0.28 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.13 g (0.84 mmol) 8-oxa-3-aza-bicyclo[3.2.1]octane hydrochloride and 0.20 g (1.4 mmol) potassium carbonate in 1 ml dimethyl sulfoxide was heated at 150° C. under microwave irradiation in a sealed tube for 30 min. Another portion of 0.06 g (0.4 mmol) 8-oxa-3-aza-bicyclo[3.2.1]octane hydrochloride was added and the reaction mixture was heated at 150° C. under microwave irradiation in a sealed tube for 30 more minutes. After cooling to room temperature the reaction mixture was diluted with water and extracted with four portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated. Flash column chromatography gave 32 mg (18%) of the title compound as a light yellow solid.
  • MS m/e (%): 610 (M+H+, 100)
    • EXAMPLE 345 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as light orange foam in 19% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 155) using 2-(methylthio)ethylamine instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 588 (M+H+, 100)
    • EXAMPLE 346 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 54% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl ester (Example 307a)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide instead of (S)-2-methylsulfanylmethyl-pyrrolidine-1-carboxylic acid benzyl ester.
  • MS m/e (%): 620 (M+H+, 100)
    • EXAMPLE 347 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.25 g (0.47 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 0.59 g (6.6 mmol) thiazolidine was heated three times at 180° C. for 30 minutes and once at 250° C. for 15 minutes under microwave irradiation in a sealed tube. The reaction mixture was diluted with a 0.2 M aqueous solution of sodium hydroxide and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography and drying in high vacuo (70-90° C./1-2 mbar) for three hours gave 33 mg (12%) of the title compound as a yellow oil.
  • MS m/e (%): 586 (M+H+, 100)
    • EXAMPLE 348 (1RS,4RS)- or (1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 349) and EXAMPLE 349 (1RS,4SR)- or (1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-1%4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example 348)
  • a) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 42% yield after flash chromatography according to the procedure described above for the preparation of (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine (Example 174a)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 142) instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
  • MS m/e (%): 702 (M+H+, 100)
  • b) (RS)-Thioacetic acid 2-[5-f [2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-(tert-butyl-dimethyl-silanyloxy)-propyl ester
  • To a solution of 0.19 mg (0.71 mmol) triphenylphosphine in 10 ml dry THF were added 0.12 g (0.71 mmol) diethyl azodicarboxylate at 0° C. under argon. After 30 min a solution of 0.50 g (0.71 mmol) (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in 5 ml dry THF and 0.06 g (0.9 mmol) thioacetic acid were added. The reaction mixture was allowed to warm to room temperature over night. Dilution with a saturated aqueous solution of sodium hydrogencarbonate was followed by extraction with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.28 g (52%) of the title compound as a white solid.
  • MS m/e (%): 760 (M+H+, 100)
  • c) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-mercaptomethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.28 mg (0.37 mmol) (RS)-thioacetic acid 2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-(tert-butyl-dimethyl-silanyloxy)-propyl ester in 10 ml ethanol and 4 ml of a 2 N solution of ammonia in ethanol was heated at reflux for 4 h. After cooling to room temperature the reaction mixture was concentrated in vacuo to give 0.22 g of the crude title compound as a light brown amorphous residue, which was used in the next step without any further purification.
  • d) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-mercaptomethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The crude title compound was obtained as a light brown amorphous residue in quantitative yield after extraction according to the procedure described above for the preparation of (S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine (Example 174a)) using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-mercaptomethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
  • e) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[4-(tert-butyl-dimethyl-silanyloxymethyl)-thiazolidin-3-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 39% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 342) using (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-mercaptomethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 730 (M+H+, 100)
  • f) (1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
  • (1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 50 mg (0.069 mmol) (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[4-(tert-butyl-dimethyl-silanyloxymethyl)-thiazolidin-3-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in 2 ml dichloromethane were added 17 mg (70%, 0.069 mmol) 3-chloroperbenzoic acid at 0° C. After completed addition, the reaction mixture was allowed to warm to room temperature during 3 h. A saturated aqueous solution of sodium carbonate was added and the mixture was extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. The residue, 80 mg of a brown oil, was dissolved in 2 ml THF and treated with 0.07 ml (0.07 mmol) of a 1 M solution of tetrabutylammonium fluoride in THF at room temperature. After stirring at room temperature over night the reaction mixture was diluted with a 2 N aqueous solution of sodium carbonate and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulphate and concentrated. Preparative thin layer chromatography gave 24 mg (55%) of one diastereomeric racemate of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white solid and 11 mg (25%) of the second diastereomeric racemate of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white solid. The assignement of the relative configuration of the two diastereomeric racemates was not possible.
    • (3RS,4RS)- or (1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 632 (M+H+, 100)
    • (1RS,4SR)- or (1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • MS m/e (%): 632 (M+H+, 100)
    • EXAMPLE 350 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1,1-dioxo-lλ6-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 83% yield from (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[4-(tert-butyl-dimethyl-silanyloxymethyl)-thiazolidin-3-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide after flash chromatography according to the procedure described above for the preparation of (1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide and (1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (step f)) using two instead of one molar equivalents of 3-chloroperbenzoic acid.
  • MS m/e (%): 648 (M+H+, 100)
    • EXAMPLE 351 (1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8λ6-thia-3-aza-bicyclo [3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-8-thia-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light yellow viscous oil in 22% yield after flash chromatography according to the procedure described above for the preparation of (2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 155) using (1S,5R)-8-thia-3-azabicyclo[3.2.1]octane hydrochloride instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
  • MS m/e (%): 626 (M+H+, 100)
  • b) (1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8λ6-thia-3-aza-bicyclo [3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 42% yield after flash chromatography according to the procedure described above for the preparation of (S)-2-methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl ester (Example 307a)) using (1S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-8-thia-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of (S)-2-methylsulfanylmethyl-pyrrolidine-1-carboxylic acid benzyl ester.
  • MS m/e (%): 658 (M+H+, 100)
    • EXAMPLE 352 (+)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid by preparative HPLC separation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 178) on a Chiralpak AD column (heptane/ethanol 85:15).
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 353 (−)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-lλ6-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in 81% enantiomeric excess as a white solid by preparative HPLC separation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 178) on a Chiralpak AD column (heptane/ethanol 85:15).
  • MS m/e (%): 644 (M+H+, 100)
    • EXAMPLE 354 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide and EXAMPLE 355 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[1,4]thiazepan-4-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 41% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 323) using [1,4]thiazepane hydrochloride instead of 4-(trifluoromethyl)piperidine hydrochloride.
  • MS m/e (%): 614 (M+H+, 100)
  • b) (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-11,41 thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
  • 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.11 g (0.18 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[1,4]thiazepan-4-yl-pyridin-3-yl]-N-methyl-isobutyramide in 2 ml dichloromethane were added 63 mg (70%, 0.27 mmol) 3-chloroperbenzoic acid at room temperature. The reaction mixture was stirred over night. Dilution with a 2 M aqueous solution of sodium carbonate was followed by extraction with three portions of dichloromethane. The combined organic extracts were dried over sodium sulphate and concentrated. Flash column chromatography gave 71 mg (66%) of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white solid and 32 mg (29%) of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide as a white solid.
    • (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide: MS m/e (%): 630 (M+H+, 100)
    • 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide: MS m/e (%): 646 (M+H+, 100)
    EXAMPLE 356 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 2.0 g (3.8 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 5.6 g (75 mmol) 3-amino-1-propanol was heated at 180° C. under microwave irradiation for 40 min. Dilution with water was followed by extraction with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash chromatography gave 1.9 g (87%) of the title compound as a white solid.
  • MS m/e (%): 572 (M+H+, 100)
  • b) Thioacetic acid 3-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino 1-propyl ester
  • The title compound was obtained as a white solid in 69% yield after flash chromatography according to the procedure described above for the preparation of (RS)-thioacetic acid 2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-(tert-butyl-dimethyl-silanyloxy)-propyl ester (Example 349 b)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide instead of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 630 (M+H+, 100)
  • c) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-mercapto-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 1.3 g (2.0 mmol) thioacetic acid 3-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-propyl ester in 20 ml methanol were added 5 ml of a 25% aqueous solution of ammonium hydroxide. The reaction mixture was heated at 50° C. for 1 h. After cooling to room temperature the mixture was acidified with 1 N aqueous hydrochloric acid solution and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give the crude title compound in quantitative yield as a light yellow solid.
  • MS m/e (%): 588 (M+H+, 100)
  • d) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[1,3]thiazinan-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 68% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 342) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-mercapto-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 600 (M+H+, 100)
  • e) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 73% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 324 b)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[1,3]thiazinan-3-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 632 (M+H+, 100)
    • EXAMPLE 357 N-[6-(2-Amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 1.0 g (1.9 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and 5.0 ml (75 mmol) ethylenediamine was heated at 130° C. for 6 h. After cooling to room temperature the reaction mixture was diluted with 20 ml tert-butyl methyl ether and washed with 20 ml of a saturated aqueous solution of sodium carbonate, 20 ml of water and 20 ml of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 0.92 g (88%) of the title compound as a white foam.
  • MS m/e (%): 557 (M+H+, 100)
    • EXAMPLE 358 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 89% yield after flash chromatography according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 317) using N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 633 ([M−H+]−, 74)
    • EXAMPLE 359 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.20 g (0.36 mmol) N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 2 ml 1,2-dichloroethane were added 42 mg (0.48 mmol) paraformaldehyde and 0.13 g (1.1 mmol) magnesium sulfate. After stirring at room temperature for 18 h 0.14 g (1.1 mmol) N,N-diisopropylethylamine, 2 mg (0.02 mmol) 4-(N,N-dimethylamino)pyridine and 62 mg (0.54 mmol) methanesulfonyl chloride were added. The reaction mixture was heated to 80° C. and kept at this temperature for 4 h. After cooling to room temperature the reaction mixture was diluted with 20 ml tert-butyl methyl ether and washed with two 20-ml portions of a saturated aqueous solution of sodium carbonate. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 93 mg (40%) of the title compound as a white foam.
  • MS m/e (%): 647 (M+H+, 100)
    • EXAMPLE 360 N-[6-(2-Acetylamino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 48% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 356a)) using N-acetylethylenediamine instead of 3-amino-1-propanol.
  • MS m/e (%): 599 (M+H+, 100)
    • EXAMPLE 361 N-[6-(3-Acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • To a solution of 50 mg (0.090 mmol) N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 2 ml 1,2-dichloroethane were added 3 mg (0.1 mmol) paraformaldehyde and 32 mg (0.27 mmol) magnesium sulfate. After stirring at room temperature over night another 3 mg (0.1 mmol) paraformaldehyde were added and the reaction mixture was heated to 85° C. After 1 h the reaction mixture was cooled to room temperature and treated with 14 mg (0.13 mmol) triethylamine and 11 mg (0.13 mmol) acetyl chloride. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash chromatography to give 40 mg (73%) of the title compound as an off-white solid.
  • MS m/e (%): 611 (M+H+, 100)
    • EXAMPLE 362 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
  • The crude title compound was obtained as an off-white solid in 98% yield after extraction according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide (Example 115) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and piperazine instead of 2-(methylamino)ethanol.
  • MS m/e (%): 565 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.16 g (0.31 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide and 38 mg (0.38 mmol) triethylamine in 4 ml dichloromethane were added 38 mg (0.33 mmol) methanesulfonyl chloride at 0° C. After completed addition the reaction mixture was allowed to warm to room temperature. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with water and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. Flash cholumn chromatography gave 0.15 g (75%) of the title compound as a white solid.
  • MS m/e (%): 643 (M+H+, 100)
    • EXAMPLE 363 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 73% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a).
  • MS m/e (%): 663 (M+H+, 100)
    • EXAMPLE 364 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 79% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4K) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a).
  • MS m/e (%): 677 (M+H+, 100)
    • EXAMPLE 365 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 77% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4E) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a).
  • MS m/e (%): 661 (M+H+, 100)
    • EXAMPLE 366 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 83% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a).
  • MS m/e (%): 661 (M+H+, 100)
    • EXAMPLE 367 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 78% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a) and ethanesulfonyl chloride instead of methanesulfonyl chloride in step b).
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 368 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 84% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a) and chloromethylsulfonyl chloride instead of methanesulfonyl chloride in step b).
  • MS m/e (%): 695 (M+H+, 100)
    • EXAMPLE 369 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 84% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in step a) and dimethylsulfamoyl chloride instead of methanesulfonyl chloride in step b).
  • MS m/e (%): 695 (M+H+, 100)
    • EXAMPLE 370 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.20 g (0.38 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 0.11 g (1.1 mmol) (R)-2-methylpiperazine and 0.10 g (0.72 mmol) potassium carbonate in 0.3 ml dimethyl sulfoxide was heated at 180° C. under microwave irradiation in a sealed tube for 30 min. After cooling to room temperature the reaction mixture was diluted with a 0.3 M aqueous solution of sodium hydroxide and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated. Flash column chromatography gave 0.12 g (51%) of the title compound as an off-white solid.
  • MS m/e (%): 597 (M+H+, 100)
  • b) (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 87% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 371 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(R)-1-Benzyl-3-methyl-piperazine
  • A mixture of 1.0 g (10 mmol) (R)-2-methylpiperazine, 1.3 g (10 mmol) benzyl chloride and 4.1 g (30 mmol) potassium carbonate in 10 ml ethanol was heated at reflux over night. After cooling to room temperature the reaction mixture was diluted with a 0.5 M aqueous solution of sodium hydroxide and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated. Flash column chromatography gave 0.93 g (49%) of the title compound as an off-white solid.
  • MS m/e (%): 191 (M+H+, 100)
  • b) (R)-N-[6-(4-Benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • A mixture of 0.20 g (0.38 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 93 mg (0.49 mmol) (R)-1-benzyl-3-methyl-piperazine, 0.01 g (0.03 mmol) cetyltrimethyl-ammonium bromide, 0.038 g (0.074 mmol) bis(tri-t-butylphosphine)palladium(0), 0.05 ml NaOH 50% and 2 ml toluene was degassed by two freeze-thaw cycles. The reaction mixture was heated under argon at 90° C. for 48 h. After cooling to room temperature the mixture was diluted with water and brine and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. Flash column chromatography gave 95 mg (37%) of the title compound as a light yellow solid.
  • MS m/e (%): 687 (M+H+, 100)
  • c) (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A solution of 0.11 g (0.17 mmol) (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in 3 ml acetic acid was deoxygenated by three cycles of evacuation and flushing with argon. After addition of 0.02 g palladium on charcoal (10%) the reaction vessel was evacuated and filled with hydrogen gas. The reaction mixture was stirred at room temperature under an atmosphere of hydrogen for 3 h. The reaction mixture was filtered over decalite followed by washing with tert-butyl methyl ether. The filtrate was washed with a 2 M aqueous solution of sodium hydroxide. The aqueous layer was extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give 98 mg (98%) of the crude title compound as an off-white solid, which was used in the next step without further purification.
  • MS m/e (%): 597 (M+H+, 100)
  • d) (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 87% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 372 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4A) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 677 (M+H+, 100)
    • EXAMPLE 373 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide (Intermediate 4G) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 657 (M+H+, 100)
    • EXAMPLE 374 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 370) using (S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a).
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 375 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 370) using (S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4A) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 677 (M+H+, 100)
    • EXAMPLE 376 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 370) using (S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide (Intermediate 4G) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 657 (M+H+, 100)
    • EXAMPLE 377 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a).
  • MS m/e (%): 675 (M+H+, 100)
    • EXAMPLE 378 (2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.20 g (0.38 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, 87 mg (0.75 mmol) (2RS,5SR)-dimethyl-piperazine, 0.01 g (0.03 mmol) cetyltrimethyl-ammonium bromide, 0.01 g (0.02 mmol) bis(tri-t-butylphosphine)palladium(0), 0.075 ml NaOH 50% and 3 ml toluene was degassed by two freeze-thaw cycles. The reaction mixture was heated under argon at 90° C. for 48 h. After cooling to room temperature the mixture was diluted with water and brine and extracted with three portions of tert-butyl methyl ether. The combined organic layers were dried over sodium sulphate and concentrated in vacuo. Flash column chromatography gave 96 mg (42%) of the title compound as a light yellow solid.
  • MS m/e (%): 611 (M+H+, 100)
  • b) (2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 69% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using (2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,5-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 379 (2S,6R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 1% overall yield after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using cis-2,6-dimethyl-piperazine instead of (R)-2-methylpiperazine in step a).
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 380 (3S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 56% yield after flash chromatography according to the procedures described above for the preparation of (2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using cis-2,6-dimethyl-piperazine instead of (2RS,5SR)-dimethyl-piperazine in step a).
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 381 (1S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(1S,4S)-N-lλ6-(5-Benzyl-2,5-diaza-bicyclo[2.2.11 hept-2-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 85% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide using (1S,4S)-(+)-2-benzyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide instead of 4-(trifluoromethyl)piperidine hydrochloride.
  • MS m/e (%): 685 (M+H+, 100)
  • b) (1S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 80% yield after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 371 steps c) and d)) using (1S,4S)-N-[6-(5-benzyl-2,5-diaza-bicyclo [2.2.1]hept-2-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide in step c).
  • MS m/e (%): 673 (M+H+, 100)
    • EXAMPLE 382 (1R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (1R,5S)-8-benzyl-3,8-diazabicyclo[3.2.1]octane dihydrochloride instead of (1S,4S)-(+)-2-benzyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide in step a).
  • MS m/e (%): 687 (M+H+, 100)
    • EXAMPLE 383 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-N-[6-(2-Benzyloxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in comparable yields according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 371c)) using (S)-1-benzyl-3-(benzyloxymethyl)piperazine (prepared as described in WO2001009111) instead of (R)-1-benzyl-3-methyl-piperazine in step b).
  • MS m/e (%): 703 (M+H+, 100)
  • b) (S)-N-[6-(2-Benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 89% yield after flash chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using (S)-N-[6-(2-benzyloxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 781 (M+H+, 100)
  • c) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in 72% yield after flash chromatography according to the procedures described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 152 b)) using (S)-N-[6-(2-benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 691 (M+H+, 100)
    • EXAMPLE 384 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A mixture of 0.35 ml (3.7 mmol) acetic anhydride and 0.17 ml (4.6 mmol) formic acid was heated at 50° C. for 2 h. After cooling to room temperature a portion of 0.08 ml of this mixture was added to 0.5 ml THF. A solution of 0.10 g (0.14 mmol) (S)-N-[6-(2-benzyloxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide (Example 383a)) in 1 ml THF was added dropwise at 0° C. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo to give 0.11 g of crude (S)-N-[6-(2-benzyloxymethyl-4-formyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide as a light yellow solid.
  • The title compound was obtained as a white solid in 58% yield after flash chromatography according to the procedure described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 152 b)) using crude (S)-N-[6-(2-benzyloxymethyl-4-formyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 641 (M+H+, 100)
    • EXAMPLE 385 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using cyclopropanecarboxylic acid chloride instead of methanesulfonyl chloride in step b).
  • MS m/e (%): 681 (M+H+, 100)
    • EXAMPLE 386 (S)-N-[6-(4-Acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using acetic anhydride instead of methanesulfonyl chloride in step b).
  • MS m/e (%): 655 (M+H+, 100)
    • EXAMPLE 387 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-N-[6-(2-Benzyloxymethyl-4-ethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a light brown solid in 5% yield in step c) according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 371c)) using (S)-1-benzyl-3-(benzyloxymethyl)piperazine (prepared as described in WO2001009111) instead of (R)-1-benzyl-3-methyl-piperazine in step b) and ethanol instead of acetic acid as a solvent in step c).
  • MS m/e (%): 731 (M+H+, 100)
  • b) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 58% yield after flash chromatography according to the procedure described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 152 b)) using (S)-N-[6-(2-benzyloxymethyl-4-ethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 641 (M+H+, 100)
    • EXAMPLE 388 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-[5-{[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(2-chloro-phenyl)-pyridin-2-ylamino]-ethanesulfonic acid
  • The title compound was obtained as a light brown solid in 49% yield after flash column chromatography according to the procedure described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 165) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4A) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and taurine instead of L-prolinol.
  • MS m/e (%): 622 ([M−H+]−, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 77% yield after flash column chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 331 step c)) using a 12 M aqueous solution of N-methylamine instead of a solution of dimethylamine.
  • MS m/e (%): 637 (M+H+, 100)
    • EXAMPLE 389 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methyl-1,1-dioxo-lλ6-thiadiazinan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 31% yield after flash chromatography according to the procedure described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 342) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
  • MS m/e (%): 649 (M+H+, 100)
    • EXAMPLE 390 (RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-2λ4-[1,2,3]oxathiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • To a solution of 0.20 g (0.36 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide in a 5 ml dichloromethane were added consecutively 0.11 g (1.1 mmol) triethylamine and 0.05 g (0.4 mmol) thionyl chloride at room temperature. After 1 h the reaction mixture was diluted with water and extracted with three portions of dichloromethane. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 0.17 g (77%) of the title compound as a white solid.
  • MS m/e (%): 606 (M+H+, 100)
    • EXAMPLE 391 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)(S)-4-Benzyl-2-benzyloxymethyl-1-methanesulfonyl-piperazine
  • The crude title compound was obtained as a light brown oil in quantitative yield after extraction according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using (S)-1-benzyl-3-(benzyloxymethyl)piperazine instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 375 (M+H+, 100)
  • b) (S)-2-Benzyloxymethyl-1-methanesulfonyl-piperazine
  • The crude title compound was obtained as a light brown oil in 60% yield after extraction according to the procedure described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 371c)) using (S)-4-benzyl-2-benzyloxymethyl-1-methanesulfonyl-piperazine instead of (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 285 (M+H+, 100)
  • c) (S)-N-[6-(3-Benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 55% yield after flash chromatography according to the procedure described above for the preparation of (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide (Example 371 b)) using (S)-2-benzyloxymethyl-1-methanesulfonyl-piperazine instead of (R)-1-benzyl-3-methyl-piperazine.
  • MS m/e (%): 781 (M+H+, 100)
  • d) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 96% yield after flash chromatography according to the procedure described above for the preparation of (1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide (Example 152 b)) using (S)-N-[6-(3-benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of (1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
  • MS m/e (%): 691 (M+H+, 100)
    • EXAMPLE 392 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as white solid in comparable yields after flash column chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (R)- instead of (S)-1-benzyl-3-(benzyloxymethyl)piperazine in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide (Intermediate 4G) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
  • MS m/e (%): 673 (M+H+, 100)
    • EXAMPLE 393 (R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as white solid in comparable yields after flash column chromatography according to the procedures described above for the preparation of (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (R)- instead of (S)-1-benzyl-3-(benzyloxymethyl)piperazine in step a).
  • MS m/e (%): 691 (M+H+, 100)
    • EXAMPLE 394 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,3-dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a light brown amorphous resin in 27% yield after flash column chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide (Example 323) using 2,2-dimethyl-piperazine di-acetic acid salt instead of 4-(trifluoromethyl)piperidine hydrochloride.
  • MS m/e (%): 611 (M+H+, 100)
  • b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in 69% yield after flash column chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(dimethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 395 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as white solid in comparable yields after flash column chromatography according to the procedures described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide (Intermediate 4G) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step a).
  • MS m/e (%): 671 (M+H+, 100)
    • EXAMPLE 396 (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Example 370) using (S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl}-N-methyl-isobutyramide (Intermediate 4L) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 787 (M+H+, 100)
  • b) (S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • A solution of 73 mg (0.093 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 5 ml of a 1 M solution of hydrochloric acid in methanol was stirred at room temperature. Conversion was monitored by thin layer chromatography. After complete consumption of the starting material the reaction mixture was diluted with a 1 M aqueous solution of sodium hydroxide and extracted with three portions of tert-butyl methyl ether. The combined organic extracts were dried over sodium sulfate and concentrated in vacuo. Flash column chromatography gave 62 mg (quantitative) of the title compound as a light yellow solid.
  • MS m/e (%): 673 (M+H+, 100)
    • EXAMPLE 397 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,2-dimethyl-piperazine di-acetic acid salt instead of (R)-2-methyl-piperazine in step a).
  • MS m/e (%): 689 (M+H+, 100)
    • EXAMPLE 398 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as an off-white solid in comparable yields after flash chromatography according to the procedures described above for the preparation of (R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using 2,2-dimethyl-piperazine di-acetic acid salt instead of (R)-2-methyl-piperazine in step a) and 2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide (Intermediate 4G) instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
  • MS m/e (%): 671 (M+H+, 100)
    • EXAMPLE 399 (S)-2-(3,5-Dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a white solid.
  • MS m/e (%): 439 (M+H+, 100).
  • b) (S)-2-(3,5-Dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a light yellow foam.
  • MS m/e (%): 504 (M+H+, 100).
    • EXAMPLE 400 (2S,4R)-2-(3,5-Dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 520 (M+H+, 100).
    • EXAMPLE 401 2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a white solid.
  • MS m/e (%): 457 (M+H+, 100).
  • b) 2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1b) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and ethanolamine as an off-white foam.
  • MS m/e (%): 482 (M+H+, 100).
    • EXAMPLE 402 (S)-2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 522 (M+H+, 100).
    • EXAMPLE 403 (2S,4R)-2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 538 (M+H+, 100).
    • EXAMPLE 404 (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
  • a) N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine and 2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a light yellow solid.
  • MS m/e (%): 459 (M+H+, 100).
  • b) (2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 540 (M+H+, 100).
    • EXAMPLE 405 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dihydroxy-phenyl)-N-methyl-isobutyramide
  • To a solution of 2.8 g (6.4 mmol) N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide in 70 ml CH2Cl2 19 ml (19 mmol) BBr3 (1 M in CH2Cl2) were added at 0° C. The reaction mixture was allowed to reach ambient temperature and stirred for 15 h After addition of 50 ml water the mixture was extracted with three portions of dichloromethane. The combined organic extracts were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/methanol) to give 2.5 g (95%) of the title compound as a white foam.
  • MS m/e (%): 409 (M+H+, 87).
  • b) 2-(3,5-Bis-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
  • To a solution of 2.5 g (6.1 mmol) N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dihydroxy-phenyl)-N-methyl-isobutyramide in 60 ml DMF 1.7 g (12 mmol) K2CO3 and 1.5 ml (12 mmol) ethyl chlordifluoroacetate were added and the resulting suspension heated at 65° C. for 15 h. After cooling to ambient temperature, the reaction mixture was poured into 250 ml water and extracted with three portions of CH2Cl2. The combined organic extracts were dried (Na2SO4), filtered and evaporated. The residue was purified by flash-chromatography (SiO2, CH2Cl2/ethyl acetate) to give 0.71 g (23%) of the title compound as a colorless viscous oil.
  • MS m/e (%): 511 (M+H+, 100).
  • c) 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1b) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and ethanolamine as an off-white foam.
  • MS m/e (%): 536 (M+H+, 100).
    • EXAMPLE 406 (2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 592 (M+H+, 100).
    • EXAMPLE 407 (S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 576 (M+H+, 100).
    • EXAMPLE 408 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 406a), b) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide as a colorless oil.
  • MS m/e (%): 529 (M+H+, 100).
  • b) 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1b) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and ethanolamine as a white foam.
  • MS m/e (%): 554 (M+H+, 100).
    • EXAMPLE 409 (S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and L-prolinol as a light brown foam.
  • MS m/e (%): 594 (M+H+, 100).
    • EXAMPLE 410 (2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • a)2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 406a), b) from N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide as a colorless oil.
  • MS m/e (%): 531 (M+H+, 100).
  • b) (2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 612 (M+H+, 100).
    • EXAMPLE 411 (S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and L-prolinol as a white foam.
  • MS m/e (%): 596 (M+H+, 100).
    • EXAMPLE 412 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1b) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and ethanolamine as a white foam.
  • MS m/e (%): 556 (M+H+, 100).
    • EXAMPLE 413 (2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow foam.
  • MS m/e (%): 610 (M+H+, 100).
    • EXAMPLE 414 (2S,4R)-N-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • a) N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from (6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and 2-methyl-2-(3-trifluoromethoxy-phenyl)-propionyl chloride (Intermediate 5I) as a light yellow oil.
  • MS m/e (%): 462 (M+, 8).
  • b) (2S,4R)-N-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 544 (M+H+, 100).
    • EXAMPLE 415 (2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • a) N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 1a) from [6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine and 2-methyl-2-(3-trifluoromethoxy-phenyl)-propionyl chloride (Intermediate 5I) as white solid.
  • MS m/e (%): 481 (M+H+, 100).
  • b) (2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 3) from N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
  • MS m/e (%): 562 (M+H+, 100).
    • EXAMPLE 416 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and piperazine instead of L-prolinol as a light yellow foam.
  • MS m/e (%): 581 (M+H+, 100).
    • EXAMPLE 417 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from 2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and piperazine instead of L-prolinol as an off-white foam.
  • MS m/e (%): 579 (M+H+, 100).
    • EXAMPLE 418 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 84% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 659 (M+H+, 100)
    • EXAMPLE 419 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 88% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using 2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 657 (M+H+, 100)
    • EXAMPLE 420 2-(3,5-Bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
  • The title compound was obtained in an analogous manner to that described in example 2) from N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and piperazine instead of L-prolinol as a light yellow foam.
  • MS m/e (%): 561 (M+H+, 100).
    • EXAMPLE 421 2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
  • The title compound was obtained as a white foam in 61% yield after flash chromatography according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 362 b)) using 2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide instead of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
  • MS m/e (%): 639 (M+H+, 100)
    • EXAMPLE A
  • Tablets of the following composition are manufactured in the usual manner:
    mg/tablet
    Active substance 5
    Lactose 45
    Corn starch 15
    Microcrystalline cellulose 34
    Magnesium stearate 1
    Tablet weight 100
    • EXAMPLE B
  • Capsules of the following composition are manufactured:
    mg/capsule
    Active substance 10
    Lactose 155
    Corn starch 30
    Talc 5
    Capsule fill weight 200
  • The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelatine capsules.
    • EXAMPLE C
  • Suppositories of the following composition are manufactured:
    mg/supp.
    Active substance 15
    Suppository mass 1285
    Total 1300
  • The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool, the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.

Claims (37)

1. A method of treating schizophrenia comprising administering to an individual an effective amount of a compound of formula I
Figure US20050090533A1-20050428-C00475
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl,
 —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
 —Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′R″,
 —(CH2)cNR′C(O)-alkyl,
 —(CH2)cNR′S(O)2-alkyl,
 —(CH2)dS(O)-alkyl,
 —(CH2)dS-alkyl,
 —(CH2)dS(O)2-alkyl, or
 —(CH2)dS(O)2—NR′R″;
R′ is hydrogen, alkyl, —(CH2)oOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)e-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with
 —(CH2)2—S(O)2N(CH3)—CH2, or with
 —S(O)—O—(CH2)2,3—;
or —NR4R5 is
Figure US20050090533A1-20050428-C00476
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3;
e is 3, 4, or 5; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
2. The method of claim 1, wherein the compound of formula I is a compound of formula IA
Figure US20050090533A1-20050428-C00477
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH, or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other and are hydrogen, or
 Cb-alkyl;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl;
a is 0 or 1;
b is 1 or 2; and
d is 0, 1, 2 or 3;
or a pharmaceutically acceptable acid addition salt thereof.
3. The method of claim 1, wherein the compound of formula I is a compound of formula IB
Figure US20050090533A1-20050428-C00478
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently hydrogen, —(CH2)2SCH3, —(CH2)2S(O)2CH3, —(CH2)2S(O)2NHCH3, —(CH2)2NH2, —(CH2)2NHS(O)2CH3, or —(CH2)2NHC(O)CH3;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2; and
d is 0, 1, 2, or 3;
or a pharmaceutically active acid-addition salt thereof.
4. The method of claim 1, wherein the compound of formula I is a compound of formula IC
Figure US20050090533A1-20050428-C00479
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 is hydrogen;
R5 is —(CH2)0-cycloalkyl, unsubstituted or substituted by hydroxy;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl,
 —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2; and
d is 0, 1, 2, or 3;
or a pharmaceutically active acid-addition salt thereof.
5. The method of claim 1, wherein the compound of formula I is a compound of formula ID
Figure US20050090533A1-20050428-C00480
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)e-, which is unsubstituted or substituted by one or more substituents selected from the group consisting of —(CR′R″)dOH;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl,
 —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2;
d is 0, 1, 2, or 3; and
e is 3, 4, or 5;
or a pharmaceutically active acid-addition salt thereof.
6. The method of claim 1, wherein the compound of formula I is a compound of formula IE
Figure US20050090533A1-20050428-C00481
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3; and
e is 3, 4, or 5;
or a pharmaceutically active acid-addition salt thereof.
7. The method of claim 1, wherein the compound of formula I is a compound of formula IF
Figure US20050090533A1-20050428-C00482
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3; and
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl,
 —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3; and
e is 3, 4, or 5;
or a pharmaceutically active acid-addition salt thereof.
8. The method of claim 1, wherein the compound of formula I is a compound of formula IG
Figure US20050090533A1-20050428-C00483
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl and —NR′S(O)2-alkyl;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)c—S(O)f—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)d, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, 3 or 4;
e is 3, 4, or 5; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
9. The method of claim 1, wherein the compound of formula I is a compound of formula IH
Figure US20050090533A1-20050428-C00484
wherein
R1 is heteroaryl selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a— alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
 —Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′R″,
 —(CH2)cNR′C(O)-alkyl,
 —(CH2)cNR′S(O)2-alkyl,
 —(CH2)dS(O)-alkyl,
 —(CH2)dS-alkyl,
 —(CH2)dS(O)2-alkyl, or
 —(CH2)dS(O)2—NR′R″;
R′ is hydrogen, alkyl, —(CH2)oOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)c—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with
 —(CH2)2—S(O)2N(CH3)—CH2, or with
 —S(O)—O—(CH2)2,3—;
or —NR4R5 is
Figure US20050090533A1-20050428-C00485
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d iso, 1, 2, or 3;
e is 3, 4, or 5; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
10. The method of claim 1, wherein the compound of formula I is a compound of formula I J,
Figure US20050090533A1-20050428-C00486
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl, selected from the group, consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
—NR4R5 are
Figure US20050090533A1-20050428-C00487
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl;
b is 1 or 2;
d is 0, 1, 2, or 3; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
11. The method of claim 1, wherein the compound of formula I is a compound of formula I-1
Figure US20050090533A1-20050428-C00488
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN,
 S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl, selected from the groups consisting of pyridin-2-or 3-yl, imidazolyl or oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(C+R′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-lower alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
 —Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′C(O)-lower alkyl,
 —(CH2)cNR′S(O)2-lower alkyl, or
 —(CH2)dS(O)2-lower alkyl;
R′ is hydrogen, lower alkyl, —(CH2)oOH, —C(O)H, —C(O)-lower alkyl, —C(O)-cycloalkyl, —S(O)2-lower alkyl;
R″ is hydrogen or lower alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)e-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, CF3, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl,
—(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl,
—(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with
—(CH2)e, or
by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-loewr alkyl,
—(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with
—(CH2)e, or
by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl,
—(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of lower alkyl, halogen, —(CR′R″)dOH, ═O, and —NR′R″, wherein R′ and R″ may form together with the N-atom to which they are attached a ring with
—(CH2)e, or
by —(CH2)dNR′—C(O)-lower alkyl, —(CH2)d—C(O)-lower alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-lower alkyl,
—(CH2)d-pyrrolidinyl or —C(O)NR′R″;
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3;
e is 3, 4, or 5; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
12. A compound selected from the group consisting of
N-[6-(2-acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifuoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-butylamino)-pyrin-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxyethyl)-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[(2-hydroxy-ethyl)-propyl-amino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifuoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1′-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl-(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide, and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide.
13. A composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.
14. A compound of formula IB
Figure US20050090533A1-20050428-C00489
wherein
R1 is phenyl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl;
R and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently hydrogen, —(CH2)2SCH3, —(CH2)2S(O)2CH3, —(CH2)2S(O)2NHCH3, —(CH2)2NH2, —(CH2)2NHS(O)2CH3 or —(CH2)2NHC(O)CH3;
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl;
R″ is hydrogen or alkyl;
b is 1 or 2; and
d is 0, 1, 2, or 3;
or a pharmaceutically active acid-addition salt thereof.
15. A composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier.
16. A compound selected from the group consisting of
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide, and
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
17. A composition comprising a compound of claim 16 and a pharmaceutically acceptable carrier.
18. A compound selected from the group consisting of
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrol idin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrol idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
(S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide, and
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
19. A composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier.
20. A compound selected from the group consisting of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-benzamide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrol idin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide, and
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
21. A composition comprising a compound of claim 20 and a pharmaceutically acceptable carrier.
22. A compound selected from the group consisting of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrol idin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrol idin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide.
23. A composition comprising a compound of claim 22 and a pharmaceutically acceptable carrier.
24. A compound selected from the group consisting of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide,
(S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-dimethyl-carbamic acid 1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-pyrrolidin-2-ylmethyl ester,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-(2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[4-amino-4′-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
N-[4-acetylamino-4′-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide, and
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl-4′-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl)-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide and
(2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4′-(2-chloro-phenyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl]-N-methyl-isobutyramide.
25. A composition comprising a compound of claim 24 and a pharmaceutically acceptable carrier.
26. A compound selected from the group consisting of
N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-oxo-[1,4]diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-piperazin-1-y)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-(4-acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide, and
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
27. A composition comprising a compound of claim 26 and a pharmaceutically acceptable carrier.
28. A compound selected from the group consisting of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
29. A composition comprising a compound of claim 28 and a pharmaceutically acceptable carrier.
30. A compound selected from the group consisting of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-lλ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
(1RS,4RS)- or (1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(1RS,4SR)- or (1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-lλ4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1,1-dioxo-lλ6-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l□6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(−)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l□6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-oxo-lλ4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-lλ6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide, and
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
31. A composition comprising a compound of claim 30 and a pharmaceutically acceptable carrier.
32. A compound of formula IH
Figure US20050090533A1-20050428-C00490
wherein
R1 is heteroaryl selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
 —Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′R″,
 —(CH2)cNR′C(O)-alkyl,
 —(CH2)cNR′S(O)2-alkyl,
 —(CH2)dS(O)-alkyl,
 —(CH2)dS-alkyl,
 —(CH2)dS(O)2-alkyl;
 —(CH2)dS(O)2—NR′R″
R′ is hydrogen, alkyl, —(CH2)cOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring with —(CH2)c—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with
 —(CH2)2—S(O)2N(CH3)—CH2, or with
 —S(O)—O—(CH2)2,3—;
or —NR4R5 is
Figure US20050090533A1-20050428-C00491
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3;
e is 3, 4, or 5;
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
33. A composition comprising a compound of claim 32 and a pharmaceutically acceptable carrier.
34. A compound of formula IJ,
Figure US20050090533A1-20050428-C00492
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN, S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl,
 or is heteroaryl, selected from the group, consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
—NR4R5 are
Figure US20050090533A1-20050428-C00493
R′ is hydrogen, alkyl, —(CH2)dOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl;
b is 1 or 2;
d is 0, 1, 2, or 3; and
f is 0, 1, or 2;
or a pharmaceutically active acid-addition salt thereof.
35. A composition comprising a compound of claim 34 and a pharmaceutically acceptable carrier.
36. A process for preparing a compound of formula I
Figure US20050090533A1-20050428-C00494
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN,
 S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
 —Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′R″,
 —(CH2)cNR′C(O)-alkyl,
 —(CH2)cNR′S(O)2-alkyl,
 —(CH2)dS(O)-alkyl,
 —(CH2)dS-alkyl,
 —(CH2)dS(O)2-alkyl, or
 —(CH2)dS(O)2—NR′R″;
R′ is hydrogen, alkyl, —(CH2)cOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N-di-alkyl,
R″ is hydrogen or alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)e-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″; or with
 —(CH2)2—S(O)2N(CH3)—CH2, or with
 —S(O)—O—(CH2)2,3—;
or —NR4R5 is
Figure US20050090533A1-20050428-C00495
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3;
e is 3, 4, or 5; and
f is 0, 1, or 2;
which process comprises reacting a compound of formula
Figure US20050090533A1-20050428-C00496
 with a compound of formula

NHR4R5  III
 to produce a compound of formula
Figure US20050090533A1-20050428-C00497
 wherein R1, R2, R3, R4 and R5 are as defined above.
37. A process for preparing a compound of formula I
Figure US20050090533A1-20050428-C00498
wherein
R1 is aryl, unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, —(CH2)dOH, —C(O)H, CF3, CN,
 S-alkyl, —S(O)b-alkyl, —C(O)NR′R″, —NR′R″, —NR′C(O)-alkyl, and —NR′S(O)2-alkyl, or
 is heteroaryl, selected from the group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R2 and R3 are each independently hydrogen, halogen, alkyl, alkoxy, OCHF2, OCH2F, OCF3 or CF3;
R4 and R5 are each independently
 hydrogen,
 —(CR′R″)l—(CR′R″)l—(CR′R″)a—OH or —(CR′R″)l—(CR′R″)l—(CR′R″)a-alkyl, wherein R′ and R″ on each carbon atom may be the same or different from each other,
Cb-alkyl,
 —C(O)H,
 —(CH2)dcycloalkyl, unsubstituted or substituted by hydroxy,
 —(CH2)cNR′R″,
 —(CH2)cNR′C(O)-alkyl,
 —(CH2)cNR′S(O)2-alkyl,
 —(CH2)dS(O)-alkyl,
 —(CH2)dS-alkyl,
 —(CH2)dS(O)2-alkyl; or
 —(CH2)dS(O)2—NR′R″;
R′ is hydrogen, alkyl, —(CH2)oOH, —C(O)H, —C(O)-alkyl, —C(O)-cycloalkyl, —S(O)2-alkyl, —S(O)2-halogen-alkyl, —S(O)-alkyl, —S-alkyl or —S(O)2—N′-di-alkyl,
R″ is hydrogen or alkyl; or
R4 and R5 form together with the N-atom to which they are attached a ring
 with —(CH2)e-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl, or —C(O)NR′R″, or with
 —(CH2)c—NR′—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—O—(CH2)2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —(CH2)c—S(O)f—(CH2)c-, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″, or with
 —CH2CH═CH—CH2—, which is unsubstituted or substituted
by one or more substituents selected from the group consisting of alkyl, halogen, CF3, —(CR′R″)dOH, ═O, —CHO, and —NR′R″, wherein R′ and R″ are as described above or may form together with the N-atom to which they are attached a ring with —(CH2)e, or
by —(CH2)dNR′—C(O)-alkyl, —(CH2)d—C(O)-alkyl, —(CH2)d—C(O)-cycloalkyl, —(CH2)dOC(O)NR′R″, —(CH2)d—S(O)2-alkyl, —(CH2)d—S(O)-alkyl, —(CH2)d—S-alkyl, —(CH2)d—S(O)2—NR′R″, —(CH2)d-pyrrolidinyl or —C(O)NR′R″;
or with
 —(CH2)2—S(O)2N(CH3)—CH2, or with
 —S(O)—O—(CH2)2,3—;
or —NR4R5 is
Figure US20050090533A1-20050428-C00499
a is 0 or 1;
b is 1 or 2;
c is 1, 2, or 3;
d is 0, 1, 2, or 3;
e is 3, 4, or 5; and
f is 0, 1, or 2;
which process comprises reacting a compound of formula
Figure US20050090533A1-20050428-C00500
 with a compound of formula

R1—B(OH)2
 or a compound of formula
Figure US20050090533A1-20050428-C00501
 or a compound of formula

R1—ZnCl
 to produce a compound of formula
Figure US20050090533A1-20050428-C00502
 wherein R1, R2, R3, R4 and R5 are as defined above.
US10/884,707 2003-07-03 2004-07-02 Dual NK1/NK3 receptor antagonists Abandoned US20050090533A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/361,569 US7939533B2 (en) 2003-07-03 2009-01-29 Dual NK1/NK3 receptor antagonists
US13/076,891 US8404708B2 (en) 2003-07-03 2011-03-31 Dual NK1/NK3 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03014513.0 2003-07-03
EP03014513 2003-07-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/361,569 Continuation US7939533B2 (en) 2003-07-03 2009-01-29 Dual NK1/NK3 receptor antagonists

Publications (1)

Publication Number Publication Date
US20050090533A1 true US20050090533A1 (en) 2005-04-28

Family

ID=33560750

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/884,707 Abandoned US20050090533A1 (en) 2003-07-03 2004-07-02 Dual NK1/NK3 receptor antagonists
US12/361,569 Expired - Fee Related US7939533B2 (en) 2003-07-03 2009-01-29 Dual NK1/NK3 receptor antagonists
US13/076,891 Expired - Fee Related US8404708B2 (en) 2003-07-03 2011-03-31 Dual NK1/NK3 receptor antagonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/361,569 Expired - Fee Related US7939533B2 (en) 2003-07-03 2009-01-29 Dual NK1/NK3 receptor antagonists
US13/076,891 Expired - Fee Related US8404708B2 (en) 2003-07-03 2011-03-31 Dual NK1/NK3 receptor antagonists

Country Status (27)

Country Link
US (3) US20050090533A1 (en)
EP (1) EP1643998B1 (en)
JP (1) JP4490421B2 (en)
KR (1) KR100744859B1 (en)
CN (1) CN1852712B (en)
AR (1) AR044974A1 (en)
AT (1) ATE371451T1 (en)
AU (1) AU2004253267B2 (en)
BR (1) BRPI0412291A (en)
CA (1) CA2530886C (en)
CO (1) CO5650234A2 (en)
DE (1) DE602004008631T2 (en)
DK (1) DK1643998T3 (en)
ES (1) ES2291891T3 (en)
HR (1) HRP20070471T3 (en)
IL (1) IL172614A (en)
MX (1) MXPA06000192A (en)
MY (1) MY137156A (en)
NO (1) NO20056007L (en)
NZ (1) NZ544244A (en)
PL (1) PL1643998T3 (en)
PT (1) PT1643998E (en)
RU (1) RU2347777C2 (en)
SI (1) SI1643998T1 (en)
TW (1) TW200502230A (en)
WO (1) WO2005002577A1 (en)
ZA (1) ZA200510453B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034619A1 (en) * 2004-07-16 2006-02-23 Grünenthal GmbH Substituted amino compounds as 5-HT / NA uptake inhibitor
US20060217393A1 (en) * 2005-03-23 2006-09-28 Christoph Funk NK-1 receptor antagonists
WO2006119390A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US20080255147A1 (en) * 2005-05-31 2008-10-16 Dean Wilson Heterocycles useful as modulators of ion channels
US7919491B2 (en) 2005-09-09 2011-04-05 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
US20110136798A1 (en) * 2008-08-05 2011-06-09 Clare Louise Anderton Crystalline Forms Of A Pyridine Derivative
US10100030B2 (en) 2013-11-08 2018-10-16 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DE102004039789A1 (en) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
ES2872962T3 (en) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronophthalides for therapeutic use
CA2601935C (en) * 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Nk1 antagonists
GB0518472D0 (en) * 2005-09-09 2005-10-19 Glaxo Group Ltd Novel compounds
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
CN102532180B (en) * 2005-12-30 2016-06-29 安纳考尔医药公司 The little molecule of boracic
CN106008571A (en) 2005-12-30 2016-10-12 安纳考尔医药公司 Boron-containing small molecules
CN101379034B (en) 2006-02-07 2011-12-28 弗·哈夫曼-拉罗切有限公司 Benzamide and heteroarene derivatives as CETP inhibitors
WO2008128891A1 (en) 2007-04-20 2008-10-30 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
MX2010001080A (en) 2007-08-07 2010-03-01 Hoffmann La Roche Pyrrolidine aryl-ether as nk3 receptor antagonists.
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
CA2772168C (en) * 2009-08-27 2019-01-08 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
TWI649307B (en) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
HUE047732T2 (en) * 2015-05-18 2020-05-28 Nerre Therapeutics Ltd Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
RS60209B1 (en) 2017-03-20 2020-06-30 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EA202092131A1 (en) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед NEW PHARMACEUTICAL PREPARATION CONTAINING DUAL ANTAGONISTS OF THE NK-1 / NK-3 RECEPTOR
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
MX2022005867A (en) 2019-11-15 2022-06-14 Kandy Therapeutics Ltd New chemical process for making 6-chloro-4-(4-fluoro-2-methylphen yl)pyridin-3-amine a key intermediate of nt-814.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
US20030004157A1 (en) * 2001-04-23 2003-01-02 Susanne Buser Use of NK-1 receptor antagonists against benign prostatic hyperplasia
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6576762B2 (en) * 2000-07-24 2003-06-10 Hoffmann-La Roche Inc. Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
US5612337A (en) 1993-12-29 1997-03-18 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
ATE496032T1 (en) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS
EP1157006B1 (en) 1999-02-24 2006-10-25 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
PT1103545E (en) 1999-11-29 2004-03-31 Hoffmann La Roche 2- (3,5-BIS-TRIFLUOROMETHYL-PHENYL) -N-METHYL-N- (6-MORFOLIN-4-YL-4-O-TOTIL-PYRIDIN-3-YL) -ISOBUTYRAMIDE
NZ523273A (en) * 2000-07-14 2004-08-27 F N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
US6576762B2 (en) * 2000-07-24 2003-06-10 Hoffmann-La Roche Inc. Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors
US20030004157A1 (en) * 2001-04-23 2003-01-02 Susanne Buser Use of NK-1 receptor antagonists against benign prostatic hyperplasia
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034619A1 (en) * 2004-07-16 2006-02-23 Grünenthal GmbH Substituted amino compounds as 5-HT / NA uptake inhibitor
US7211579B2 (en) * 2005-03-23 2007-05-01 Hoffmann-La Roche Inc. NK-1 receptor antagonists
US20060217393A1 (en) * 2005-03-23 2006-09-28 Christoph Funk NK-1 receptor antagonists
US7683065B2 (en) 2005-05-04 2010-03-23 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US20070082889A1 (en) * 2005-05-04 2007-04-12 Dean Wilson Pyridines useful as modulators of ion channels
WO2006119390A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US20080255147A1 (en) * 2005-05-31 2008-10-16 Dean Wilson Heterocycles useful as modulators of ion channels
US7880008B2 (en) 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US20110059984A1 (en) * 2005-05-31 2011-03-10 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US8329702B2 (en) 2005-05-31 2012-12-11 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US7919491B2 (en) 2005-09-09 2011-04-05 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
US8097618B2 (en) 2005-09-09 2012-01-17 Glaxosmithkline Llc Pyridine derivatives and their use in the treatment of psychotic disorders
US20110136798A1 (en) * 2008-08-05 2011-06-09 Clare Louise Anderton Crystalline Forms Of A Pyridine Derivative
US8093242B2 (en) 2008-08-05 2012-01-10 Glaxosmithkline Llc Crystalline forms of a pyridine derivative
US10100030B2 (en) 2013-11-08 2018-10-16 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative

Also Published As

Publication number Publication date
ATE371451T1 (en) 2007-09-15
PL1643998T3 (en) 2008-01-31
WO2005002577A1 (en) 2005-01-13
JP2009500290A (en) 2009-01-08
PT1643998E (en) 2007-11-21
AR044974A1 (en) 2005-10-12
IL172614A (en) 2010-12-30
MY137156A (en) 2008-12-31
SI1643998T1 (en) 2007-12-31
AU2004253267B2 (en) 2008-12-04
DE602004008631T2 (en) 2008-07-10
DK1643998T3 (en) 2007-12-27
KR20060030893A (en) 2006-04-11
US8404708B2 (en) 2013-03-26
US20110178055A1 (en) 2011-07-21
AU2004253267A1 (en) 2005-01-13
ZA200510453B (en) 2007-01-31
EP1643998B1 (en) 2007-08-29
CA2530886C (en) 2013-05-28
NZ544244A (en) 2008-10-31
DE602004008631D1 (en) 2007-10-11
ES2291891T3 (en) 2008-03-01
BRPI0412291A (en) 2006-09-19
RU2006103010A (en) 2007-08-10
US7939533B2 (en) 2011-05-10
KR100744859B1 (en) 2007-08-01
CA2530886A1 (en) 2005-01-13
MXPA06000192A (en) 2006-04-11
RU2347777C2 (en) 2009-02-27
CO5650234A2 (en) 2006-06-30
HRP20070471T3 (en) 2007-11-30
JP4490421B2 (en) 2010-06-23
IL172614A0 (en) 2006-04-10
US20090137806A1 (en) 2009-05-28
NO20056007L (en) 2006-01-19
CN1852712A (en) 2006-10-25
EP1643998A1 (en) 2006-04-12
TW200502230A (en) 2005-01-16
CN1852712B (en) 2010-06-09

Similar Documents

Publication Publication Date Title
US8404708B2 (en) Dual NK1/NK3 receptor antagonists
US9079907B2 (en) Fused heterocyclic compound and use thereof
US7893062B2 (en) Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
US6534496B1 (en) Thermogenic composition and benzazepine thermogenics
JP2018115183A (en) Use of active pharmaceutical compounds for treatment of central nervous system diseases
US20060030600A1 (en) Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US10822338B2 (en) Substituted aminoquinazoline compounds as A2A antagonist
US11684625B2 (en) Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
ES2209995T3 (en) PROPYLE DERIVATIVES REPLACED WITH TIENOISOXAZOLIL- AND TIENOPIRRAZOLIL-FENOXI, USEFUL IN QUALITY OF ANTAGONISTS D4.
TWI491614B (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
US7498438B2 (en) Fused ring NK1 antagonists
US20110257402A1 (en) Pyrrazolopyridine compounds as dual nk1/nk3 receptor antagonists
US20110136788A1 (en) Therapeutic agent for irritable bowel syndrome
CN114728929A (en) Pyridine methylene piperidine derivatives and use thereof
US20200121657A1 (en) SUBSTITUTED METHANOPYRIDO [2, 1-a] ISOINDOLONES AS mAChR MODULATORS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS AND PROCESS FOR PREPARATION THEREOF
US20220002295A1 (en) Heterocyclic compounds and medical use thereof
WO2021046789A1 (en) Indazole-carboxamide derivative and use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:016150/0096

Effective date: 20040803

AS Assignment

Owner name: F. HOFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOFFMANN, TORSTEN;KOBLET, ANDREAS;PETERS, JENS-UWE;AND OTHERS;REEL/FRAME:016156/0159

Effective date: 20040802

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION